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Magnetic Resonance Spectroscopy (MRS) provides unique and clinically relevant information
for the assessment of several diseases. However, using the currently available tools, MRS
processing and analysis is time-consuming and requires profound expert knowledge. For these
two reasons, MRS did not gain general acceptance as a mainstream diagnostic technique yet,
and the currently available clinical tools have seen little progress during the past years.
MRS provides localized chemical information non-invasively, making it a valuable technique
for the assessment of various diseases and conditions, namely brain, prostate and breast cancer,
and metabolic diseases affecting the brain. In brain cancer, MRS is normally used for: (1.)
differentiation between tumors and non-cancerous lesions, (2.) tumor typing and grading,
(3.) differentiation between tumor-progression and radiation necrosis, and (4.) identification
of tumor infiltration. Despite the value of MRS for these tasks, susceptibility differences
associated with tissue-bone and tissue-air interfaces, as well as with the presence of post-
operative paramagnetic particles, affect the quality of brain MR spectra and consequently
reduce their clinical value. Therefore, the proper quality management of MRS acquisition and
processing is essential to achieve unambiguous and reproducible results. In this thesis, special
emphasis was placed on this topic.
This thesis addresses some of the major problems that limit the use of MRS in brain tumors
and focuses on the use of machine learning for the automation of the MRS processing pipeline
and for assisting the interpretation of MRS data. Three main topics were investigated: (1.)
automatic quality control of MRS data, (2.) identification of spectroscopic patterns characteristic
of different tissue-types in brain tumors, and (3.) development of a new approach for the
detection of tumor-related changes in GBM using MRSI data.
The first topic tackles the problem of MR spectra being frequently affected by signal
artifacts that obscure their clinical information content. Manual identification of these artifacts
is subjective and is only practically feasible for single-voxel acquisitions and in case the user has
an extensive experience with MRS. Therefore, the automatic distinction between data of good
or bad quality is an essential step for the automation of MRS processing and routine reporting.
The second topic addresses the difficulties that arise while interpreting MRS results: the
interpretation requires expert knowledge, which is not available at every site. Consequently,
the development of methods that enable the easy comparison of new spectra with known
spectroscopic patterns is of utmost importance for clinical applications of MRS.
The third and last topic focuses on the use of MRSI information for the detection of tumor-
related effects in the periphery of brain tumors. Several research groups have shown that MRSI
information enables the detection of tumor infiltration in regions where structural MRI appears
normal. However, many of the approaches described in the literature make use of only a very
limited amount of the total information contained in each MR spectrum. Thus, a better way to
exploit MRSI information should enable an improvement in the detection of tumor borders,
and consequently improve the treatment of brain tumor patients.
The development of the methods described was made possible by a novel software tool for
the combined processing of MRS and MRI: SpectrIm. This tool, which is currently distributed
as part of the jMRUI software suite (www.jmrui.eu), is ubiquitous to all of the different methods
presented and was one of the main outputs of the doctoral work.
Overall, this thesis presents different methods that, when combined, enable the full au-
tomation of MRS processing and assist the analysis of MRS data in brain tumors. By allowing
clinical users to obtain more information from MRS with less effort, this thesis contributes to
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the transformation of MRS into an important clinical tool that may be available whenever its
information is of relevance for patient management.
Keywords: Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Spectroscopic Imag-
ing (MRSI), quality control, nosologic imaging, machine learning, brain tumors, glioblastoma
multiforme, brain tumor delineation
“ A day will come when war will seem as absurd between Paris and London, between Petersburg
and Berlin, between Vienna and Turin, as it would today between Rouen and Amiens or between
Boston and Philadelphia. A day will come when you – France, Russia, Italy, England, Germany –
all you nations of the continent will merge, without losing your distinct qualities and your glorious
individuality, in a close and higher unity to form a European brotherhood...
A day will come when the only fields of battle will be markets opening up to trade and minds
opening up to ideas. A day will come when bullets and bombs will be replaced by votes, by universal
suffrage of the peoples, by the venerable arbitration of a great sovereign senate which will be to Europe
what Parliament is to England, (...) what the Legislative Assembly is to France. A day will come when
we will display cannon in museums just as we display instruments of torture today, amazed that such
things could ever have been. (...)
A day will come when we shall see those two immense groups, the United States of America and
the United States of Europe, stretching out their hands across the sea, exchanging their products, their
arts, their works of genius (...) And to bring about that day will not take another 400 years, for we are
living in a fast-moving age. ”
Victor Hugo, International Peace Congress, 1849.
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1 | Introduction
Magnetic Resonance Spectroscopy (MRS) enables the non-invasive retrieval of localized bio-
chemical information from different parts of the human body and allows to quantify different
metabolites that can not be analyzed using conventional MRI techniques. The ability to detect
metabolic changes in various tissues makes it a very appealing technique for initial diagnostics,
treatment planning, and follow-up in many diseases and conditions.
Currently, the main clinical applications of MRS are found in oncologic imaging
[García-Figueiras 2016] of the brain [Preul 1996, Howe 2003, Dowling 2001, Majós 2004],
prostate [Costello 1999, Mueller-Lisse 2007, Tayari 2017] and breast [Suppiah 2013, Cen 2014,
Baltzer 2013], as well as in the evaluation of several metabolic diseases affecting the brain
[Zimmerman 2011, Harting 2015, Razek 2014]. Other interesting applications include the
assessment of neonatal hypoxic injury [Boichot 2006, Peden 1993] and the measurement of
intramyocellular lipid content in skeletal muscle to assess insulin sensitivity in pre-diabetic
patients [Boesch 1999, Boesch 2006].
Proton MRS, the most common type of MR spectroscopy, can be performed in almost every
MRI scanner if the right software (i.e. pulse sequence) is installed. Despite this and of its
relevance, MRS is clinically used only in a few specialized centers.
1.1 Current limitations and challenges in clinical MRS
In 2012, a survey conducted by R. Kreis [Kreis 2012], aimed at collecting information regard-
ing the reasons that limit the use of MRS in clinical practice. In that survey, 35 different
professionals from various hospitals of more than 15 countries, were asked the following
question:
What does it take for an MR site to perform MRS exams that can be useful for patient manage-
ment?.
Figure 1.1 shows the different items that could be selected, as well as the percentage of
participants that selected each one of them. In the same figure, "orange" was used to highlight
the topics from the list that, directly or indirectly, were addressed in this thesis. The results
of the survey show that the need for expertise in the different aspects associated with MRS
acquisition, post-processing, and interpretation, is regarded as the most limiting factor for the
clinical use of MRS. This thesis presents methods that aim at addressing this problem by (1.)
enabling the fully automatic post-processing of MRS, and (2.) assisting clinicians in the analysis
and interpretation of MRS data. Moreover, a complete chapter was dedicated to the topic of
quality management in in vivo MRS, whose content should assist non-experienced users with
the different quality-related technological aspects that are essential to guarantee unambiguous
and reproducible results.
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Figure 1.1: Results of a survey conducted by R. Kreis in 2012 [Kreis 2012] where the participants were asked the following
question: "What does it take for an MR site to perform MRS exams that can be useful for patient management?". Each participant
could select any number of items from the list shown in the figure. The graph shows the percentage of participants that selected
each item. From those topics, the ones that are, directly or indirectly, addressed in this thesis are marked in orange, and the
remaining ones in blue.
1.2 Hypothesis and aim of the thesis
As discussed in the previous section, the need for expertise is one of the main limiting factors
for the clinical use of MRS. Therefore, new methods are needed that simplify the use of MRS
and allow clinical centers with less experience to use the technique whenever its information
may be of relevance for patient management. The need for the simplification of the analysis
is further emphasized in a review paper published in 2016 on the use of MRS in oncologic
imaging [García-Figueiras 2016]:
”1H-MRS has achieved great strides as a molecular imaging technique since its introduction, and
its scope in many clinical scenarios and research settings is rising. However, MRS needs expertise and
is time-consuming, which limit its clinical applicability. In this setting, spectra analysis needs to be
simplified.”
This thesis addresses the issues related to the need for expertise and to the time required
for the processing and analysis of MRS. More precisely, the work here presented aimed at
improving and fully automatizing MRS post-processing, as well as assist the analysis and
interpretation of MRS data. This was done considering the following hypothesis:
Using machine learning methods, it is possible to fully automatize MRS post-processing, as well
as produce results that may be easily interpreted by non-experienced clinical MRS users.
The focus on the automation and simplification of MRS is a constant aspect of the topics
presented in this thesis.
1.3 Thesis structure
This thesis is organized as follows:
• Part I: Theoretical Background - covers the theory that underlies the topics presented in
this thesis.
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– Chapter 2: From NMR to MRI and MRS - introduces the reader to the main theoret-
ical concepts of Nuclear Magnetic Resonance (NMR), Magnetic Resonance Imaging
(MRI) and Magnetic Resonance Spectroscopy (MRS).
– Chapter 3: MRS Data Processing & Machine Learning - covers the main post-
processing steps used in MRS.
– Chapter 4: Brain Tumor Characterization using in vivo proton MRS - presents the
main metabolites visible in in vivo proton MR spectra of the brain and discusses the
main applications of MRS for the characterization of brain tumors.
• Part II: Quality management of MRS and automation of quality control - covers differ-
ent quality related aspects of MRS.
– Chapter 5: Quality Management in in vivo proton MRS - discusses various as-
pects related to the quality management of in vivo proton MRS that are essential to
guarantee unambiguous and reproducible results with MRS.
– Chapter 6: Automatic Quality Control of proton MRSI data - presents a machine
learning based method for the automatic quality control of MRS data that was trained
to mimic the judgment of MRS experts on the acceptance or rejection of spectra
based on the subjective quality of the MRS signal.
– Chapter 7: Improving labeling efficiency in automatic QC of MRSI data - contin-
ues the work of the previous chapter and proposes a new approach to improve the
efficiency of labeling the examples used to train quality control classifiers.
• Part III: Assisting the interpretation of brain tumor MRS data - covers different meth-
ods to improve and simplify the analysis and interpretation of brain tumor MRS data.
– Chapter 8: Highlighting differences between GBM and metastasis using cNMF -
presents a method based on convex non-Negative Matrix Factorization (cNMF) that
was used to highlight differences between GBM and Metastasis, which are two of the
most common types of brain tumors and for which the correct differentiation using
conventional medical imaging/spectroscopy is not always straightforward.
– Chapter 9: Automatic tissue-type classification of 1H-MRSI spectra in GBM pa-
tients - presents the results of an approach where the MRSI data of GBM patients is
clustered and the different prototype spectra of each cluster are then used to classify
new spectra.
– Chapter 10: BraTSIS: Brain Tumour Spectroscopy Imaging Segmentation proto-
col - continues the work of the previous chapter and presents a decision-tree based
algorithm that allows to consistently identify the main types of tissue-type spectro-
scopic patterns seen in MRSI examinations of GBM patients.
– Chapter 11: MRS features and distance to MRI-visible Solid Tumor in GBM - ex-
plores the relationship between the distance to solid tumor as is visible in structural
MR-imaging, and MR-spectroscopy derived features. By doing so, the spatial proper-
ties of different metabolite features are compared. Moreover, a new method for the
analysis of MRSI data of brain tumors is presented that may improve the detection of
tumor-related changes in brain MRSI data. This method predicts the distance to the
solid tumor for each voxel based solely on its metabolite content allowing to create
Expected Distance to Tumor (EDT) maps.
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• The thesis finishes with Chapter 12 (Overall Discussion & Outlook), where the main





2 | From Nuclear Magnetic Resonance to Magnetic
Resonance Imaging and Spectroscopy
2.1 Nuclear Magnetic Resonance (NMR)
The Nuclear Magnetic Resonance (NMR) effect was first observed by Isidor Isaac Rabi in 1938
[Rabi 1938], a discovery that justified his recognition with a Nobel prize in physics in 1944 "for
his resonance method for recording the magnetic properties of atomic nuclei". Cornelius Jacobus
Gorter from the Zeeman laboratory in Amsterdam attempted to measure the NMR effect a
few years before [Gorter 1942] but his experiments were unsuccessful. Besides Gorter’s lack of
success, he visited Rabi’s lab in September 1937, an event that is believed to have been crucial
for Rabi’s results. The initial discovery was made using a beam of lithium chloride molecules
in a vacuum [Rabi 1938], and it was not until 1945 that NMR was shown in condensed matter
by Felix Bloch and Edward Purcell working independently [Bloch 1946, Purcell 1946]. Bloch
and Purcell received the physics Nobel prize in 1952 "for their development of new methods for
nuclear magnetic precision measurements and discoveries in connection therewith".
The discovery of NMR led to the invention of two technologies that revolutionized chemistry
and medicine and impacted many other areas: NMR spectroscopy and Magnetic Resonance
Imaging (MRI). Besides exploring the exact same principles, NMR spectroscopy and MRI
became two distinct fields of research and, today, are normally used in different contexts. On
one hand, MRI is an essential tool used in modern medicine that enables the non-invasive in-vivo
visualization of the structure and function of different organs and tissues. NMR spectroscopy,
on the other hand, has become an important tool used in chemistry and physics for analyzing
the chemical composition and properties of both organic and inorganic samples. Magnetic
Resonance Spectroscopy (MRS), the technique explored in this thesis, is found at the intersection
between MRI and NMR spectroscopy. MRS refers to the use of NMR spectroscopy for the
analysis of in vivo samples and is normally performed using the same hardware as in MRI.
In the next sections, the NMR principles will be presented, followed by the basic concepts
that underlie MRI and MRS.
2.2 NMR principles
2.2.1 Nuclear spin and magnetic momentum
Nuclear Magnetic Resonance is a physical process where a nucleus absorbs or emits a photon
whose energy is in resonance with the transition between different nuclear spin angular mo-
mentum energy levels. The effect only occurs for nuclei with a non-zero spin quantum number
(I) that are subject to an external magnetic field. In the absence of an external magnetic field,
and for nuclei with I equal to zero, there is only a single energy level and, consequently, nuclear
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Table 2.1: Isotope natural abundance, spin quantum number, number of protons and neutrons and gyromagnetic ratios for
different nuclei. Source: Department of Chemistry Instrumentation Facility, MIT, Massachusetts, USA, 2017
Isotope Abundance (%) I #protons #neutrons γ(MHz/T)
1H 99.98 1/2 1 0 42.58
2H 1.5× 10−2 1 1 1 0.15
3He 1.3× 10−4 1/2 2 1 0.71
13C 1.11 1/2 6 7 0.33
14N 99.63 1 7 7 0.29
15N 0.37 1/2 7 8 1.40
17O 3.7× 10−2 5/2 8 9 1.34
19F 100 1/2 9 10 6.94
23Na 100 3/2 11 12 0.28
31P 100 1/2 15 16 1.53
magnetic resonance is not possible. The spin quantum number is a property of each nucleus
that depends on the number of protons and neutrons:
• For nuclei with odd number of protons and odd number of neutrons, I is a positive integer
(I = {1,2,3, ...});
• For nuclei with odd number of protons and even number of neutrons, or vice versa, I is a
positive half-integer (I = {1/2,3/2,5/2, ...});
• For nuclei with even number of protons and even number of neutrons, I is zero (I = 0);
The spin quantum number of a nucleus determines the quantization of the nuclear angular
momentum (J). The magnitude of J is given by:
|J | = ~
√
I(I + 1) (2.1)
where ~ is the reduced Planck constant (1.055× 10−34Js/rad). Because nuclei contain charged
particles (protons), its rotation is associated with a magnetic momentum (µ). For a given
nucleus, the relation between its magnetic momentum (µ) and angular momentum (J) is given
by a physical constant named gyromagnetic ratio (γ):
γ = µ/J (2.2)
Table 2.1 shows the spin quantum number and gyromagnetic ratios for various nuclei
corresponding to different isotopes.
In the presence of a strong magnetic field (B0) in a given spatial direction z, the magnetic
momentum vector in the same direction can only have the following values:
µz = γ~mI , mI = −I,−I + 1, ..., I − 1, I (2.3)
where mI is the nuclear magnetic quantum number. The x and y components of the vector can
assume any value, provided that the magnitude of µ respects equation 2.1. This means that, in
the case of the proton, due to its spin quantum number of 1/2, the magnetic momentum vector














) ≈ 54.74° (2.4)
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Figure 2.1: Possible orientations for a nucleus with a spin quantum number of 1/2. The figures show the precession movement
of the protons as a result of the torque exerted by the static magnetic field B0.
2.2.2 Larmor frequency
The energy associated with the magnetic momentum depends on the strength of the external
magnetic field (B0) and the magnetic momentum in the direction of the field (µz):
E = −µzB0 = −γ~mIB0, mI = −I,−I + 1, ..., I − 1, I (2.5)





The two energy levels correspond to the magnetic momentum in the z direction being either
positive or negative, meaning that the magnetic momentum vector is either parallel or anti-
parallel to the static external magnetic field (B0). The energy associated with the transition
between these two levels is given by:
∆E = γ~B0 (2.7)
In order to calculate the corresponding resonance frequency, we need to consider the relation
between the energy of a photon and its frequency (Planck-Einstein relation):
E = ~ω (2.8)
Consequently, the resonance frequency, or Larmor frequency (ω0), is given by:
ω0 = γB0 (2.9)
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2.2.3 Population difference between orientations
In an NMR experiment, the detected signal corresponds not to a single nucleus but to the
combined effect of all nuclei of the sample. The NMR signal is proportional to the population
difference between the parallel and anti-parallel states. The ratio between the two populations











where k is the Boltzmann constant (1.381 × 10−23J/K) and T is the temperature in Kelvin.
Following the first-order approximation of equation 2.10, the population difference is given by:




where N is the total number of nuclei in the sample. This equation shows that in the case of 1H ,
at room temperature (296.15K), and for a magnetic field of 1.5T, there is only a difference of
approximately 5 nuclei between the two states for every million nuclei.
2.2.4 Macroscopic Magnetic Dipolar Momentum
The net magnetization of a sample ( ~M0) corresponds to the combined effect of all nuclei present












where V is the volume of the sample. From this expression, it is seen that, in equilibrium,
~M0 has only a component in the z-direction. This results from the fact that each individual
magnetic momentum vector assumes a random orientation in the x and y directions, which
means that all vector components in the plane perpendicular to the external magnetic field
cancel each other.
2.2.5 Bloch Equations and Relaxation
In every NMR experiment, the information from our sample is collected by first interacting
with the spins of the sample in such a way that these will respond differently depending on the
properties that are targeted by the experiment. The main interaction with the different nuclei
is made by applying a time-varying magnetic field perpendicular to the main static magnetic
field B0, that superimposes B0. Consequently, the total magnetic field ~B(t) is given by:
~B(t) = (Bx(t),By(t),B0) (2.13)
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Table 2.2: Relaxation times for different tissues at 1.5T. Sources: [Webb 2003, Meier 2012]
Tissue T1 (ms) T2 (ms)
Fat 260 80
Muscle 870 45
Gray Matter 900 100
White Matter 780 90
Cerebrospinal Fluid 2400 160
Liver 500 40
Kidney 650 450
whereMz is referred to as longitudinal magnetization, andMx andMy as transverse magnetization.
In these equations it is possible to distinguish two main effects:
1. The torque that the magnetic field ~B exerts on ~M;
2. The relaxation of the magnetization with time-constants T1 and T2. These constants
depend on the local environment and change between different tissues.
The two time-constants that describe the relaxation of ~M, T1 and T2, are manifestations of
different effects. The first constant, T1, is a result of the loss of energy of the nuclei to the
surrounding atoms, bringing the system back to the equilibrium. Consequently, T1 is called
spin-lattice relaxation time. In contrast, T2 does not depict the exchange of energy but the loss of
phase coherence between the different magnetic momentum vectors of the multiple nuclei. This
loss of coherence leads to the cancellation of the transverse components of ~M. Given that this
effect is related to the phase-coherence between different spins, T2 is called spin-spin relaxation
time. It is important to note that two different phenomena are responsible for the loss of phase
coherence between spins. One one hand, the neighborhood of each spin and the interactions
with the surrounding atoms causes each nuclei to experience a slightly different magnetic
field that leads to the accumulation of a phase difference between spins. This mechanism
for loosing phase-coherence is called the "true" T2 relaxation. Additionally to this effect, the
fluctuations in the magnetic field due to hardware imperfections (e.g. imperfect shimming),
as well as magnetic susceptibilities differences between different materials, cause local field
inhomogeneities that accelerate the loss of coherence between spins. Therefore, the observed











where T +2 represents the contribution of the local field inhomogeneities to T
∗
2 . For the sake of
accuracy, it should be clarified that in the Bloch equations above presented, the constant T2 is,
in fact, T ∗2 .
The different time-constants, T1, T2 and T ∗2 , can vary considerably between different tissues.
This allows MRI to have a high soft-tissue contrast, which is one of the main advantages of
MRI relatively to other medical imaging techniques such as computer-tomography (CT) or
ultrasound (US). Table 2.2 shows the observed approximate relaxation times (T1 and T2) for
different tissues at 1.5T.
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2.2.6 NMR Signal
As it was shown in the Bloch equations, the static magnetic field ~B0 exerts a torque on ~M. In
the presence of transverse magnetization, the torque causes ~M to precess around the z-axis,
creating a time-varying magnetic field that can be detected using a coil with a cross-section
perpendicular to the transverse plane xOy. The relation between a time-varying magnetic flux
and the electric field is described by the Maxwell-Faraday equation:




The integral of the curl of the electric field over the cross-section of the coil corresponds to an
electromotive force that creates a time-dependent voltage (u(t)) between the ends of the coil.
The voltage u(t) is proportional to the precession of the transverse components of ~M. More
specifically, if we consider that the magnetization is rotated 90° so that Mz is fully converted in








Equation 2.17 shows that the NMR signal scales quadratically with the magnetic field. However,
this does not necessarily translate into a quadratic relation between magnetic field strength and
the intrinsic signal-to-noise-ratio (SNR) of a given MR system, since the noise also increases
with B0. As described by [Ocali 1998], for low field strengths (< 3T ), the relation between B0
and SNR is approximately linear. However, for higher field strengths the relation between these
two quantities becomes more complex due to the interaction between the used radio-frequency
waves and the sample (e.g. human body) that create spatial dependencies between the SNR and
B0.
2.2.7 Spatial Localization and Small Tip-Angle Approximation
In in vivo NMR, it is essential to be able to selectively interact with spins of a given spatial
region. In order to achieve this, magnetic field gradients can be used in combination with
a time-varying magnetic field, i.e. an RF-pulse. The gradients superimpose ~B0, creating a
spatially dependent resonance frequency ωL:
B(x,y,z) = B0 +Gyy +Gxx+Gzz =⇒ ωL(x,y,z) = ω0 +γ(Gyy +Gxx+Gzz) (2.18)
where Gx, Gy and Gz are the linear gradients in the x, y and z directions. Once these gradients
are active, an RF-pulse with a narrow band of frequencies will select only those regions where
the resonance conditions are met.
In order to better understand the relation between the RF-pulse and how the transverse
magnetization varies in a given direction, the Bloch equations will be solved for the particular
case of the selection of a slice orthogonal to ~B0 using a linear gradient in the z-direction.
Before solving the equations, two concepts will be introduced that simplify its resolution.
The first one corresponds to the concept of the rotating frame of reference, more precisely, a
coordinate system that rotates at the Larmor frequency about the z-axis. Given that the effect
of the static component of the magnetic field B0 is a precession of ~M0 about the z-axis, in the
rotating frame this movement is "eliminated", and consequently, considering Bz = B0 +Gselz the
effective magnetic field becomes:
~Bef f = B1,x′ (t) ~ex′ +B1,y′ (t) ~ey′ + (Bz −
ω0
γ
)~ez = B1,x′ (t) ~ex′ +B1,y′ (t) ~ey′ +Gselz~ez (2.19)
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where x′ and y′ correspond to the transverse coordinates in the rotating frame of reference
(the z coordinate is identical for both coordinate systems). The second concept that will be
introduced is the small tip-angle approximation which assumes that the pulse does not change
the longitudinal magnetization, i.e. Mz(t) ≈M0. Thus, if the relaxation components are ignored,
the Bloch equations can be written as:
dMx′
dt








If the transverse magnetization Mxy(t) is defined as the complex value
Mxy(t) =Mx′ (t) + iMy′ (t) (2.21)
with i =
√
−1, and the complex time-dependent field originated by the RF-pulse B1(t) as
B1(t) = B1,x′ (t) + iB1,y′ (t) (2.22)
the evolution of the transverse magnetization can be written as
dMxy
dt
= iγM0B1(t)− iγMxy(t)Gselz (2.23)
As described in [Slotboom 1993] and [Noll 2006], the solution for the differential equation 2.23







To better understand the meaning of this equation, a variable substitution is performed, t′ =



























−iγGselzτ/2F −1[B1(t′ + τ/2)]|ω′= γGsel2π z
(2.25)
This result shows that the profile of the slice selected with the RF-pulse is proportional to its





Moreover, the RF-pulse causes a phase-shift in the z-direction of:
∆φ = e−iγGselzτ/2 (2.27)
which can be easily eliminated if a gradient with slope −Gsel is applied during half the duration
of the pulse, i.e., τ/2.
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2.2.8 RF-pulses
As was shown in the previous subsection, RF-pulses can be used to convert longitudinal
magnetization into measurable transverse magnetization. Such pulses are named excitation
pulses. In general, RF-pulses can be divided into the following types ([Slotboom 1993]):
• Non-self-refocused excitation pulses. This corresponds to the RF-pulse type described in
the previous section that aims at transforming longitudinal magnetization into transverse
magnetization. As shown in the previous section (eq. 2.27), the selected region is left with
a phase-shift that needs to be corrected afterward. Examples of such pulses include the
Gauss and the sinc pulses.
• Self-refocused excitation pulses. Such pulses are a variation of the previous type that is en-
gineered to eliminate the phase-shift created by the RF-pulse [Pauly 1991]. The advantage
of these pulses is that immediate signal acquisition after the pulse can take place.
• Inversion pulses. Inversion pulses aim at inverting the longitudinal magnetization. Such
pulses are the basis of sequences such as Inversion Recovery sequences, where the differ-
ences in recovery times between different tissues or metabolites are used to selectively
eliminate the signal of one of the sources. An example of such a sequence is FLAIR
(Fluid Attenuated Inversion Recovery), where the signal corresponding to the CSF is
selectively eliminated. In MRS, the same technique can be used to separate signals of
macromolecules, i.e. lipids and proteins, from metabolites with longer T1 relaxation times
(metabolite nulling [Mader 2001]).
• Refocusing pulses. These pulses invert the transverse magnetization, performing a rotation
of 180° of the magnetization vector and are the basis of the spin-echo (see section 2.3.2). It
can be proven that a time-symmetric inversion pulse is a refocusing pulse, and vice-versa.
• Saturation pulses. Saturation pulses are used to eliminate the signal of a given region or
frequency. These pulses are similar to excitation pulses but are designed to produce a
considerable phase-shift in the selected spins and, consequently, no refocusing is applied.
Saturation pulses are usually followed by spoiler gradients that further dephase the
selected spins. Such pulses are used to eliminate undesirable sources of signal, such as
signal originating from the regions adjacent to a selected slice or fat signals that may
contaminate the signal. For more information, see section 2.5.5.
2.2.9 Adiabatic pulses
B1 field inhomogeneities can change the flip angle produced by an RF-pulse and consequently
impact the quality of the signal obtained with a pulse sequence. MRS is particularly sensitive
to B1-inhomogeneities, since even in perfect acquisition conditions the SNR of most of the
metabolites of interest is already low. Adiabatic pulses are a subset of pulses that are particularly
insensitive to B1-inhomogeneities. In these pulses:




which means that the change of the magnetization vector (d ~Mdt ) is always perpendicular to the
effective magnetic field, or in other words, that the magnetization vector always precesses
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around ~Bef f . In order to achieve this, the changes in the effective field need to be slow enough.
This condition is the basis for the adiabacity factor Q [Baum 1985] that measures how adiabatic
a given pulse is:
Q(t,∆ω) =
|γ ~Bef f (t)|
|dϑdt |
(2.29)
where dϑ/dt is the angular speed, with ϑ being the angle between ~Bef f and ~ez. A pulse is
said to be adiabatic if Q > 5 ([Slotboom 1993]). In subsection 2.5.3 an MRS pulse sequence
(SADLOVE/LASER) using adiabatic pulses is presented.
2.3 Magnetic Resonance Imaging (MRI)
2.3.1 Spatial-encoding and K-Space
In order to produce NMR-based images, i.e. MRI images, it is necessary to encode the spatial
coordinates in the signal. This can be done using gradients to create phase and frequency
spatial dependencies. In both types of encoding, a gradient in a given direction is switched on.
In the case of phase-encoding, this is done before signal acquisition which will cause spins to
accumulate different phase-shifts depending on their location. In contrast, frequency-encoding
is performed by activating a "readout" gradient during acquisition, which will cause spins
in different locations to be precessing at different frequencies while the signal is recorded.
Considering a 2D slice and a spatially dependent property ρ(x,y) that we aim to map, the







where frequency-encoding was applied in the x-direction and phase-encoding in the y-direction.
In order to acquire enough information to produce a NxM image, the same number of points
needs to be collected. This can be achieved, for instance, with M experiments where, in each
experiment, N points are acquired from the NMR signal. To guarantee that each experiment
conveys different information, the phase gradient is changed between experiments. The change
in the phase-encoding gradient is usually performed by changing the amplitude of the gradient,
however, since the dephasing effect is given by amplitude × duration of the gradient, the
duration could potentially be changed between experiments. This latter option becomes less
practical, since it can potentially increase the time required for acquisition, as well as increase
the minimum echo-time possible with the sequence (see the next section for more details 2.3.2).
Using the described approach, the frequency and phase dependencies are given by:
ω(x,n)t = γGxxn∆Tx, −N/2 ≤ n ≤N/2
φ(y,m) = γm∆GyTyy, −M/2 ≤m ≤M/2
(2.31)
where m and n represent the discrete coordinates of the collected data, ∆Gy is the amplitude
increment of the phase-encoding gradient between two consecutive experiments, and ∆Tx is
the time interval between two consecutive points of the discrete signal that is recorded in each
experiment. To facilitate the notation, we introduce the k-space formalism, a coordinate system
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Figure 2.2: MRI image and corresponding k-space images (real and imaginary components). For visualization purposes the
maximum value of the k-space color-scale was lowered, given that the amplitude of the center elements (low frequencies) are
considerably higher than the rest of the k-space.







This means that for each k-space coordinate, the signal contains information from every spatial
coordinate of the slice. Moreover, the value of ρ(x,y) can be seen as the Fourier coefficient
associated with the Fourier series element ei(kx[n]x+ky [m]y). Consequently, using a 2D Discrete-
Fourier-Transform (DFT) it is possible to obtain the image in spatial coordinates corresponding











Figure 2.2 shows an example of a 2D MRI image and the corresponding real and imaginary
k-space images.
Finally, some important relations between the dimensions and resolution of the k-space and
its corresponding image should be highlighted. The size of the image (Field-Of-View (FOV)),




Where r represents a given spatially encoded direction and N is the corresponding number of
encoding steps in the same direction. Considering now the relation between sampling frequency
(ωs) and maximum signal frequency (ωM ) given by Nyquist-Shannon sampling theorem:
2ωM < ωs (2.36)












which shows that FOV and BW are inversely related. This means, for instance, that a larger
spatial coverage (larger FOV) using the same number of voxels can be obtained by reducing
the spatial frequency bandwidth and the k-space spacing ∆kr . This can be seen as removing
the the higher spatial frequency components of the k-space and using them to better cover the
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Figure 2.3: Schematic diagram of the spin-echo pulse sequence.
low-frequency region of the k-space, which becomes more important since the image is bigger
and has a lower resolution. Similarly, the spatial resolution over the same FOV can be increased
by covering a larger area of the k-space while maintaining the spacing ∆kr , i.e., adding more
information concerning higher spatial frequencies.
2.3.2 Spin-echo sequence
The spin-echo (SE) sequence is one of the most fundamental pulse sequences in MRI and its
basic elements are the basis for many of the pulses sequences currently used. The diagram of
the sequence is presented in Figure 2.3 and in Figure 2.4 a schematic is shown showing the
different steps that lead to the formation of the spin-echo.
The spin-echo sequence starts with a 90° excitation pulse that rotates the magnetization
vector to the transverse plane (Figure 2.4, stage 1). To enable slice selection, a gradient is
switched on at the same time as the 90° pulse. Directly after applying the pulse, the gradient is
inverted and applied for half of the time to ensure that the phase-shift described previously in
equation 2.27 is eliminated (Figure 2.4, stages 2 to 3). After this initial pulse, the effects related
with T ∗2 relaxation cause the different spins to dephase. The accumulated phase is given by:
∆φ = τ∆ω (2.38)
where ∆ω is the difference between the frequency of each spin and the Larmor frequency,
and τ is the time since the 90° excitation pulse. In order to rephase the spins, a refocusing
pulse is applied that converts the accumulated phase from φ to −φ (Figure 2.4, stages 4 to 5).
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Figure 2.4: Different stages of the echo formation in a spin-echo sequence. For more details see description in the main text.
Consequently, after the same time interval as the one between the two RF-pulses, the spins
refocus and a spin-echo is produced (Figure 2.4, stage 6). During the echo, the Analog to Digital
Converter (ADC) is turned on and the signal is recorded. In a spin-echo sequence, the time
between the magnetic center of the excitation pulse and the echo is called the echo-time (TE).
The experiment can be repeated consecutively several times to allow for spatial-encoding or to
improve SNR. The time between the initial excitation pulses of two consecutive experiments
is called the repetition-time (TR). For spatial encoding, the phase-gradient is applied with a
different magnitude in every experiment. Additionally, the readout gradient is switched on
during acquisition. Given that the readout gradient will cause a phase shift, a preparatory
inverted gradient is applied before the acquisition. In Figure 2.3 the preparatory gradient is
applied before the 180° pulse and consequently has the same direction as the readout gradient.
Due to the "unwinding" of the phase prior to acquisition, the echo will occur then the phase of
the spins is fully refocused.
For the spin-echo sequence, the steady-state 1 relation between the signal amplitude and the
tissue properties ρ (proton density), T1 ,T2, and sequence parameters TR and T E, is given by:




Consequently, the weighting of the image in terms of the properties ρ, T1 and T2 depends on
the values of T E and TR. Short T E and TR times are used to produce T1-weighted images. In
contrast, to create T2-weighted images, long T E and TR times are required. Finally, proton-
density (ρ) weighted images can be generated using long TR and short T E times.
2.3.3 Gradient-echo sequence
The gradient-sequence (Figure 2.5) is a sequence where the refocusing of the transverse mag-
netization is obtained using a gradient. In this sequence, the phase and readout gradients are
switched on after the slice selection excitation pulse. These gradients lead to quick dephasing of
the transverse magnetization that is refocused as result of the inversion of the readout gradient.
1Steady-state is the state reached after a few TRs, when the magnetization at the beginning of each repetition
becomes constant.
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Figure 2.5: Schematic diagram of the gradient-echo pulse sequence.
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In gradient-echo sequences, excitation pulses with a flip-angle smaller than 90° are often used.
This leads to a lower SNR but allows a quicker recovery of the magnetization after each exper-
iment, which allows for shorter TR values. For a given tissue having an average spin-lattice
relaxation time of T1 and a sequence with repetition time TR the angle that provides the best




In the case of gradient-echo sequences, the flip-angle is often used to determine the contrast:
large flip-angles are used to produce T1-weighted images and short flip-angles T ∗2-weighted
images. For large flip-angles, the higher the T1 value the higher the saturation of the signal. In
contrast, for small flip-angles the recovery of the longitudinal magnetization is quicker and
signal saturation plays a less important role. In this case the main effect is related with T ∗2 :
signals with short T ∗2 values will dephase quicker and, as explained, this sort of dephasing is not
recovered by the field-gradients, leading to smaller signal amplitudes in those regions where
T ∗2 is shorter.
2.4 NMR Spectroscopy
2.4.1 Chemical-Shift
The external magnetic field is normally not directly experienced by the nuclei due to the
electronic currents that it induces in the vicinity of each nucleus. These effects are proportional
to the external field and, consequently, the local magnetic field is given by:
Blocal = B0(1− σ ) (2.41)
where σ is the shielding constant, which has no units and is most of the times positive, i.e.
the induced currents normally oppose ~B0, shielding the nucleus. For the same isotope, the
shielding constant depends on the electronic structure in the vicinity of the nucleus, which
changes depending on the molecular environment of the atom.
The change in the local magnetic field translates into in a shift of the Larmor or resonance
frequency:
ωL = γB0(1− σ ) (2.42)
Given that the change in frequency due to the shielding effects linearly scales with the external
magnetic field B0, the frequencies are often converted to chemical shift (δ) values which are
given in the "ppm scale" and are independent of B0. The conversion between a given resonance
frequency ω and the corresponding chemical shift (δ) value is made using a reference signal




× 106 + δref =
σref − σ
1− σref
× 106 + δref (2.43)
Where δref , ωref and σref correspond to the chemical shift, resonance frequency and shielding
constant of the reference signal. The multiplication by 106 (which explains the name "ppm
= parts per million", not to be confused with ppm used to describe chemical concentrations),
results from the differences in the resonance frequencies due to the shielding effects being
usually extremely small compared to the Larmor frequency. Another important aspect of the
ppm scale is that it is normally inverted, i.e. the numeric ppm values increase from right to
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Figure 2.6: Image showing a schematic example of a proton NMR spectrum of Creatine, showing the different resonance peaks
and the corresponding protons in the chemical structure (same color). Reference resonances from [Govindaraju 2000].
left. This is due to historical reasons, given that the first spectrometers searched for resonance
signals by increasing the magnetic field strength, which is inversely related with the shielding
constant.
One of the most commonly used reference signals is given by tetramethylsilane (TMS) which
provides a strong signal due to its 12 equivalent protons. By convention, the ppm value of TMS
has been defined as 0. Despite this, in in vivo applications water is most commonly used as
reference signal (δH2O = 4.7ppm).
The dependency of the resonance frequency on the "neighboring" atoms, means that, in the
same molecule, different nuclei (with non-zero spin) will have different frequencies depending
on their location. Some of these nuclei might be equivalent and have the same resonance
frequency. This can be the case for nuclei belonging to the same chemical group, as in −CH2
and −CH3 groups, where the protons of the same group are often chemically equivalent. The
ensemble of resonances corresponding to a given molecule constitutes its NMR spectrum and
given that, in most cases, is unique and can be regarded as the "chemical fingerprint" of the
molecule. This feature is what enables NMR spectroscopy to be used for chemical composition
analysis. Moreover, since for the same measurement conditions, the signal amplitude is
proportional the number of nuclei (equation 2.17), NMR spectroscopy allows not only to detect
the presence of a given compound but also to determine its quantity.
Figure 2.6 shows the proton NMR spectrum of Creatine, where the different resonance
peaks can be seen. The area of the 3 peaks is proportional to the relative number of protons
of each group. In this case, the relatively high electronegativity of the nitrogen, causes the
proton of the −NH group to be less "shielded" and consequently resonate at a higher frequency
than the protons from the other groups. Another interesting aspect of the spectrum is that the
protons of the −NH2 group are not visible given that they exchange extremely rapidly with the
solvent (water).
2.4.2 J-coupling
Besides the chemical shift, the magnetic moments of the different spins of the same molecule
can influence each other and affect their resonance frequencies. In those cases, the spins are
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said to be "coupled" and can not be described as two separate entities.
The effects of spin coupling can be described in terms of the energy levels of a group of nuclei
and the corresponding transitions. For a system of two protons, A and X, with considerably
different chemical shifts, there are 4 separate states. These states correspond to the different
combinations of the individual states of the two spins, i.e.: αAαX , βAαX , αAβX , βAβX . Taking in
consideration the energy of each spin:
E = −γ~mI (B0 − σ ) = −~ωmI , mI = −1/2,1/2 (2.44)
The energy of the system is given by the sum of the energies of both spins and the effect of
spin-spin coupling:
E = −~ωAmI,A − ~ωXmI,X + hJmI,AmI,X (2.45)
Where J is the scalar coupling constant in Hz, which reflects the strength of the interaction
between the two spins and does not depend on the strength of the external magnetic field. The
transitions associated with the different energy states can be given from expression 2.45, and
considering that for every transition only one spin changes its state:









Which means that the spectrum shows 4 peaks instead of 2. The 2 peaks corresponding to the
transition of one nucleus are centered in the corresponding Larmor frequency and separated by
J Herz.
For a AXn, where Xn are equivalent nuclei, the signals corresponding to the resonances of
the X spins only change in amplitude in proportion to the number of spins. In contrast, the A
resonances are further split with increasing number of equivalent protons. Moreover, since the
splitting always separates one peak in two new peaks centered in the original resonance and
separated by J Hertz, some of the resonances may have more than one origin. As a consequence,
the relative height of the resonances reflects the number of possible origins for each resonance.
This means that the splitting pattern in function of n, leads to 1 +n peaks whose heights follow
Pascal’s triangle. The number of peaks originating from the splitting is called the multiplicity
of the signal, and the naming convention depending on the number of peaks is: 1-singlet (s),
2-doublet (d), 3-triplet (t), 4-quadruplet (q), 5-quintuplet (quint), 6-sextuplet (sext), 7-septuplet
(sept), >7-multiplet (m). Figure 2.7 shows the splitting patterns for different multiplicities.
Whenever a spin is coupled to more than one spin, the corresponding splitting pattern is
a combination of the above-mentioned splitting patterns. For instance, if a spin A is coupled
with two other spins with two different coupling constants, J1 and J2, a doublet of doublets (dd)
is observed where the four lines correspond to the four different energy transitions given by:







Similarly, other combined patterns may be observed, such as doublet of doublet of doublets
(ddd), triplet of doublets (td), etc..
The splitting due to spin-spin coupling described above hold whenever J is considerably
smaller than the difference in resonance frequency between the two groups of coupled spins.
This is called the "weak-coupling". In the remaining cases, when J is close to the difference in
Larmor frequency of the coupled spins, the nuclei are said to be "strongly coupled" and the
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Figure 2.7: Splitting patterns originating from weak spin-coupling. The height of the peaks is proportional to its amplitude.
determination of the corresponding splitting patterns is considerably more complicated and
often performed using computer simulations. Given that J does not depend on the magnetic
field strength but the difference in resonance frequency does, a spin system can be either weakly
or strongly coupled depending on the field strength.
2.4.3 J-coupling evolution (J-modulation)
The classical description used in the previous sections is adequate to describe the evolution
of isolated spins in MRI-pulse sequences. However, the evolution of coupled spin systems
can only be described using quantum mechanics. Despite a complete description of quantum
mechanics being out of the scope of this thesis, a few important aspects necessary to understand
the evolution of coupled spins are here introduced. For the interested reader, more information
on the quantum mechanics description of NMR can be found in the source material of this
section: [Rule 2006, Keeler 2004, Slotboom 1991].
In quantum mechanics, the state of a system is described probabilistically, using wave
functions usually denoted as Ψ , that describe the probability of each state of the system. The
probability density associated with a wave-function is given as Ψ ∗Ψ , where Ψ ∗ is the complex
conjugate of the wave-function. Measurable quantities are described using operators, that when
applied to the wave-function, return the value of the observable multiplied by a wave-function.
The evolution of the wave-function in time follows the principle of conservation of energy and




Ψ = HΨ (2.48)
where i =
√
−1, ~ is the reduced Planck constant and H is the Hamiltonian operator which
represents the total energy, depending the exact form of the Hamiltonian on the system being
analyzed. In the specific case of NMR, the Hamiltonian is the sum of the Zeeman-energy,
RF-pulse energy, influence of gradient fields, and J-coupling.
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Given that the wave-function describes the probabilities of the different states, the observed
quantities corresponding to a group of identical particles can be determined as the expectation
values of the corresponding operators. For a given observable associated with an operator A,




Ψ ∗AΨ dχ (2.49)
where χ represents the coordinates of the coordinate-system in which the wave function is
defined.
In NMR experiments, it is necessary to describe an ensemble of spins and their associated
quantum states. In quantum mechanics, the description of an ensemble of quantum states
is usually performed using the density matrix operator σ whose elements correspond to the
average probability of all possible states of the ensemble. The expectation value of a given
observable can be calculated from the density matrix as:
A = trace(σA) (2.50)
The evolution in time of the density matrix can be derived from the Schrödinger equation
and is given by the Liouville-von Neumann equations ([Canavagh 2007]):
dσ
dt
= −i[H,σ ] (2.51)
where [A,B] = AB−BA is the commutator of the operators A and B.
The density matrix for a system with a single spin (with I = 1/2) can be described using a
linear combination of 4 operators: U , Ix, Iy and Iz where U is the identity operator and Ix, Iy
and Iz are the angular momentum operators in each spatial direction. Considering quadrature
detection and the operator describing the transverse angular momentum Ixy = Ix + iIy , the FID
can be obtained as the expectation value of Ixy .
A system containing two coupled spins requires not only 4 operators but also the ones
that account for the spin-spin coupling. The complete system is described by 16 independent
operators: U , I1x, I1y , I1z, I2x, I2y , I2z, I1xI2x, I1xI2y , I1xI2z, I1yI2x, I1yI2y , I1yI2z, I1zI2x, I1zI2y
and I1zI2z. In this convention the subscript identifies the two spins and, as in the single spin
system, U corresponds to the unitary operator. The terms I1x and I2x represent in-phase
magnetization of spins 1 and 2 aligned along x. Similarly, I1y and I2y represent in-phase
magnetization components for each spin along y. The operators I1xI2z, I1yI2z, I1zI2x and I1zI2y
correspond to anti-phase magnetization. Only the in-phase operators are directly related with
observable quantities. However, as will be shown, in coupled spins the anti-phase components
are connected with the in-phase magnetization and consequently can be indirectly observed.
The different operators and corresponding line-shapes are presented in Figure 2.8.
The Bloch equations for system of two strongly coupled spins can be derived from the
Liouville-von Neumann equations, as described in [Slotboom 1994a], leading to the following
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Figure 2.8: Different product operators of a two-spin coupled system. The in-phase operators were colored in green and the
anti-phase operators in red. The operators in gray correspond to non-observable quantities. For all observable operators, the
corresponding line-shape is displayed, where Ω1 and Ω2 correspond to the Larmor frequencies of each spin. Material used for
image: [Keeler 2004, Rule 2006].













































































































=Ω1I1yI2x +Ω2I1xI2y −ωyI1zI2x −ωyI1xI2z
dI1yI1y
dt
=−Ω1I1xI2y −Ω2I1yI2x +ωxI1zI2y +ωxI1yI2z
dI1zI1z
dt
=−ωxI1yI2z −ωxI1zI2y +ωyI1xI2z +ωyI1zI2x
dI1xI1y
dt
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In these equations ωx and ωy are the frequencies of the x and y components of the amplitude-




where ω1 and ω2 are the Larmor frequencies of each spin, and ω(t) is the frequency of the
frequency-modulated pulse component. The terms containing a † sign correspond to terms
that are only relevant for strong-coupling and may be ignored for weakly-coupled spins. These
equations show that the evolution of the magnetization of coupled spins is tightly connected to
each other through the J-coupling terms. In the previously described Bloch equations derived
using classical mechanics (equations 2.14) these terms are missing, showing that the classical
description of NMR is unable to describe the evolution of coupled spin systems.
A manifestation of the effects described by these equations is seen, for instance, in the
TE-dependent line-shapes of coupled spins. It can be shown that in a spin-echo the 180° pulse
does not affect the evolution under J-coupling. Consequently, the conversion between in-phase
and anti-phase magnetization leads to different line-shapes depending on the TE and the
J-coupling constant. Pure in-phase magnetization is observed for T E =m/J , with m = 1,2,3, . . . ,
being the signal negative for odd m numbers, and positive for even m numbers. In brain MRS,
one of the most common examples of this is the doublet of lactate at 1.3ppm, which has a
coupling constant of about 6.933Hz ([Govindaraju 2000]). This means that the lactate doublet
is inverted for echo-times of about 144 ms, and shows a positive doublet for TE values around
288 ms. For very short echo times, since there is no time for J-evolution to occur, only positive
in-phase magnetization is observed. Finally, it should be emphasized that at 1.5T most of the
metabolites assessed in vivo contain spins that are strongly coupled.
2.5 In vivo Magnetic Resonance Spectroscopy (MRS)
In this section, we will introduce some of the most important pulse sequences used for clinical
in vivo MRS.
2.5.1 PRESS sequence
The PRESS (Point RESolved Spectroscopy) sequence[Bottomley 1987] is one of the most widely
available and commonly used sequences for in vivo MRS and is the sequence that was used
to acquire the data explored in this thesis. The diagram of the PRESS sequence is shown in
Figure 2.9. As it can be seen, the PRESS sequence shares some of the elements of the spin-echo
sequence but includes some important adaptations. As in the SE-sequence, PRESS starts with a
slice selective excitation pulse which is followed by a refocusing pulse, however, PRESS includes
a second refocusing pulse. The working principle of PRESS is that only those spins that are
excited and properly refocused in a given Volume of Interest (VOI) contribute to the localized
signal. This is done by applying 3 orthogonal gradients, each one accompanying one of the
three selective RF-pulses. During acquisition, no readout gradient is applied to guarantee that
the observed differences in resonance frequency only originate from chemical-shift effects.
PRESS, as the other MRS sequences presented in this chapter, can be used to acquire a
single spectrum originating from a single VOI or MRS voxel (Single Voxel Spectroscopy - SVS),
or multiple spectra from multiple voxels contained in the spatially selected VOI (Magnetic
Resonance Spectroscopic Imaging - MRSI). In MRSI, spatial encoding is performed by adding 2
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Figure 2.9: PRESS sequence diagram.
(or 3) orthogonal phase encoding gradients to the sequence. The use of no readout gradient
means that, for every TR, instead of reading one line of k-space, only the information of a
single k-space coordinate is collected. This difference makes PRESS considerably slower than
conventional MRI sequences such as the SE or GE. Due to clinical time constraints, the slower
acquisition speed translates into PRESS-MRSI being normally acquired with a considerably
lower spatial resolution than structural MRI images.
Finally, the amplitude of the steady-state PRESS signal, not considering coupling effects, is
identical to the spin-echo, i.e.:





The STEAM (Stimulated Echo Acquisition Mode) sequence[Frahm 1987] is, together with
PRESS, one of the most frequently used sequences for in vivo MRS. The main difference
between STEAM and PRESS is that STEAM uses 3 90° selective excitation pulses and no
refocusing pulses (see Figure 2.10). The first pulse rotates the magnetization vector into the
xOy plane. After this pulse, the spins dephase due to T ∗2 effects and a second selective pulse
is applied which brings the magnetization into the z-direction. Assuming that before the
second pulse the magnetization was equally distributed along the xOy plane, only about half
of the magnetization is successfully brought along the z-direction. After the second pulse,
the signal decays due to T1 relaxation effects. Finally, the third pulse is applied which brings
the magnetization back to the transversal plane. Given that the phase of the spins is inverted
relatively to the moment immediately before the second pulse, a stimulated echo is created
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Figure 2.10: Schematic diagram of the STEAM pulse sequence.
after a period τ equivalent to the time between the first two pulses, i.e., T E = 2τ . The period
between the second and third pulses is called mixing time (TM). The signal amplitude of the
stimulated echo is, without considering coupling effects, given by:








Since selective pulses have less SAR and a better selection properties, STEAM normally leads to
smaller energy deposition and has better spatial selectivity than PRESS. However, these benefits
come at the price of SNR reduction, which in theory is about half of that which can be achieved
with PRESS for the same echo-time. The SNR and selection properties of PRESS and STEAM
are further discussed in chapter 5, section 5.3. Another advantage of STEAM is that it allows
for shorter TEs[Moonen 1989] since during the mixing time the signal does not decay with T2,
which means that less components need to be placed during the time equivalent to TE. Despite
these advantages, the greater SNR of PRESS makes it superior for long TE acquisitions.
2.5.3 SADLOVE/LASER sequence
Non-adiabatic pulses, such as the ones used in PRESS and STEAM, require homogeneous B1
fields to work properly. Therefore, given that at higher field strengths (>3T ), homogeneous
B1 fields are more challenging to achieve[Ibrahim 2007], sequences using adiabatic pulses
are desired. Moreover, when compared to conventional pure amplitude modulated pulses,
adiabatic pulses have normally a considerably larger bandwidth at the same SAR. This allows
to reduce the Chemical-Shift-Displacement-Artifact (CSDA), which increases linearly with the
field strength and decreases with RF-pulse bandwidth. The CSDA is described in more detail in
section 5.5.4.
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Figure 2.11: Schematic diagram of the SADLOVE (also known as LASER) pulse sequence.
Figure 2.12: Variation of SADLOVE (also known as semi-LASER) sequence diagram.
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In order to solve some of the issues with spectroscopy acquisition at high field strengths,
a fully adiabatic localized MRS sequence was developed in 1991 by Slotboom et al.
[Slotboom 1991]. The sequence, named Single shot ADiabatic LOcalized Volume Excitation
(SADLOVE)[Slotboom 1991], was later on published with a different name (Localized by Adi-
abatic SElective Refocusing - LASER[Garwood 2001]) that is more commonly used. The se-
quence diagram of SADLOVE/LASER is presented in Figure 2.11. SADLOVE starts with
an adiabatic non-selective half-passage excitation pulse that brings the magnetization to the




where Ω0 is the pulse amplitude, β is the damping constant, µ is the selectivity constant
and i =
√
−1. The need to use pairs of identical 180° pulses results from the non-linear offset
frequency dependent phase variations produced by the first pulse, which are canceled by the
second identical pulse[Zhu 2011]. Spatial selection is achieved by accompanying the 3 pulse
pairs with 3 orthogonal selection gradients.
Besides the advantages of SADLOVE/LASER, i.e. insensitivity to B1-inhomogeneities and
low CSDA, the sequence does not allow for very short TE values, since all pulses and gradients
need to fit in the interval corresponding to TE. To solve this, the first adiabatic excitation
pulse can be substituted by a non-adiabatic slice selection pulse which enables removing one
of the selective-refocusing pairs. This variation of SADLOVE/LASER is referred to as semi-
LASER[Slotboom 1994b, Scheenen 2008] and the corresponding sequence diagram is presented
in Figure 2.12.
2.5.4 SNR relation in MRS
In MRS, since the concentration of the metabolites of interest is usually very low, the pulse
sequences are performed multiple times and relatively big selection volumes are normally used.
If hardware and RF coil step considerations are ignored, the SNR relation for a given metabolite
X can be approximated as described in ([Philips 2016]), by:
SNR ∝ B0V [X]
√
ttotal = B0V [X]
√
N · tacquisition (2.57)
where ttotal is the total measurement time, tacquisition is the acquisition time for each repetition,
N is the number of repetitions, V is the volume and [X] is the molar concentration of X. As
shown in this equation, the SNR increases with
√
N given that the signal scales linearly with the
number of repetitions but the (stochastic) noise scales with the square root of the measurement
time.
2.5.5 Water and Lipid Suppression
Water and lipids are considerably more abundant in the human body than almost every target
metabolite that can be assessed in vivo. Consequently, water and lipid high signal amplitudes
can obscure the proper assessment of other metabolite signals. In order to solve this, frequency
selective pulses that only rotate the magnetization of spins whose chemical shift is within a
narrow band can be used. Once these spins are in the transverse plane, crusher gradients are
used to destroy the phase coherence of the selected spins. This technique is called CHESS
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(CHEmical Shift Selective) and depending on the frequency band used for selection it can be
used to eliminate the signals originating from water, lipids or any other resonances within a
certain ppm range. In the brain, CHESS is often included as the first block of the spectroscopy
sequence and is often applied in two different ways:
1. Water suppression - water suppression is normally performed in the whole FOV, i.e., no
selection gradients are used when the CHESS pulses are applied.
2. Lipid suppression bands - lipid suppression is often performed to prevent the signals
originating from the scalp to contaminate brain spectra. However, given that lipids
(and lactate, whose major resonances are located in the same frequency range) contain
relevant information for the assessment of several diseases, namely brain tumors, often
the elimination of the lipid signals in the VOI is not of interest. Therefore, the chemical
selective pulses are accompanied by selection gradients that allow the pulses to be applied
only in certain regions.
2.6 MR Spectroscopy data explored in this Thesis
The work presented in this thesis explored a dataset of MRSI examinations collected from brain
tumor patients. The acquisition was performed using the PRESS sequence (TE=135 ms and
TE=30 ms, TR=1500 ms) combined with CHESS water suppression and using 1.5T Siemens
scanners (models ‘Aera’ and ‘Avanto’, Siemens, Erlangen, Germany). The MRSI data had an
original resolution of 12x12, with a voxel size of 13.33x13.33x15 mm, and was interpolated
before DICOM storage to a resolution of 32x32 and a voxel size of 5x5x15 mm. Other details
concerning the data used in each experiment/study are described in the corresponding chapters.
The measurements were performed in conformance to local and national ethical regulations,
meaning that all patients gave their written informed consent that their data could be used for
scientific purposes.

3 | MRS Data Processing & Machine Learning
After data acquisition, processing of MR spectra is required to enable the proper analysis of the
acquired data. This chapter provides an overview of the most commonly used (pre) processing
steps in MRS. The different methods presented here are available in the software tool jMRUI
(www.jmrui.eu). From these, the majority is implemented in a novel jMRUI plugin named
SpectrIm (Figure 3.1) that was developed during this thesis. Table 3.1 shows all different
methods that were implemented in SpectrIm, as well as the methods from jMRUI that can be
controlled from SpectrIm. Besides the methods shown in this table, a user may access all other
jMRUI’s methods by exporting the data from SpectrIm to jMRUI’s main interface.
Most methods included in Table 3.1 are described in different sections of this chapter.
However, the advanced methods that are considered to be the core of this Ph.D. thesis are
presented in their own chapters, i.e.:
• Automatic quality control: chapters 6, 5 and 7.
• Brain Tumor Spectroscopic Imaging Segmentation (BraTSIS): chapter 10.
• Expected Distance to Tumor (EDT) maps: chapter 11.
All of the advanced methods developed during the Ph.D. programme are based on machine
learning. Consequently, this chapter finishes with a section describing the main concepts of
machine learning and the main machine learning algorithms explored in the next chapters of
this thesis.
Table 3.1: Methods available in SpectrIm. The table shows which methods were implemented in SpectrIm and which methods
from jMRUI can be can be controlled from SpectrIm through the batch processing interface. (X)-The two newest methods are not
yet available in the distributed version of SpectrIm.
Method Chapter/Section Aim SpectrIm jMRUI
HLSVD section 3.1.1 residual water removal X
Automatic Quality Control chapters 6, 5, 7 filter bad quality spectra X
Apodization section 3.1.2 reduce noise X
Zero-filling section 3.1.3 interpolate spectra X
Frequency-shift correction section 3.1.4 align spectra X
Auto-phasing section 3.1.5 adjust phase X
QUEST section 3.1.6 quantification X
BraTSIS chapter 10 assist interpretation (X)
Expected Distance to Tumor chapter 11 assist interpretation (X)
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Figure 3.1: Main Graphical User Interface of SpectrIm. The figure shows a Cho/Cr map of a initial diagnostic acquisition of a
GBM patient. MRSI data acquired at 1.5T, long TE (135 ms), PRESS.
3.1 Conventional MRS Post-Processing Methods
3.1.1 Residual water removal using Hankel Lanczos singular value decomposi-
tion (HLSVD)
Water signals have an amplitude several orders of magnitude greater than most of brain
metabolites and, consequently, water-suppression techniques such as CHESS (section 2.5.5)
are often required to enable the proper quantification of brain metabolites. However, in most
situations water suppression is not complete, and a residual water signal is still left with
an amplitude often superior to the amplitudes of the metabolites of interest. The residual
water signal can influence the quality of quantification and, as it is discussed in chapter 6, the
performance of automatic quality control. Thus, elimination of the residual water signal is an
important post-processing step.
Residual water peak removal can be performed using the Hankel Lanczos singular value
decomposition (HLSVD) method. HLSVD is a method used to decompose a time-domain signal






where Ak , ωk , φk and αk are, respectively, the amplitude, frequency, phase and damping factor
of the kth component.
For water removal, a frequency window for the exponential components corresponding
solely to the residual water peak is set. Finally, once the different components with ωk corre-
sponding to the water resonance are estimated, residual water peak removal is performed by
simply subtracting those components from the original signal.
The determination of the different components is made using the Lanczos algorithm
[Pijnappel 1992, de Beer 1992], which is used to accelerate the Singular Value Decomposi-
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Figure 3.2: Proton NMR spectrum of the brain before and after residual water removal with HLSVD (jMRUI implementation).
tion (SVD) of the Hankel matrix form of the time-domain signal. Considering a time-domain
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After SVD, the singular values correspond to the amplitudes Ak , and the singular vectors to the
exponentially damped sinusoids.
The impact of the selection of the parameters N , M and K in HLSVD’s performance for
residual water removal is discussed in [Cabanes 2001], and the jMRUI implementation of the
HLSVD algorithm is presented in [Beer 2015]. Figure 3.2 shows a brain spectrum before and
after residual water peak removal.
3.1.2 Apodization
Apodization is a time-domain filtering technique used to improve the SNR of a spectrum. Signal
filtering is performed by multiplying the time-domain signal with a weighting function, i.e.:
s′(t) = s(t) ·W (t,θ) (3.3)
The weighting function W (t,θ), where θ represents the parameters of the function, usually
assigns higher weights to the points closer to the maximum of the time-domain signal, and
lower weights to the points far from the maximum where the signal is dominated by noise. In





where AGauss and Aexp are, respectively, the Gaussian and exponential line broadening factors
given in frequency units. The choice between these two filters depends on the type of line shape
(Lorentzian, Gaussian or Voigt) considered in the quantification model.
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Figure 3.3: Frequency and time domain MRS signals (PRESS, 1.5T, TE=135ms) of the brain, before and after gaussian and
exponential apodization with 5 and 20 Hz.
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Figure 3.4: Zero-filling applied to increase the spectral resolution by a factor 4.
Figure 3.3 shows an example of spectra before and after apodization with a Gaussian and
an exponential weighting functions. In these examples, the denoising effect is well visible, as
well as the (undesirable) line-broadening that results from the apodization.
3.1.3 Zero-filling
Zero-filling, or Fourier interpolation, is an interpolation technique that explores the "scaling"
properties of the Fourier transform.
In the previous chapter, the following relationship between bandwidth and spatial resolution





where r is a given spatial direction with a pixel spacing ∆r, and BWr is the bandwidth of the





where Tacq is the acquisition time and ∆f is the frequency spacing of the spectrum. From this
relation, it follows that an increase in the duration of the signal (Tacq) leads to an increase in the
spectral resolution. Zero-filling is an interpolation technique where the duration of the signal
is artificially increased by adding zeros to the end of the time-domain signal. After Fourier
transformation of the zero-filled time-domain signal, an interpolated spectrum is obtained.
Figure 3.4 shows the result of applying zero-filling to increase the spectral resolution of a
spectrum by a factor 4.
Zero-filling can also be used to interpolate MR images by extending the k-space with zeros,
as implied by equation 3.6.
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3.1.4 Frequency-shift correction
B0-drifts, as well as changes in temperature and pH, cause frequency shifts to the resonances
of the NMR spectra. B0-drifts affect all resonances equally and, consequently, if the reference
frequency is adequately set, no changes in the ppm position of the peaks is observed. However,
when B0 changes and the synthesizer frequency is not adapted accordingly, the different
metabolite peaks are recorded with a shifted frequency. Similarly, hardware problems that
cause changes in the frequency of the synthesizer may lead to the same effect.
In contrast, frequency shifts due to temperature and pH changes affect different spins
differently, causing resonance-specific ppm shifts. This effect can be used to determine the
temperature from a proton NMR spectrum. In order to do so, the differences between the
resonances of the main metabolites seen in the brain (water, Cho, NAA and Cr) can be used,
as described in [Zhu 2008]. For pH measurements in the brain, however, either phosphorus
spectra or proton spectra of exogenous compounds are used, given that the main metabolites
visible in proton spectra do not provide enough information for measuring pH [Coman 2009].
Given that several methods rely on the exact ppm location of certain peaks to work properly
(e.g. quantification and machine learning methods based on ppm-dependent features), the
correction of the frequency shift is an important post-processing step. Most frequency-shift
correction methods aim at correcting the global shift that affects all peaks of the same spectrum.
Therefore, even after frequency shift correction some metabolite peaks might be displaced due
to pH and temperature effects. As will be discussed further in this chapter, in the quantification
section (section 3.1.6), quantification algorithms often allow the different peaks of the metabolite
model to shift relatively to each other in order to accommodate metabolite-specific shifts.
Different approaches have been used to perform frequency-shift correction. In the INTER-
PRET project [Pérez-Ruiz 2010], for instance, an alignment algorithm was defined that used
an hierarchical approach where a reference peak between choline, creatine and lipid (1.3),
is selected based on the relative height. After selection of the reference peak, a ∆ppm shift
corresponding to the difference between the location of the reference peak and its reference
ppm value is applied to the spectrum. This method has the advantage of using fixed ppm
references that are used to aligned all spectra, facilitating result comparison between different
acquisitions. However, a very limited amount of information is used in the alignment process,
namely only the position of the maximum corresponding to the selected reference peak, which
may sacrifice the robustness of the method.
A different approach, named Spectral Registration, is proposed by Near et al. [Near 2015].
Spectral registration of a signal S is performed by least squares minimization of the difference




This method has the advantage of using more information than the previous given that the
whole signal is used for alignment. However, it depends on the selection of an appropriate
reference signal. In focal diseases, for instance, the spectra of the lesion may vary considerably
relatively to a normal brain spectrum, possibly causing the alignment method to fail when
the differences between the reference signal and the signal to be aligned are too big. In such
situations, the Spectral Registration method can be adapted to allow for multiple reference
signals. After performing the minimization with the different reference signals, the result with
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Figure 3.5: GUI of SpectrIm’s frequency shift correction method.




where Rk(t) is the k-th reference signal.
In SpectrIm, a novel (yet unpublished) method was implemented that combines some of
the approaches used in the previous methods. The method was developed to allow robust




In the global alignment step, the global shift (∆δGlobal) is determined using the magnitude
of the average spectra of all of the selected voxels. This allows for the global shift to be
determined using a spectrum with higher SNR. Moreover, given that peaks with higher SNR are
more reliable, the global shift is determined as the SNR-weighted average over the N detected
peak-shifts ∆δl , where l is the index of the reference peak:
∆δGlobal =
∑N
l=1 I(SNRl) · SNRl ·∆δl∑N
l=1 I(SNRl) · SNRl
, I(SNRl) =
1, SNRl ≥ T0, SNRl < T (3.10)
In this expression, the indicator function I(SNR) ensures that only peaks with an SNR above
a defined threshold T are considered. The peak-shifts ∆δl are calculated as the difference
between the reference chemical shift of the peak and the observed chemical shift in the average
spectrum. For peaks with odd multiplicity, the target chemical shift is the maximum value in a
defined interval. In contrast, for peaks with even multiplicity, like lactate and citrate, the axis
of symmetry is used instead and the reference δ value is provided accordingly. In SpectrIm, the
information concerning the reference peaks can be stored in a reference peak library (Figure 3.5),
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Figure 3.6: Short and long TE frequency domain signals before and after frequency shift correction using SpectrIm’s algorithm
(see description in main text). Different colors were used to discriminate solid tumor/necrosis spectra (blue) from the remaining
spectra (red), showing that the method robustly corrects different types of spectra.
from which the user can select which peaks to use as reference for the alignment task. After
determining ∆δGlobal , the shift is removed from the selected spectra.
The local alignment step aims at identifying the MRSI grid voxel-specific shifts, denoted
as ∆δi,j,k, where (i, j,k) are the voxel coordinates. This is done by determining the local shift
that maximizes the correlation between the magnitude spectrum of the voxel (i, j,k) and the
magnitude of the average spectrum, i.e.:
∆δi,j,k = ∆δGlobal + argmax
−K≤∆δ≤K
(corr(Xi,j,k[δ −∆δ], X̄[δ])) (3.11)
where K is the maximum allowed local shift defined by the user.
Once all local shifts are determined, the outlier correction step is performed which ensures
that there are no abrupt changes between the ∆δi,j,k of neighboring voxels. Outlier correction is
made using a Hampel Filter [Pearson 2016]:
∆δi,j,k =

∆δi,j,k , |∆δi,j,k − ∆̃δi,j,k,R| ≤ C · MAD
r∈[−R,R]
(∆δi+r,j+r,k+r )




where C is a user defined constant and MAD
r∈[−R,R]
(∆δi+r,j+r,k+r) and ∆̃δi,j,k,R are, respectively, the
median absolute deviation and the median of the voxel-specific shifts in the neighborhood R
around the voxel (i, j,k).
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Figure 3.7: Selective auto-phasing performed using the method described by expression 3.15 in the chemical shift interval
[0,5]ppm. The spectra of two different regions with different phase errors was colored differently to highlight their phase dif-
ferences. All spectra belong to the same MRSI grid of a GBM patient. Acquisition details: PRESS, 1.5T, TE=135ms.
Figure 3.5 shows the GUI of SpectrIm’s frequency shift method where the different pa-
rameters that can be set by the user are visible, and Figure 3.6 shows the spectra of an MRSI
acquisition of a GBM patient, showing the robustness of the method to align different types of
spectra.
3.1.5 Auto-phasing
As described in section 2.2.6, the NMR signal originates from an oscillation of the transverse
components of the net magnetization, Mx and My . The oscillation is detected as two separate
signals sx(t) and sy(t), which can be seen as the real and imaginary parts of a complex time-
domain signal s(t), with amplitude A, frequency ω and phase φ:
s(t) = sx(t) + isy(t) = Acos(ωt +φ) + iAsin(ωt +φ) = A · ei(ωt+φ) (3.13)
where relaxation was not included and only zero-order phase was considered. Since the initial
phase of the signal is often non zero, phase correction often needs to be performed. Zero-order
phase correction of the whole signal (global-auto-phasing) can be performed using the first point
of the time-domain signal:




Global-auto-phasing of the signal can be performed whenever the different resonances of the
signal have identical phases. However, in many cases this is not the case and it is interesting to
selectively phase only some of them (selective-auto-phasing). This can be done by determining
the phase that maximizes the sum of the absorption of the frequency-domain signal in a given
chemical shift range [δmin,δmax], i.e.:







For this method to work properly, the limits of the chemical shift interval selected should
not coincide with any peak. An example of the results of this method for the auto-phasing of
all spectra of one MRSI grid are shown in Figure 3.7.
3.1.6 Quantification (QUEST)
Quantification aims at extracting metabolite quantities from MR spectra. Depending on the
acquisition and quantification method used, quantification can result in absolute concentration
values (absolute quantification), or be semi-quantitative, when the output is in the form of
relative metabolite quantities. Absolute metabolite quantification, despite desirable, requires in-
formation that is not always available, such as: the tissue/compartment fractions for each voxel,
the relaxation properties of the different metabolites in the each compartment, and the knowl-
edge of the evolution of the spins for the sequence used ([Gaparovic 2016, Slotboom 1998]).
Consequently, semi-quantitative methods are more frequently used in in-vivo clinical applica-
tions of MRS.
In this thesis, semi-quantitative quantification was performed using QUEST (QUantita-
tion based on QUantum ESTimation, [Ratiney 2004, Ratiney 2005]). The QUEST algorithm
performs quantification by modeling the acquired time-domain signal of dimension N , with
sampling interval ∆t, as a combination ofM different known metabolite signals x̂m, as described





m[n]e(∆αm+i∆ωm)(n∆t+t0)+i∆φm , n = 1, . . . ,N (3.16)
where x̂ is the model estimate of the signal, x̂m is the m-th metabolite signal of the pre-defined
basis set, i =
√
−1, φ0 is the global phase of the signal, t0 is the dead time of the receiver, am is
the amplitude of the m-th metabolite signal, and ∆αm, ∆ωm and ∆φm are the adjustments to the
damping factor, angular frequency and phase shifts of the m-th metabolite signal. Therefore,
QUEST receives as input the different signals x̂m, and estimates the relative amplitudes of the
different metabolites, as well as the other described model parameters. The estimation is made
by minimizing the squared euclidean distance between the estimated and the acquired signals
using the Levenberg-Marquardt algorithm, i.e.:
θ̂ = min
θ
||x − x̂(θ)||2 (3.17)
where θ is the vector of the 4M + 2 parameters estimated by QUEST:
θ = [φ0, t0, a1, . . . , aM ,∆α1, . . . ,∆αM ,∆ω1, . . . ,∆ωM ,∆φ1, . . . ,∆φM ] (3.18)
Besides the parametric model of expression 3.16, QUEST is also able to estimate the macro-
molecular background signal. This is done under the assumption that the background signals
decay rapidly and are mainly present in the first points of the time-domain signal. Conse-
quently, in order to estimate the background signal, the first L points of the signal are truncated,
and the previously described parametric model is fitted to the truncated signal. Then, the
signal defined by the fitted parameters is extrapolated back to t = 0, which results in a signal
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estimate x̂Met. The estimate of the background signal b̂ is given by the subtraction between the
original signal, x, and the estimate of the signal based on the truncated signal, x̂Met, i.e.:
b̂ = x − x̂Met (3.19)
The estimate of the background, b̂, can then be used in two different manners: InBase and
Subtract. In the first approach, b̂ is added to the basis-set as the M+1 metabolite, and QUEST is
executed again to model the original acquired signal. In the second approach, the determined
background signal is subtracted from the original signal and the resulting signal is then modeled
using the described parametric model.
3.2 Machine Learning
Machine learning is, as described by Arthur Samuel in 1959, the "field of study that gives
computers the ability to learn without being explicitly programmed". A more precise definition of
machine learning was given later, in 1997, by Tom M. Mitchel:
"A computer program is said to learn from experience E with respect to some class of tasks T and
performance measure P, if its performance at tasks in T, as measured by P, improves with experience
E".
Machine learning has allowed to solve problems that, given their degree of complexity,
couldn’t be solved in the past using traditional programming, where the behavior of the program
for every situation is explicitly defined. One of the most famous examples of such a problem
is the development of bots, i.e. software agents that act as players, for the board game Go.
Currently, the most successful Go bot is AlphaGo, the computer program that defeated the
world champion of Go for the first time. As explained in the original paper [Silver 2016], the
number of possible sequences of moves in Go is approximately 250150, making it virtually
impossible, using current computers, to compute the optimal move by exhaustive search.
AlphaGo works by learning how to evaluate board positions and to select moves. This is done
using reinforcement learning, a type of machine learning methods that is described below. The
first versions of AlphaGo were initialized by training from human data and improved by self
play. However, the most recent version of AlphaGo, Alpha Go zero [Silver 2017], has learned
completely from scratch, starting with random play and learning by playing against itself.
Due to the increasing amount of available data and computing power, in part due to the
advent of smart-phones, machine learning has become increasingly popular in the most recent
years, as shown by the increasing google searches on the topic (Figure 3.8).
Machine learning methods can be distinguished in 5 main categories (https://en.
wikipedia.org/wiki/Machine_learning):
1. Supervised Learning - Methods that learn from labeled data a function that, for a given
input, predicts the output. Depending on whether the output is a continuous or a discrete
variable, the learned model is referred to as, respectively, a regressor or a classifier.
2. Semi-Supervised Learning - Methods that aim at improving the performance of super-
vised learning using, besides the available labeled data, additional unlabeled examples.
3. Active Learning - Methods that aim at improving the learning efficiency of supervised
methods by allowing the model to actively select the examples that carry the most
information for training.
44 3. MRS Data Processing & Machine Learning
Figure 3.8: Popularity of the searches on "Machine Learning" in the past years. The y-axis shows the relative popularity index,
which corresponds to the % of total number of searches in a given period of time on the topic "Machine Learning" rescaled to
[0,100]. Source: Google Trends, https://trends.google.com/trends/explore?date=all&q=%22Machine%20Learning%22
4. Reinforcement Learning - Methods with a predefined goal that learn through its interac-
tion with a dynamic environment.
5. Unsupervised Learning - Methods that learn the structure of unlabeled data. The most
common example of unsupervised learning corresponds to clustering algorithms that
identify clusters or groups in a given dataset.
In this thesis, different machine learning algorithms were used to develop novel MRS
processing methods that aimed of tackling some of the difficulties associated with the clinical
use of in vivo MRS. The main machine algorithms explored in this thesis, i.e. random forests,
cNMF and X-means, are described in the next sections of this chapter. Furthermore, the
machine-learning based methods for MRS data processing are described in the next chapters,
more precisely:
• Chapter 6 describes the use of a supervised method that is capable of learning to discrimi-
nate "good" quality from "bad" quality spectra based data labeled by two spectroscopists.
The presented method is based on the Random Forests classifier [Breiman 2001, Liaw 2002].
Chapter 6 presents the results of the method for long TE data. The results for both short
(30 ms) and long TE (135 ms) data are described in chapter 5.
• Chapter 7 continues the work on automatic quality control and evaluates the use of an
active learning approach to increase the efficiency of the labeling required to train the
automatic quality control classifier.
• Chapter 8 presents the results obtained with an unsupervised method named convex Non-
Negative-Factorization (cNMF) ([Ding 2010, Ortega-Martorell 2012b]) that is used to
learn a basis of spectra. The determined vectors are then used to perform fuzzy clustering
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Figure 3.9: Schematic representation of a decision tree and its nodes.
of the spectra. The method was used to highlight differences between the spectra of GBM
and metastasis patients.
• Chapters 9 and 10 describe the use of an (unsupervised) clustering method, named X-means
[Pelleg 2000] that is used to identify the main groups of spectra existent in MRSI exami-
nations of GBM patients.
• Chapter 11 describes the use of a supervised method, named Regression Forest
[Breiman 2001, Liaw 2002], that is used to estimate the distance to the solid part of
the tumor based on features extracted from individual spectra.
3.2.1 Random-Forests
Random forests (RF) [Breiman 2001] are supervised learning models that consist of an ensemble
of randomly generated decision trees (Figure 3.9). The RF algorithm explores the concept of
bagging (bootstrap aggregating, [Breiman 1994]), in which a prediction is made by averaging
several versions of the same model, trained using different bootstrap1 samples of the training
set.
Bagging is used to improve the accuracy of a model by reducing the variance2 of its predic-
tions. Therefore, bagging is particularly interesting when applied to models with high variance
and low bias, such as decision trees, given that the bagging reduces the prediction variance but
not the bias [Hastie 2001]. The variance reduction achieved by bagging is limited by the corre-
lation between the averaged models, i.e. the greater the correlation, the smaller the reduction
in variance. Consequently, the random forests algorithm was developed as an improvement
to bagging where the correlation between trees is decreased by injecting randomness in the
creation of the decision trees. More precisely, in random forests, the input feature that is used in
each node to split the data is chosen from a randomly selected subset of m features. This allows
to reduce the correlation between the decision trees, and consequently increase the prediction
accuracy in comparison with pure bagging approaches[Hastie 2001].
1A bootstrap sample is a sample drawn from a dataset using random sampling with replacement.
2Prediction variance and bias are two components of the prediction error. Variance refers to the square of the
expected difference between each prediction and the expected value of the prediction. Bias, on the other hand,
refers to the difference between the expected prediction and the true value being predicted.
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The pseudo-code describing the random forests training process is presented in algorithm 1.
As it is described in line 12 of the algorithm, after randomly selecting m features in each node,
the feature that leads to the greatest reduction in "impurity" of the node is chosen. The lowest
possible "impurity" after splitting is achieved when each child-node only contains examples
of the same class. In contrast, the highest "impurity" level corresponds to a situation where
the class distribution is the same in all child-nodes. Thus, the use of an "impurity" metric to
drive the growth of the decision trees aims at generating leaf-nodes with members of only one
class. For a given node i, the decrease in "impurity" resulting from splitting the node into two
child-nodes is defined as:
∆Fi = Fparent − c1Fchild1 − c2Fchild2 (3.20)
where Fparent, Fchild1 and Fchild2 are the values of a given "impurity" metric F measured in
each node, and c1 and c2 are the weights of each child-node corresponding to the fraction
of examples of the parent-node that were moved to each one of the child-nodes. Different
"impurity" metrics for driving the selection of features in random forests are described in
the literature [Hastie 2001, Criminisi 2013, Menze 2009]. For classification, the most common










where M is the number of classes, and pi is the fraction of elements of class i in a given node.




(yi − ȳ)2 (3.23)
where yi is the value of the output variable for the case i and ȳ is the average value of the output
variable in all examples of the node. In this case, given that the RSS scales with the number of
examples in each node, the weights c1 and c2 of formula 3.20 are set to 1.
After training, the random forests model can be used to predict the output of a new example.
This is done by taking the following steps:
1. In every tree, the test example is placed at the root-node and follows the path determined
by the splitting rules defined during training (Θi,j ).
2. The information (Θ′i,j ) collected from the training examples that, in each tree, reached the
same leaf-nodes as the new test example is used to generate a prediction in the following
manner:
• In the case of classification, majority voting is usually performed, where each tree
casts a vote. The vote corresponds to the majority class of the training examples that
reached the same leaf-node as the test example.
• In the case of regression, the prediction corresponds to the average value predicted
by all trees. The prediction performed by each tree may correspond to the average
value of the training examples that reached the same leaf-node as the test example.
However, other approaches can be used, as described in [Criminisi 2013].
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Algorithm 1 Random forests training pseudo-code.
1: for i = 1 to nT rees do
2: Draw a bootstrap sample Si from the training set with the same size as the training set;
3: Create a new tree Ti with a root-node ni,0;
4: Place the bootstrap sample Si on node ni,0;
5: Create a set Leaf Nodes = {ni,0};
6: Initialize node index counter: k = 0;
7: while Leaf Nodes , ∅ do
8: Select a node ni,j from set Leaf Nodes;
9: if NumberOf Examples(ni,j ) > minNodeSize then
10: Create 2 new child-nodes ni,k+1 and ni,k+2 and add them to set Leaf Nodes;
11: Select m features randomly;
12: From the m features, select the feature that splits the data of node ni,j with the
greatest reduction in "impurity"*;
13: Split the examples using the selected feature;
14: Move each part of the examples to the child-nodes ni,k+1 and ni,k+2;
15: Save selected feature and decision rule parameters used for splitting as Θi,j ;
16: Update node index counter: k = k + 2;
17: else
18: Save as Θ′i,j the information of the training examples of node ni,j that is required
for predicting the output of new test examples;
19: end if
20: Remove node ni,j from set Leaf Nodes;
21: end while
22: end for
*- The different measures of node "impurity" are described in the main text.
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As shown in algorithm 1, there are 3 main parameters of an RF model: (1.) the number of
trees (nT rees), (2.) the minimum size of samples required for a node to be split (minNodeSize),
and (3.) the number of randomly selected features per node (m). The selection of these
parameters is normally made with the following considerations in mind:
• Increasing nT rees leads to an asymptotic reduction in variance but a linear increase of
the computational costs. Consequently, the number of trees is usually chosen at the point
where the small gains in performance, obtained by further increasing the number of trees,
do not justify an increase in computational costs. Depending on the problem, this number
usually sits between 200 and 1000.
• The minNodeSize controls the complexity of each tree and, therefore, smaller bias is
usually associated with fully grown trees, i.e. minNodeSize = 1. However, when a consid-
erable amount of noisy variables are present, fully grown trees might be highly unstable
and may be prone to overfitting, namely when used for regression [Segal 2004]. Increasing
minNodeSize has a considerable impact on the computational costs, nevertheless, the pre-
diction performance is usually the main factor driving the decision on minNodeSize. The
selection of minNodeSize is problem specific, however, in most cases, the optimization of
this parameters leads to small gains in performance [Hastie 2001]. Consequently, this pa-
rameter is often not optimized. In the "R" implementation of random forests [Liaw 2002],
the standard value for minNodeSize is 1 for classification and 5 for regression.
• To understand the decision of the selection of m it is helpful to consider the two extremes
first, i.e. m = 1 and m = p where p is the total number of input features of the training set.
In the first case (m = 1), the selection of the splitting feature in each node becomes purely
random and consequently, the correlation between trees is minimal and the reduction in
variance is maximal. However, given the lack of optimization of the features used in each
node for splitting, the resulting decision trees will normally have a higher bias, which
will govern the prediction error of the random forests model. In the second case (m = p),
RF becomes essentially a pure bagging model. Consequently, the correlation between
decision trees is maximal and the reduction in variance minimal. In this case, the bias
is expected to be minimal, if overfitting is ignored, and the prediction error is governed
by the variance. In summary, the selection of m corresponds to an optimization of a bias-
variance trade-off and is problem specific. In the "R" implementation of random forests
[Liaw 2002], the standard value for m is
√
p for classification and p/3 for regression.
The simplicity and easy tunning of RF, combined with its elevated performance in various
problems, has made random forests very popular [Hastie 2001]. Moreover, the RF provides
some extra features that are extremely interesting in different problems: Out-Of-Bag (OOB)
error estimates and variable importance assessment.
The OOB error estimates are made by measuring the prediction error of the examples left
out of the bootstrap sample used for training each tree, i.e. using the OOB examples. In most
situations, the OOB error is a good estimator of the prediction error of the classifier and come
almost for "free", with a little extra amount of computation. However, in cases where the
bootstrap sample is not completely independent of the OOB sample, the OOB error estimates
may not generalize. In this thesis, for instance, OOB error estimates were not used given that
the datasets were always composed of spectroscopic voxels from several MRSI examinations.
Given that the sampling process of the random forests does not "know" the structure of the
data, the voxels from each MRSI examination would be found, in most situations, both in the
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bootstrap sample and the OOB sample, possibly leading to unrealistic performance estimations.
The problem is aggravated by the fact that the different voxels are obtained after interpolation,
meaning that the correlation between the voxels of the same examination is considerably
high. Moreover, given that voxels of the same patient are likely to be correlated, even if
originating from different examinations, the training and test sets used in the different projects
presented in this thesis separated always the data into different datasets at the patient level,
i.e. all the examples of the same patient were always placed in the same group (training,
test or validation). Alternatively, this problem could’ve been solved by including information
regarding the structure of the data on the sampling process that would sample the data at the
patient-level, instead of the voxel-level. Such a strategy could also potentially increase the
performance of the random forests models, given that it would reduce the correlation between
different trees.
Regarding feature importance, the RF algorithm offers 2 types of measures to evaluate the
relative importance of the input features: permutation-based and "impurity"-reduction-based.
The first type corresponds to the average increase in error measured in each OOB sample
after randomly permuting the values of a given feature between different Out-Of-Bag (OOB)
examples. The greater the error increase, the greater the importance of the permuted feature
for the predictions. The second type of measure assesses the contribution of each feature to
split the data into leaf-nodes with members of only one class. This is done by summing, for
each feature, the decrease in "impurity" (see equation 3.20) in all nodes where that feature was
chosen for splitting. Thus, the features with the highest overall reduction in node "impurity"
are deemed the most important. The feature importance measures described were used to
analyzed different random forests models presented in this thesis (chapters 5, 6 and 11). The
corresponding feature importance plots can be found in figures 5.7, 6.7 and 11.5.
3.2.2 cNMF
Non-negative-matrix-factorization (NMF) is a factorization method of the form [Ding 2010]:
X ≈ FGT (3.24)
where:
• X ∈Rp×n is matrix representing the input data with n examples of size p.
• F ∈Rp×k is a matrix whose rows correspond to a set of k basis-vectors, named the sources.
• G ∈ Rn×k is a positive matrix, named the mixing-matrix, whose elements correspond to
the reconstruction factors used to describe X as a positive linear combination of the
basis-vectors, or sources.
Convex-NMF (cNMF) is a variation of NMF, where the sources are determined as a convex
combination3 of the data points, i.e.:
F = XW =⇒ X ≈ XWGT (3.25)
where W ∈ Rn×k contains the coefficients that define the sources as a convex combination of
input data vectors. Compared to conventional NMF, cNMF has several interesting properties,
namely:
3 a convex combination is a linear combination where all coefficients are positive and their sum is 1.
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• The sources derived from cNMF are normally easier to interpret. In the case of the
application of cNMF to factorize a set of MR spectra, this means that the sources are often
"realistic" spectra, i.e. spectra that could potentially be observed. Conventional NMF, on
the other hand, usually produces "unrealistic" sources that do not correspond to plausible
MR spectra.
• In cNMF, the sources can be regarded as centroids, which allows interpreting cNMF as a
clustering method such as K-means.
• The matrices W and G in cNMF are usually very sparse.
• In conventional NMF, the data matrix X is required to be positive, however, in cNMF, X is
unconstrained.
A complete description of the cNMF algorithm is presented in [Ding 2010].
3.2.3 X-means
X-means [Pelleg 2000] is an extension of the clustering method K-means that defines a strategy
to determine the number of clusters K . This is performed following the algorithm 2, where the
minimum and maximum number of clusters, Kmin and Kmax, are user-defined model parameters.
Algorithm 2 X-means pseudo-code.
1: Initialize K = Kmin;
2: while K ≤ Kmax do
3: Perform K-means until convergence;
4: for each centroid ci do
5: BICi(k = 1)←BIC score of the local data associated with ci ;
6: Perform 2-means on the local data associated with ci , leading to centroids ci,1 and
ci,2;
7: BICi(k = 2)←BIC score of the local data after 2-means;
8: if BICi(k = 2) < BICi(k = 1) then
9: Substitute ci with ci,1 and ci,2;
10: end if
11: end for
12: Evaluate BIC-score of the clustering model considering all data points;
13: end while
14: Report model with highest overall BIC-score.
As it can be seen, the X-means algorithm is a hierarchical approach, where in each node
a decision is made on whether to divide the local data into two new separate clusters using
2-means (K = 2) or not. The decision is made based on the Bayesian information criterion,
defined as:
BIC = p log(N )− 2logL(X |θ) (3.26)
where logL(X |θ) is the log-likelihood of the data X according to the K-means model parameters
θ, p is the number of model parameters, and N is the number of data points of the data. BIC
corresponds to measure of the quality of the fit of a model to the data (log-likelihood term),
penalized by the model complexity (p log(N ) term). The lower the BIC value, the better the
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model. For local decisions on whether to subdivide a centroid, the data used to determine BIC
corresponds solely to the data points associated with that specific centroid. In contrast, the
overall BIC score calculated in step 12 of the X-means algorithm, considers all data points of
the input dataset.
A more in-depth description of the X-means algorithm is found in the original paper by
Dan Pelleg and Andrew Moore [Pelleg 2000].

4 | Brain Tumor Characterization using in vivoproton
MRS
As we saw on chapter 2, Magnetic Resonance Spectroscopy (MRS) allows the retrieval of lo-
calized biochemical information from different parts of the human body in a non-invasive
manner. The ability to detect metabolic changes in various tissues makes it a very appealing
technique for diagnostics, treatment planning, and follow-up of many diseases. Currently,
the main clinical applications of MRS are found in oncologic imaging[García-Figueiras 2016]
of the brain[Preul 1996, Howe 2003, Dowling 2001, Majós 2004], prostate[Costello 1999,
Mueller-Lisse 2007, Tayari 2017], and breast[Suppiah 2013, Cen 2014, Baltzer 2013], as well
as in the evaluation of several metabolic diseases affecting the brain[Zimmerman 2011,
Harting 2015, Razek 2014]. Other interesting applications include the assessment of neona-
tal hypoxic injury[Boichot 2006, Peden 1993] and the measurement of intramyocellular lipid
content in skeletal muscle to assess insulin sensitivity in pre-diabetic patients[Boesch 1999,
Boesch 2006].
This doctoral thesis is based on work performed in the Neuroradiology department of the
University Hospital Bern. Consequently, the main clinical application explored in this thesis
was brain cancer. Therefore, in the next two subsections, we first introduce the main brain
metabolites measurable with MRS and, then, discuss what motivates the use of MRS for the
clinical management of brain tumor patients.
4.1 Detectable Brain Metabolites in in vivo 1H-MRS
Figure 4.1 shows a normal brain spectrum acquired using PRESS, where the resonances of the
most important metabolites seen in healthy brain spectra can be seen. A brief description of the
most important brain metabolites observed at 1.5T are described below.
4.1.1 Choline
Choline is an important constituent of cell membranes and myelin sheets, and is a precursor
of the neurotransmitter acetylcholine [Govindaraju 2000, Mountford 2010]. In in vivo MRS,
choline produces one of the most easily identifiable singlets in brain NMR spectra at 3.2 ppm.
For simplicity, this resonance is frequently referred to just as choline, however, it originates
from several metabolites[Govindaraju 2000], namely: free choline, glycerophosphorylcholine
(GPC) and phosphorylcholine (PC). In the normal brain, the main contributors to the NMR
visible choline correspond to PC (0.6 mM) and GPC (1 mM). Free choline is only found in small
amounts in healthy brain tissue (<0.03 mmol/kg) but can be significantly elevated in tumors
due to the increased membrane turn over of tumor cells.
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Figure 4.1: Normal brain spectrum acquired using PRESS (135 ms). The spectrum was collected from the region demarked with
a red square in the reference image. The main visible peaks were assigned to the corresponding metabolites.
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4.1.2 Creatine
Similarly to choline, the commonly referred creatine spectrum contains contributions from
more than one metabolite, in this case, creatine and phosphocreatine. The main role of phos-
phocreatine is to act as an energy buffer[Greenhaff 2001], as it enables the process of converting
adenosine diphosphate (ADP) into adenosine triphosphate (ATP), generating creatine in the
process. Creatine is again converted into phosphocreatine in the sites of energy transduction,
where ATP is consumed and converted into ADP. Creatine and phosphocreatine are character-
ized by two main resonances[Govindaraju 2000]: a singlet at 3.0 ppm from the methyl-protons
and another singlet at 3.9 ppm from the methylene protons (see Figure 2.6). In the human
brain, both metabolites are found in similar concentrations, with a total concentration of 6.4-9.7
mM in the gray matter and 5.2-5.7 mM in the white matter[Govindaraju 2000].
4.1.3 Glutamate and Glutamine
Glutamate and glutamine are two amino-acids found in the brain which, due to the overlap
and similarity of their spectra, are frequently quantified together. The ensemble of glutamate
and glutamine resonances is referred to as "Glx". Glutamate is the principal excitatory neuro-
transmitter in the vertebrate nervous system [Meldrum 2000] and is found in the brain with
a concentration of about 12 mmol/kg, making it the most abundant amino acid found in the
brain [Govindaraju 2000]. Glutamine’s major role in the brain is a precursor to the excitatory
neurotransmitters glutamate and aspartate, and the inhibitory neurotransmitter γ-amino bu-
tyric acid (GABA) [Albrecht 2010]. Both metabolites have distinct roles in tumor development.
Glutamate is cytotoxic [Takano 2001], and its secretion induces an inflammatory response in
the surrounding tissue, possibly caused by the neuronal loss resulting from glutamate itself.
The inflammatory response is believed to contribute to tumor expansion[Takano 2001]. Glu-
tamine, on the other hand, is a tumor nutrient and contributes to several essential metabolic
tasks in tumor proliferation: it is involved in bioenergetics, protects the cells against ox-
idative stress, and complements glucose mechanism in the production of macromolecules
[DeBerardinis 2010]. Glx resonances are found between 2.12 and 2.35 ppm, and between 3.74
and 3.75 ppm [Mountford 2010].
4.1.4 Glycine
Glycine is an inhibitory neurotransmitter and an antioxidant that is found throughout the
normal brain with a concentration of about 1mmol/kgww [Govindaraju 2000]. Proton NMR
spectra of glycine shows a unique singlet at 3.55 ppm. The overlap between glycine and
myo-inositol makes identification of glycine difficult at short TE, however, at long TE the
myo-inositol resonances largely cancel each other enabling easier identification of the glycine
peak. Glycine can be considerably increased in certain tumors, namely in a subset of gliomas
[Choi 2011].
4.1.5 Lactate
Lactate is a product of anaerobic glycolysis and, consequently is a marker for reduced oxygena-
tion [Mountford 2010]. In brain tumors, elevated lactate is often found in cystic compartments
[García-Figueiras 2016]. Lactate produces a distinctive doublet at 1.33 ppm that, due to J-
evolution, is inverted for echo-times around 144ms (see description of the J-evolution of the
lactate doublet at the end of section 2.4.3).
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Figure 4.2: MR spectrum showing the macromolecular baseline in a healthy brain spectrum collected from the pons and a part of
the surrounding tissues. The spectrum was acquired at 1.5T with TE=30ms and using PRESS. The MM baseline was calculated
using QUEST [Ratiney 2005].
4.1.6 Macromolecular baseline
In in vivo MRS, the general classification of macromolecules (MM) is given to all molecules
with high molecular-weight that, due to their short T2 relaxation times, are difficult to resolve
separately. The combined signals of all macromolecules seen in short TE spectra, forms the
macromolecular baseline (see Figure 4.2). Macromolecule resonances can be separated in two
main types [Cudalbu 2012]: (1.) resonances arising from the nuclei of atoms with extremely
reduced mobility such as the ones forming the backbones of MM, and (2.) resonances from
nuclei belonging to outer regions of macromolecules or to smaller MM that have a higher
mobility than the nuclei from the previous group. In conventional MRS sequences, only the
resonances corresponding to the second group are detectable, given that the signals from the
first group decay extremely fast.
4.1.7 Mobile Lipids
The lipid signals observed at 1.3 ppm and 0.9 ppm correspond, respectively, to the −(CH2)
and −(CH3) moieties of long chain fatty acids. Consequently, the ratio between the 1.3 and
0.9 signals is correlated with the length of the fatty acid chain ([Evaristi 2016]). In the case of
unsaturated lipids, the −CH = CH− produces a resonance at 5.4 ppm [Mountford 2010]. Simi-
larly to the other macromolecules, the visibility of lipid signals in NMR is highly dependent on
their mobility. Pospholipids contained in cell membranes, for instance, are highly immobilized
and, consequently, have extremely short T2 which renders them invisible in conventional MR
spectra [Atlas 2009]. Lipids from the scalp, on the other hand, are more mobile and frequently
contaminate brain spectra. Apart from lipid contamination from the scalp, the presence of
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lipid signals in in vivo NMR spectra of the brain is often a marker of disease itself, and of tumor
necrosis [García-Figueiras 2016].
4.1.8 Myo-inositol
Myo-inositol is an astrocyte marker and an osmolyte usually found in the brain with a con-
centration between 4 and 8 mmol/kgww [Kreis 1997]. The spectrum of this metabolite is better
detected at short TE and consists of 4 groups of resonances [Govindaraju 2000]: (1.) a doublet
of doublet around 3.52 ppm, (2.) a triplet at 3.61 ppm, (3.) a triplet at 3.27 ppm that overlaps
the choline peak, and (4.) a triplet at 4.05 ppm that is often affected by water suppression. Myo-
inositol has been associated with gliosis, though the relation between high myo-inositol and
gliosis is not clear [Hattingen 2008]. In gliomas, myo-inositol provides relevant information
to predict tumor grade since it is often found elevated in low grade gliomas and decreased in
high-grade gliomas [Metwally 2014, Castillo 2000].
4.1.9 N-Acetyl-Aspartate (NAA)
N-Acetyl-Aspartate (NAA) is an amino acid found in the healthy brain at high concentration
levels (7.9-16.6 mmol/kgww [Kreis 1997]). The acetyl moiety of NAA produces a singlet around
2.0 ppm which is one of the most prominent peaks in normal brain spectra (see Figure 4.1).
Besides being relatively less visible than the acetyl singlet, the aspartate moiety leads to a few
other resonances: two doublet of doublets at 2.67 and 2.48 ppm, another doublet of doublets at
4.38 ppm, and a doublet at 7.82 ppm from the amide group. NAA is considered a neuronal
marker and low NAA levels are associated not only with neuronal loss (irreversible) but also
with neuronal dysfunction that may be reversible in some situations [Govindaraju 2000].
4.1.10 Other detectable metabolites
In addition to the referred metabolites, other important substances can be detected in in vivo
proton 1H-MRS of the brain, such as:
• Alanine - a nonessential amino acid that is found increased, for instance, in meningiomas
[Govindaraju 2000].
• Gamma-Aminobutyric acid (GABA) - the main inhibitory neurotransmitter of the cen-
tral nervous system. [Puts 2012]
• Glucose - a simple sugar that is the main source of energy in humans. [Govindaraju 2000]
• 2-HG - an oncometabolite seen in primary brain tumors that carry a mutation in the
enzyme cytosolic isocitrate dehydrogenase (IDH) gene. IDH mutated gliomas are asso-
ciated with longer overall survival. [Dang 2009, Choi 2012, Choi 2013, Andronesi 2012,
Andronesi 2013]
Despite their importance, these four metabolites were not analyzed in the work presented in
this thesis.
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4.2 MRS in Brain Tumours
The ability to provide localized chemical information non-invasively makes MRS a very inter-
esting tool for the metabolic assessment of brain lesions. As shown in the previous subsection
describing the most relevant metabolites seen in in vivo brain MRS, many of the visible metabo-
lites provide important information for the characterization of brain tumors. The use of
MRS for the characterization of brain tumors can be divided into the following categories
[Hollingworth 2006]:
1. differential diagnosis between tumor and non-cancerous lesion;
2. differential diagnosis between metastasis and high-grade tumor;
3. differential diagnosis between low-grade and high-grade tumor;
4. discrimination between tumor-progression and radiation necrosis;
5. delineation of tumor borders;
4.2.1 Tumor vs non-cancerous lesion
In some cases, conventional MRI imaging alone does not provide conclusive information to
determine if a suspect lesion is cancerous or not. However, such distinction is extremely
important given that certain benign non-cancerous lesions may not require a brain biopsy to be
performed. Therefore, the correct differentiation between cancerous and non-cancerous lesions
may eliminate unnecessary brain surgeries and all the associated risks [Horská 2010].
Figure 4.3 shows 4 different cases, 2 from brain tumors and 2 from lesions that can mimic
brain tumors in MRI. As it can be seen in this particular example, the MR spectra of the 4
different cases are substantially different. For the AVM case, a tumor can be ruled out given that
the lesion shows no brain metabolites and the surrounding tissue shows normal brain spectra.
In the case of the bacterial infection, the presence of acetate, alanine, and amino acids at 0.9
and 3.75, which are potential markers of pyogenic abscesses [Lai 2005], enables the exclusion of
a brain tumor. Regarding the brain tumor cases, the elevated metabolite ratios choline/creatine
and choline/NAA are markers of malignant processes [Hollingworth 2006] and point towards a
cancerous lesion. Despite this, diseases that lead to spectroscopic patterns with similar features
as the ones observed in brain tumors, such as acute demyelinating lesions, may complicate the
differentiation between malignant and non-malignant diseases using MRS alone [Horská 2010].
The performance of MRS to differentiate between neoplastic and nonneoplastic brain lesions
was assessed in several studies. A study published in 2007 [Hourani 2008]. In that study, the
authors showed that in a total of 69 brain lesions, including 36 brain tumors, 10 benign lesions, 4
strokes, 10 demyelination lesions and 9 stable lesions not confirmed on pathologic examination,
it was possible to distinguish cancerous lesions from non-cancerous ones with an accuracy
of 84.2%. Another study from 2002 [Möller-Hartmann 2002] where 176 brain lesions were
assessed, showed that the use of MRS for the diagnosis of brain lesions together with structural
MRI, compared to structural MRI alone, allowed to increase by 15.4% the number of correct
diagnoses, decrease 6.2% the diagnostic errors and reduce in 16% the number of equivocal
cases.
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Figure 4.3: Four different types of lesions and corresponding spectra. All spectra acquired at 1.5T and 3.0T using PRESS, TE=135
ms. The axial images show the location of the spectra. For the bacterial abscess case, given that not all metabolites were included
in the available basis set, peak assignment was made based on [Lai 2005]. The data shown in this figure was acquired at Inselspi-
tal, Bern.
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Figure 4.4: The figure shows an example comparing the spectra of the contrast-enhanced tumor region (blue region and spectrum)
and of the peritumoral region (red region and spectrum) between GBM and metastasis. The primary tumor of the metastasis case
is non-small cell lung cancer (NSCLC). Spectroscopy acquired at 1.5T using PRESS (TE=135ms). The aim of this figure is to
present an example of what is described by [Server 2010] and [Baumert 2006] regarding the higher Cho/NAA and Cho/Cr of
the peritumoral region of GBM tumors when compared to metastasis. The data shown in this figure was acquired at Inselspital,
Bern.
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4.2.2 Metastasis vs high-grade tumor
The distinction between brain metastases and high-grade tumors, such as glioblastoma, is one
of the biggest challenges in initial diagnostics of brain tumors. MR spectra of both tumor
groups may present very similar spectra which are difficult to distinguish by simple visual
inspection. Despite this, a few studies have looked at the use of systematic approaches that use
information derived from MRS and are able to distinguish metastases from high-grade tumors
with reasonable accuracy.
A study from 2009 [Server 2010], that analyzed 73 patients with histologically confirmed
diagnosis (53 high-grade tumors, 20 mestastases) looked at the peritumoral region to distinguish
these two types of tumors. The results of the study showed that by defining a simple threshold
on Cho/NAA applied to peritumoral spectra, a sensitivity of 100% and specificity of 91.1%
could be achieved. Another study from Wijnen et al. [Wijnen 2012], confirmed that the
peritumoral region contains relevant information for the distinction between metastases and
high-grade tumors. The general hypothesis for the observed results is that high-grade tumors,
namely GBM, are more infiltrative than most of the brain metastases. Consequently, the
detection of elevated tumor markers in the region surrounding the tumor enables the distinction
between these two tumor types (see example Figure 4.4). However, depending on the primary
tumor, mestastases may present more or less infiltrative phenotype [Baumert 2006] which may
complicate the differentiation between high-grade tumors and mestastases.
In this thesis, chapter 8 explores a method named convex-Non-negative Matrix Factorization
(cNMF described in section 3.2.2) to highlight differences between MRSI data of GBM and
metastasis patients.
4.2.3 Low-grade vs high-grade tumor
Several studies have confirmed the ability of MRS to grade brain tumors, namely astrocytomas,
as discussed in the review paper by Hollingworth et al. [Hollingworth 2006]. As an example,
a study from 2003 [Herminghaus 2003] used a linear discriminant analysis (LDA) classifier
trained using 126 cases (42 WHO grade I/II, 30 WHO grade III and 54 WHO grade IV). The
classifier was tested in a dataset of 94 new cases, composed of 30 grade I/II, 29 grade III and 31
grade IV. Overall the method classified correctly 86% of the cases, and differentiated low grade
(grade I/II) from high-grade tumors (grade III/IV) with a success rate of 95%. As is described in
the paper from Herminghaus et al., the ability to perform tumor grading based on MR spectra
is related to the relationship between malignant transformation and several metabolites visible
with MRS. In the malignant transformation from a low to a high grade glioma tumor, the first
observed change is an increase of choline compounds due to the increased membrane turnover
of the tumor cells, accompanied by the appearance of lactate due to anaerobic glycolysis.
Simultaneously, tumor proliferation leads to the destruction of neurons, which is visible in
MRS as a decrease in NAA. Consequently, tumor grade correlates positively with Cho/NAA
and Cho/Cr, as shown in [Naser 2016].
4.2.4 Tumor-progression vs radiation necrosis
Radiation therapy leads to the focal destruction of tumor and healthy brain tissue (radiation
necrosis) which can lead to the disruption of the blood-brain-barrier (BBB). Consequently, in T1c
sequences, new contrast enhancement is observed in those regions. Given that disruption of the
BBB and contrast enhancement are also observed in high-grade tumors, radiation necrosis and
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tumor progression are often difficult to discriminate in T1c and other structural MR sequences.
The correct differentiation between radiation necrosis and tumor progression is essential for
the follow-up evaluation of brain tumor patients.
Despite the similarities in MR imaging, MR spectra of progressive tumor tissue and radiation
necrosis can be distinguished. Given that tumor proliferation leads to an increase in free choline
concentration, tumor progression is characterized by significantly higher Cho/Cr and Cho/NAA
values, when compared to radiation necrosis [Weybright 2005]. As described by Weybright
et al., the authors were able to discriminate correctly these two tissue types in 27 out of 28
cases, using only the ratios Cho/Cr and Cho/NAA. Similar results were obtained by Rock et
al. [Rock 2004], showing that MRS provides relevant information for the distinction between
radiation necrosis and tumor progression. Moreover, as referred by Rock and his colleagues,
the combination of MRS with other modalities such as Apparent Diffusion Coefficient (ADC)
may further improve the discrimination performance.
4.2.5 Tumor border delineation
Conventional brain tumor segmentation uses as reference structural images such as T1 post
contrast (T1C), T2 and FLAIR to identify solid tumor and edema. The solid tumor contours are
normally defined as the region delimited by contrast-enhancement in T1C , and the edema as
the region that surrounds the solid tumor and which appears hyperintense on FLAIR images
or T2. Definition of tumor contours is essential for tumor patient management, namely for
the assessment of response to treatment, for radio-therapy planning and for guiding surgery.
Despite its importance, the abnormalities seen in structural images significantly underestimate
the extent of brain tumors such as glioblastoma. A study from Yamahara et al. [Yamahara 2010]
that analyzed 7 autopsy brains of deceased glioblastoma patients detected dense tumor cell
infiltration at a distance from up to 14 mm of the tumor border defined in T1C images. Moreover,
tumor infiltration was found in regions with normal appearance in T2 images. Similarly, Pallud
et al. [Pallud 2010] showed that in diffuse low-grade oligodendrogliomas tumor cells can be
found from up to 26 mm from MRI defined abnormalities.
In order to address this issue, some authors have turned to MRSI as a solution to im-
prove brain tumor delineation. Stadlbauer and his colleagues [Stadlbauer 2004] showed that
Cho/NAA maps can better estimate glioblastoma tumor extent and that the region of abnormal
Cho/NAA values extends beyond the region defined by T2 abnormalities. In this study, all
biopsy samples collected from regions normal in T2 but abnormal in Cho/NAA maps showed
tumor infiltration. A similar study [Cordova 2016] using a higher spatial resolution MRSI
sequence, showed that Cho/NAA positively correlates with tumor cell density. Moreover, in the
same study, Cho/NAA maps were shown to predict contrast-enhancement from 4 to 5 months
before its appearance on T1C images. Correlation between Cho/NAA values and tumor cell
density had previously been shown by Ganslandt et al. [Ganslandt 2005]. In the same study, it
was once more demonstrated that the region defined by the Cho/NAA maps exceed the tumor
affected area defined in T2. This was observed in all of the 7 patients analyzed.
In parallel with these positive results, a phase II trial [Einstein 2012] was conducted to
evaluate the use of Cho/NAA maps for planning radiotherapy. The study showed a significant
increase in patient survival after incorporation of MRSI for defining target volumes.
Overall, the different results of the literature here described demonstrate the added value
of MRSI for improving brain tumor segmentation. However, given that MRSI, namely high
spatial resolution sequences and other more experimental approaches used in research, is less
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available than conventional structural images such as T1C and T2, MRSI is not yet part of the
standard procedure for brain tumor segmentation.
In this thesis, chapters 10 and 11 present novel approaches that explore MRSI data with the
aim of enabling better delineation of brain tumors.

Part II
Quality management of MRS and
automation of quality control

5 | Quality Management in in vivo proton MRS
This chapter is based on the following publication:
N. Pedrosa de Barros, J. Slotboom, Quality management in in vivo proton MRS, Anal. Biochem.
529 (2017). doi:10.1016/j.ab.2017.01.017.
5.1 Abstract
The quality of MR-Spectroscopy data can easily be affected in in vivo applications. Several
factors may produce signal artefacts, and often these are not easily detected, not even by
experienced spectroscopists. Reliable and reproducible in vivo MRS-data requires the definition
of quality requirements and goals, implementation of measures to guarantee quality standards,
regular control of data quality, and a continuous search for quality improvement.
The first part of this review includes a general introduction to different aspects of quality
management in MRS. It is followed by the description of a series of tests and phantoms that can
be used to assure the quality of the MR system. In the third part, several methods and strategies
used for quality control of the spectroscopy data are presented. This review concludes with
a reference to a few interesting techniques and aspects that may help to further improve the
quality of in vivo MR-spectra.
5.2 Introduction





Quality planning consists in the definition of quality requirements and goals. Quality
assurance deals with the prediction of possible errors and defines a set of measures to prevent
them. Quality control, on the other hand, deals with situations where errors are created and its
main aim is to detect them and avoid that these cause further complications. Finally, quality
improvement defines how the quality of the results can be further improved. In Figure 5.1, a few
examples of different tasks that fall in each of the different quality management components in
MR spectroscopy are given.
Quality management is required to ensure data reproduction, and is especially important
in applications such as individual patient diagnostics, and multi-centre studies where data
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Figure 5.1: Exemplary tasks that belong to the different components of MRS quality management.
acquired in different sites, and frequently with different measurement conditions, is combined
[Podo 1995, van der Graaf 2008]. In multi-centre studies, apart from the quality management
performed at the level of each centre, further measures need to be implemented to ensure data
compatibility.
It is important to understand that none of the four quality management components are
closed or independent. Tests performed in quality assurance can loosen or tighten quality
requirements previously defined in quality planning, or even define new targets for quality
improvement. Moreover, information collected in quality control may lead to new tests and
prevention measures in quality assurance. And besides this, some actions may belong to
more than one component. For example, as proposed by Milan Hájek et al. in [Hájek 2000],
quantification calibration factors can be used both for quality assurance, improving the accuracy
of the measurement, as well as for quality control, helping to detect relevant changes in MR-
scanner performance.
The four components of quality management will now be discussed in more detail.
5.2.1 Quality planning in MRS
Quality planning in in vivo MR-spectroscopy involves the definition of quality targets and should
give answers to questions such as: what is the minimum concentration and voxel size that
needs to be detectable? What is the coarsest MRSI resolution still acceptable? What are the
minimum levels of SNR and FWHM that are considered acceptable? What is the maximum
acquisition time that is still acceptable to ensure patient or test person wellbeing? How much
error is tolerated in absolute quantification? What is the maximum acceptable rate of rejected
spectra in quality control?
Quality planning is, obviously, highly dependent on the application. For instance, in certain
diseases it may be required to detect a metabolite in very low concentrations (e.g. 2-hydroxy-
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glutarate in gliomas [Dang 2009, Choi 2012]). On the other hand, depending on the size of the
structure that is analysed, different resolution levels may be needed. Moreover, depending on
whether the application is clinical or not, the maximum possible acquisition time can change
considerably. Given that most of these factors are interdependent, some compromises need to
be made. Therefore, quality planning should start by the definition of the main goals and of
their relative importance.
5.2.2 Quality assurance in MRS
Once the goals and quality requirements are set, quality assurance actions may be initiated.
Quality assurance starts with the prediction of what might fail, and with identification of the
factors that may lead to failure. Once these factors are identified, an adequate battery of tests
should be defined. These tests should provide clear knowledge of the limitations of the scanner
hardware and software (pulse sequence). Whenever possible, the hardware and pulse sequence
should be adjusted to increase the robustness to the factors identified. Quality assurance is often
an iterative process, where tests and corrections are repeatedly performed until the targets
defined in quality planning are met. Quality assurance in MRS includes the following actions:
1. Improving the robustness of the sequence and scanner;
2. Providing information regarding the conditions under which the quality of the spectra is
guaranteed (e.g. manuals stating how the MRS measurement should be planned and the
data processed);
3. Providing information regarding the limitations of the pulse sequence and scanner (should
be provided by the manufacturer in the system specification);
In section 5.3 a few phantoms and tests to assure the quality of the spectra are presented.
5.2.3 Quality control in MRS
As stated above, the aim of quality control is to detect errors, and to prevent the impact that
these can have in the obtained results. Consequently, the definition of the appropriate control
strategy starts with the identification of all critical parts of the acquisition and processing of the
data: what aspects are most likely to fail and what factors have the biggest negative impact on
the quality of the measurement (e.g. failing auto-shim)?
After identifying the critical points, a strategy for detecting anomalies (e.g. unexpected
sudden phase jumps during acquisition or bad water suppression) can be defined. It is important
to analyse which information needs to be collected for an accurate anomaly detection. If needed,
changes can be made to the protocol so that the required information for quality control is
collected. The collected information should grant traceability to the system, or in other words,
should provide enough information for determining what failed, when and how.
Once anomaly detection is implemented, the set of actions that should follow the different
outputs of the detector, need to be defined. In some cases, the result can be the simple rejection
of data (quality filtering), whereas in others certain pre-processing steps may be triggered.
An important outcome of the quality control is the information regarding the reliability of the
measurement. A common example of this is the CRLB, which gives information regarding the
spectral reliability, i.e. the lowest possible errors in the estimated quantification parameters.
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In in vivo spectroscopy, quality control focuses on mainly two aspects: signal quality, and
quantification quality. Signal quality control aims at detecting signal artefacts and bad quality
features, and often leads to the rejection of data or the identification of those cases that are
likely to produce unreliable results. Quantification quality control deals with the performance
of the quantification process and provides measures of reliability of the output. These measures
can be used for quality filtering.
Section 5.4 describes different methods for quality control.
5.2.4 Quality improvement in MRS
Finally, quality improvement starts with the knowledge of the performance of the current system
and aims at improving it. The improvements go beyond the minimum requirements and goals
defined in quality planning, and are not necessarily triggered by undesirable events or failures.
Examples of common measures used for quality improvement in MRS include the develop-
ment and implementation of new pulse sequences, or the improvement of the currently used
ones; the use of better RF-coils; a new scanner or scanner upgrade; improved education of
MRS-users; improvements in data post processing routines; etc.
In section 5.5, several aspects that should be considered for quality improvement will be
presented.
5.3 Tests and phantoms for quality assurance
The discussion on MRS quality assurance and phantom testing cannot avoid mentioning the
European concerted action on quality assessment in in vivo NMR spectroscopy [Podo 1995,
Bovée 1995, Leach 1995, Keevil 1995, Howe 1995, de Beer 1992] from 1995. Even though it
was performed more than 20 years ago, this action was an important step for the establishment
of MRS, and the published material is still up-to-date. This action was motivated by the need for
standardized MRS-procedures. It included test measurements and methods for data analysis,
using appropriate test objects and substances to determine quality measures. Such tests are
essential for the standardization of the technique, as well as to allow data sharing between
different centres, and realization multi-centre studies on large patient numbers.
Another concerted action followed, with focus on absolute metabolite quantification by in
vivo NMR spectroscopy [Podo 1998, Keevil 1998, De Beer 1998a, Bovée 1998, De Beer 1998b].
In the context of that action, a method to evaluate the localization performance in MRSI
[Bovée 1998] was proposed which is described in more detail in subsection 5.3.4.
This section covers several aspects of phantom testing, starting with some of the key findings
of the 1995 concerted action.
5.3.1 Two-compartment phantoms for SVS sequences
Leach et al. discussed in their work [Leach 1995] a few practical considerations made in the
design, construction and solutions used in two MRS phantoms of the 1995 concerted action.
One phantom, the so called “Spectroscopy Test Object 1” (STO1 – Figure 5.2), was a sphere
with an inner cubic compartment, and was aimed at testing single voxel localisation methods.
The second phantom, named “Spectroscopy Test Object 2” (STO2 – Figure 5.3), was a cylinder
with a moveable cylindrical inner container, and was designed to test slice localisation methods.
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Figure 5.2: Spectroscopy Test Object 1 (STO1) of the 1995 Concerted Action. (A) and (B) show different perspectives and dimen-
sions of the object. Source of the image: [Bovée 1995]. Copyright by Elseviser Science Ltd.
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Figure 5.3: Spectroscopy Test Object 2 (STO2) of the 1995 Concerted Action. Source of the image: [Bovée 1995]. Copyright by
Elseviser Science Ltd.
Table 5.1: Susceptibility difference with water for several materials. Data source: [Bovée 1995].







Both phantoms and procedures were designed for testing the localization performance of pulse
sequences using homogenous bird-cage coils.
One of the critical parameters evaluated before construction of the phantoms was the sus-
ceptibility difference of several materials with water. PVC, Perspex, Teflon, Polycarbonate,
Polyethylene and Glass were tested, with Perspex showing the smallest susceptibility difference
to water and consequently becoming the material of choice to build the phantoms (Table 5.1).
Smaller differences in susceptibility pose fewer challenges for shimming and, consequently,
guarantee higher field homogeneity over the excited volume. In Figure 5.4 we show a Suscepti-
bility Weighted Image (SWI) of a phantom made using an unknown plastic material. The figure
demonstrates that the chosen material shows noticeable susceptibility differences with the
surrounding solutions. Additionally, the phantom also shows the signal degrading off effects of
paramagnetic particles contained in the material and air bubbles. This example also shows that
these susceptibility artefacts affect the SNR and linewidth (measured by the damping factor
used in quantification) of the spectra. As it can be seen, the lower right cube is the most affected,
whereas the top left cube shows better quality spectra as well as less susceptibility artefacts.
Another explanation for the poor quality of the spectra might be the cubic geometry of the
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Figure 5.4: Susceptibility artefacts caused by an unknown plastic material used for the phantom construction. The phantom is
made of 4 cubes of the same plastic material. Each cube contains a solution with an identical NAA concentration of 70 mM. The
outer compartment was filled with water. From left to right we show a susceptibility weighted image (Left); the NAA damping
factor in Hz (comparable to linewidth) used in QUEST (Middle); and SNR of NAA (Right). The measurement was performed
using a 2D MRSI PRESS sequence in a 1.5 Siemens Aera Scanner (TE 135ms and TR 1500ms). The centre of the 4 cubes was
placed at the isocentre of the magnet.
inner compartments, which is not optimal for obtaining good shimming results.
Regarding the solutions used in phantoms STO1 and STO2, the outer volume was filled
with demineralised water with 0.1 mM Gd-DTPA, 0.05 mM MnCl2 and 0.09 M NaCl (T1 of 814
ms and T2 of 235 ms). For the inner compartment the authors used Polydimethylsiloxane, and
optimized its viscosity to achieve adequate T1 and T2 values (viscosity 1070 mPa.s, T1 740 ms
and T2 180 ms). Alternatively, a conventional metabolite solution could have been used.
From the same concerted action [Podo 1995, Bovée 1995, Leach 1995, Keevil 1995,
Howe 1995, de Beer 1992], another paper [Bovée 1995] was published by Bovée and his col-
leagues on quality assessment using the two described phantoms (STO1 and STO2). The paper
introduces a set of NMR signal related parameters that describe different quality aspects that
can be evaluated using those phantoms:
1. Linearity: Relation between signal amplitude and excited volume (VOI) and between the
signal amplitude and concentration. The relation with concentration can be analysed
simply by performing several measurements of the same excited VOI, with varying
concentrations. Relation with volume can be analysed by changing the VOI. Ideally, both
relations should be linear.
2. Chemical Shift: Analysis of the chemical shift difference between the inner and outer
compartment peaks depending on the localization method. In this test, the difference
between peaks is compared between localized and non-localized spectra. The localized
spectra are acquired with a VOI centred in the inner compartment. This test may help to
detect B0 inhomogeneities and eddy currents.
3. Spectral resolution: FWHM (full width at half maximum of a certain resonance) and
full width at 1/10th of maximum height measured for both peaks with and without
localization
4. SNR per unit concentration in fixed volume.
5. Selection efficiency: ratio between the signal strength obtained from the VOI using the
localization method, divided by the maximum possible signal from the VOI measured by
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Figure 5.5: Two-compartment phantom used in the work of Slotboom et al. [Slotboom 1991, Slotboom 1993]. The phantom was
designed to test localization pulse sequences when using surface coils at high B0- field-strength. Image source: [Slotboom 1993].
a non-localized pulse sequence. Sources of inefficiency include, for example, excitation
imperfections, eddy currents or chemical shift displacement artefacts.
6. VOI profile and position accuracy.
7. Suppression factor: defined as the ratio A/B where A and B are the unwanted signal
strengths measured, respectively, without and with suppression.
8. Signal stability: repetition of the non-localized experiment several times and determination
of the mean and standard deviation of the signals.
Detailed information on how to perform the different measurements and tests can be found
in the original paper [Bovée 1995], and an example of an application of the assessment protocol
can be found in the paper of the multicentre study [Keevil 1995] of the same concerted action.
In that multicentre study, the performance of PRESS and STEAM in proton MRS were compared
using data collected from 8 different centres. The comparison confirmed what is now commonly
known: higher selection efficiency was obtained using PRESS due to the implicit 50% signal
loss of STEAM, and lower signal contamination was obtained using STEAM due to higher
selectiveness of the 90 degree pulses used in STEAM compared to the 180 degree pulses used
in PRESS.
Another two-compartment phantom containing water and nitromethane (Figure 5.5), was
used by Slotboom et al. [Slotboom 1993, Slotboom 1991] to evaluate the localization perfor-
mance, at 7T, of SADLOVE (later LASER) against PRESS and STEAM using surface coils. The
analysis uses the same principles as in [Leach 1995] to evaluate localization efficiency. The
following experiments were performed to compare selection performance between sequences:
1. Non-localized FID experiment using 90◦ adiabatic pulse with resulting peak-areas W1
and N1 for respectively water and nitromethane.
2. Localization experiment with selection gradients switched off during RF-pulse application.
Resulting peak areas for water and nitromethane: W2 and N2.
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3. Localization experiment with selection gradients on. Selection of a 4x4x4 mm cubic VOI
in the nitromethane container, as seen in Figure 5.5. Resulting peak areas (water and
nitromethane): W3 and N3.
Using the mentioned peak-areas the following parameters were derived:
1. Suppression efficiency: W1/W3;
2. Signal efficiency: (W2+N2)/ (W1+N1);
3. Overall performance: Signal efficiency / Suppression efficiency;
The study evaluated the performance of the three sequences as a function of the amplitude
of the selection pulses. For the test values obtained using surface coils, SADLOVE showed
overall performance values that were from 3 to 12 times higher than the ones of STEAM and
PRESS. STEAM and PRESS showed similar results, with STEAM having higher suppression
efficiency and PRESS higher signal efficiency, in accordance with the results of the multicentre
study described above.
When comparing the phantom of Figure 5.5 with STO1 and STO2, it is noticeable the size
difference. The difference is related with the size of the bore used: STO1 and STO2 were
designed for use in clinical scanners whereas the nitromethane and water phantom was used in
a small-bore animal scanner. The sizing aspect is also discussed in another paper [Howe 1995]
of the 1995 concerted action. In that work the authors successfully applied the same testing
protocol as defined by Bovée et al.in [Bovée 1995] to a small bore system but had to perform
some changes in the size and wall thickness of the phantoms.
A more recent example of quality assurance using phantom-tests comes from another Eu-
ropean multi-centre project: INTERPRET [Pérez-Ruiz 2010, Tate 2006, Julià-Sapé 2006]. The
aim of this project was to build automatic spectra classifiers for brain tumour typing based
on proton SVS spectra. As mentioned in the introduction, quality assurance is a key aspect of
multi-centre projects, given the need to assure data compatibility between the participating
centres. In INTERPRET, data compatibility was assured by the protocols [van der Graaf 2008]
defined for quality assurance, which will be described below, and for quality control, which will
be described in the signal quality control section (5.4.1).
INTERPRET used similar phantoms and measurements as the ones described in the con-
certed action of 1995. The two-compartment Perspex phantom used had a cylinder shape and
contained a smaller inner cubic compartment with a 20mm diameter and 3 mm wall thickness.
The outer compartment was filled with 0.15M sodium acetate solution (pH 8.3) and the inner
compartment with a solution of 0.1M lithium lactate and 0.1M creatine (pH 7.6). Sodium
azide (1g/L) was added to avoid bacterial growth. Three different measurement protocols were
used for testing the MR-scanners from the different centres. Protocol A: a simple protocol that
was repeated every 2 months using the INTERPRET phantom. Protocol B: a more extensive
one using the same phantom and performed every year, and after each hardware or software
upgrade. Protocol C: performed in vivo, applying the same measures as protocols A and B in a
group of at least five healthy volunteers. Protocol A consisted in three SVS measurements with a
cubic VOI of (15 mm)3: one VOI was placed exactly in the centre, a second VOI placed 40 mm
below the central VOI, and a third VOI placed 40 mm left of the central VOI. In protocol B, VOIs
with increasing size centred in the inner compartment (first contained inside the inner cube and
then including the inner cube and the surrounding volume) and placed 40 mm below the centre
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of the cube, were used to test volume selectivity and signal linearity. Long TE (136ms) SVS
PRESS and short TE SVS STEAM (20ms) and PRESS (30ms) were used in the measurements.
The results obtained using the bimonthly measurements (protocol A) allowed to detect
a localisation problem due to a faulty RF-transmitter in one of the participating sites. The
fault was detected based on an unexpected increase of the water bandwidth with no change
in SNR. Apart from this occurrence, the SNR was above 50 and the water bandwidth below
4 Hz for every site in all performed tests. The results of the protocol B showed that the signal
contamination – ratio between outer volume signal and total signal – measured with a voxel of
(20 mm)3 exactly covering the inner compartment of the phantom varied between 0 and 5.2%.
The signal efficiency test parameter – which is the ratio between the inner volume signal for a
certain VOI and the maximum inner volume signal measured by a non-localized experiment –
was determined. The observed signal efficiency ranged between 71 and 75% for a VOI with the
dimensions of the inner compartment, and between 90 and 98% for a slightly larger VOI of
(25 mm)3. Finally, the spectra acquired in the in-vivo tests using healthy volunteers (protocol C)
showed satisfactory quality, with no artefacts, high SNR and narrow linewidth.
5.3.2 Creating compartments without walls
Given that walls in phantoms may introduce susceptibility differences and other problems, some
groups have proposed some interesting alternative phantoms that create different compartments
without the use of a separating material. One of such examples is the oil and water phantom
proposed by the Burtscher et al. [Burtscher 1999]. The phantom is a Perspex sphere of 15
cm diameter filled half way up with a water solution containing 0.05 mM MnCl2, 0.2 mM
gadolinium DTPA and 0.09 M NaCl. The other half was filled with a polydimethylsiloxane
(PDMS) oil with a viscosity of 1000 mPa.s. The relaxation properties were: T1= 810 ms and
T2 = 220 ms for the aqueous solution, and T1= 770 ms and T2 = 200 ms for the oil. The two
substances had a chemical shift difference of 4.5 ppm. The phantom was used to compare the
localization performance of a spin echo (SE) and STEAM sequences with focus on unwanted
lipid signal contamination. Different measurements were made with different voxel sizes that
were moved along the interface between the two solutions. Short TE (10 ms) STEAM showed
smaller levels of contamination, when compared with long TE (270 and 135 ms) SE and STEAM.
This is explained by the larger bandwidth (2560 Hz) of the pulses used in short TE STEAM
when compared to the pulses used in the other sequences (850 Hz) – relation between pulse
bandwidth and localization accuracy discussed in section 5.5.4. In STEAM, bigger voxel sizes
had significant lower levels of contamination than smaller voxels. This effect was explained by
the reduction in the quality of the slice profile for smaller slice thicknesses, and the Hamming
filter applied to the RF-pulse that broadens the excited slice and which has a more significant
effect in smaller widths. The relation between contamination and VOI size was not observed for
the SE sequence.
Another example of a phantom without inner walls was proposed by Heikal et al. in 2008
[Heikal 2008]. The phantom was used to evaluate the delineation accuracy of 2D-PRESS, 2-echo
Spin Echo Spectroscopic Imaging (SESI) and 4-echo SESI. The authors used porcine gel to create
the two different compartments. For the construction, a cylinder was filled with solution with 3
mM choline chloride, 10mM creatine hydrate and 5% weight porcine gel. An acrylic wedge was
inserted in the solution to create the space for the inner compartment. After solidification of
the first solution, the wedge was removed and the corresponding space filled with a similar
solution as the previous one but with 10 mM choline chloride. 2D PRESS showed the best
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results, allowing for a more accurate delineation of the inner compartment.
5.3.3 2D-Array phantom for testing MRSI sequences
Woo et al. proposed in 2006 a phantom for testing MRSI sequences using a 2D-array of cone-
shape vials [Woo 2007]. The 64 vials (arranged in an 8x8 matrix) were made of polyethylene and
contained a rubber lid for sealing. The different vials were fixed inside a cylindrical phantom
body made of acrylic resin. Two internal circular plates were used to fix the phantoms (one
contained equally spaced holes displayed in an 8x8 matrix, and the other a regular quadrilateral
hole). The outer compartment was filled with a 0.7 g/L copper sulphate solution (Cu2SO4).
The vials were filled with different solutions using the following substances: NAA, creatine,
choline, lactate, alanine, myo-inositol, GABA, glutamine and gadopentetic acid. Sodium azide
(0.01%) was added to these solutions to prevent bacterial growth. All vials contained also 56
mM NaOH and 50 mM KH2PO4. Using the phantom, a 2D PRESS (TE/TR = 40/1500 ms) with
20x20 spatial encodings was tested. Relation between amplitude and volume was analysed by
placing the MRSI at different levels or heights of the conic vials. Even though this phantom
provides a flexible solution for testing MRSI sequences with different metabolite concentrations,
the phantom design might create some complications in terms of shimming. This may explain
the several poor quality phantom spectra presented in the paper. Multi-compartment grids can
provide interesting test objects for Spectroscopic Imaging sequences, however, as was described
above, special attention should be given to the materials and design of the phantoms, given
that spectroscopic sequences are highly sensitive to field inhomogeneities. Phantom geometries,
such as large rectangular shapes, can give rise to B0-inhomogeneities that cannot be globally
shimmed by the available shim set. The signal artefacts might have been lower with a simplified
phantom design and the use of materials with smaller susceptibility differences with water,
such as Perspex, polycarbonate or glass. A grid of gelatine[Heikal 2008] cubes with different
metabolite concentrations could potentially lead to better results.
5.3.4 Point-Spread-Function analysis
The Point-Spread-Function (PSF) is the response of the image or in this case, MRS-image, to
a source with the exact size of one voxel (a so-called Dirac δ function). The PSF of one voxel
shows the contribution to the signal of the neighbouring voxels. Detailed information on how
to determine and analyse the PSF can be found in the work of Bovée et al. [Bovée 1998] from
1998. In this paper, the authors suggest to perform localization quality assurance in MRSI by
comparing the theoretical PSF against the experimental one. It was hypothesized in that work
that deviations between the two might be caused by eddy currents and field inhomogeneities. In
order to measure the experimental PSF the author suggests the use of a simple narrow test tube
filled with water, with an inner diameter not larger than half the width of the non-interpolated
pixel. More detailed information on how to perform the proposed analysis can be found in the
original paper.
5.3.5 3D-printed phantoms
Following the recent progress in 3D printing techniques, a few authors have evaluated the use
of this technique in phantom construction. 3D-printing provides an enormous freedom in
terms of phantom design and it is becoming increasingly available for industrial use as well as
for the general consumer.
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In order to evaluate the feasibility of using 3D-printed phantoms, Bieniosek et al.
[Bieniosek 2015] compared a commercial phantom with the 3D-printed version of it. The
shape was cylindrical, with several cylindrical inner-compartments of different sizes. The
phantoms were evaluated for CT and PET and MRI, and showed that the differences in the
results obtained between the original phantom and the 3D-printed version were within the
measurement uncertainties of the setups. Unfortunately, the phantom was not tested for MRS.
Another example is the 3D-printed Shepp-Logan proposed by Kasten et al. [Kasten 2016].
The Shepp-Logan phantom [Shepp 1974] is a numerical phantom proposed in 1974 for evalu-
ation of reconstruction techniques. This standard test image contains different ellipsoids of
different shapes and intensities, which makes it an interesting object for benchmarking different
reconstruction methods. Besides its general use, to the best of our knowledge, the phantom
existed only in silico. Kasten and his colleagues created a 3D model of this numerical phantom,
which was then 3D-printed, that allows easily changing the solutions of inner compartments.
The different compartments of the phantom were filled using different concentrations of NAA,
creatine, choline, and sodium lactate. Corn oil was added to the peripheral compartment,
simulating the lipids of the scull and scalp. The work of Kasten et al. showed that the 3D-
printed Shepp-Logan phantom is an interesting test object for evaluating MRSI reconstruction
techniques.
5.3.6 Check-list for phantom design and construction
The following list gives an overview of several important points that must be considered in
phantom design and construction.
Shape and design:
1. Is the chosen shape easily shimmed?
2. Are the dimensions (including material thickness) adequate for the bore size?
3. How many compartments are needed?
4. Are there viable solutions to avoid internal walls? If not, can the walls be made thinner?
5. Can it be well sealed?
6. Does it allow changing the solutions of the different compartments easily?
Materials:
1. What is the susceptibility difference with water?
2. Does it react with the solutions we want to use?
3. How resistant is the material?
Metabolite solutions:
1. What are the relaxation properties? Are these similar to those of the target tissue?
2. What is the chemical shift? Is this close to the metabolites we want to measure in vivo?
3. How is the chemical shift of the substances affected by temperature and pH?
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4. Are the spins of the chosen substances J-coupled or uncoupled?
5. Are the compounds chemically stable?
6. Do they have special storage requirements (e.g. need to be kept refrigerated)?
7. Do they react with the wall materials of the phantom?
8. Are the solutions dangerous? (Explosive, Corrosive, etc.)
9. Should a preservative be added to the solution? (e.g. sodium azide to prevent bacterial
growth)
5.4 Methods for quality control of MRS data
In quantitative MRS, errors can occur during the signal acquisition phase, as well as during the
signal processing phase. Consequently, quality control in MRS focuses mainly on these aspects:
1. Signal quality assessment and detection of signal artefacts after acquisition (SVS and
MRSI);
2. Analysis of the quantification errors;
These two aspects are obviously related, but the approaches used in each one are different.
In the next two subsections, we will cover some of the techniques that have been used for signal
quality control and for quantification quality control.
Before diving into quality control methods, it is important to note that qualitatively good
looking spectra (high SNR, narrow linewidths, no obvious artefacts) are not necessarily reliable
[Slotboom 2009, Kreis 2004]. Several of the effects that can be analysed in quality assurance,
such as the chemical-shift artefact, the signal contamination, localization inaccuracies, signal
cancellation, etc. do not lead directly to clearly identifiable “bad-looking” signals nor even
necessarily cause problems for the quantification. Consequently, these effects are not detected
by the quality control methods that will be described in this section, methods whose input are
simply the time and frequency domain signals.
5.4.1 Signal quality control
As already mentioned, in vivo MRS-signals can easily be affected by B0- and B1-field inhomo-
geneities, eddy currents, susceptibility differences, signal contamination (e.g. subcutaneous
lipid signals), etc. In vivo proton spectra are particularly sensitive to the mentioned factors due
to the relatively low SNR of the majority of the metabolites of interest compared to the SNR of
water, which is around five orders of magnitude higher. As discussed in the previous sections,
in the context of quality assurance some of the effects that the mentioned sources of artifacts can
have are addressed, and measures for preventing them are defined. Still, signal artefacts are
very common in in vivo spectra and quality control is an essential step in the processing pipeline.
An overview over frequently occurring artefacts that can affect MRS signals, as well as some
possible corrections, can be found in the work of Kreis from 2004 [Kreis 2004].
One of the major problems with MRS artefacts is their identification. Several artefacts are
“silent” and do not show clear features that allow their easy detection (e.g. alterations in the
macro molecular baseline). In addition, artifacts might also be simply camouflaged as “just
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Figure 5.6: Example showing two Cho/Cr maps of a glioma patient acquired 4 months apart. Acquisition details: Siemens Aera
1.5 T, 2D-PRESS, 12x12 interpolated to 32x32, TE/TR 135/1500ms. The purpose of the example is to illustrate a situation where
wrong clinical interpretations could be made from poor quality spectra, such as the spectra of the second acquisition. MRSI
images should be checked for sufficient spectral quality before maps can clinically be interpreted. This quality check must be
performed by a spectroscopist with thorough knowledge of the method, or an algorithm that can substitute this expertise.
another peak” (e.g. lipid signals excited by RF-pulse sidebands that are outside the intended
excited volume VOI, and appear at wrong chemical shift position due to imperfect shimming).
In clinical applications, for instance, this might lead to wrong conclusions drawn from artefact
affected metabolic maps, since there is no time to investigate the quality of signal of all voxels
of the MRSI-grid manually. To illustrate this, we included the example of Figure 5.6 where we
present two Cho/Cr maps of the same patient and same localization acquired 4 months apart
from each other. By looking at the change in Cho/Cr between those maps, one could identify
two main regions: in blue a region with signs of response to treatment (reduction in Cho/Cr)
and, in red, a region with signs of tumour progression (increase in Cho/Cr). It’s only when we
look at the average spectra over each region that we realize that the spectra of the second MRSI
acquisition is highly affected by artefacts caused by surgical induced tissue changes (residual
blood, metallic particles of surgical instruments), and that its quality is far out too poor to allow
any clinical interpretation at all.
5.4.1.1 Rejection criteria
Several efforts have been made to define quality requirements in clinical spectroscopy. Worth
mentioning here is the extensive checklist included in [Kreis 2004] and the rejection criteria
defined in [Kreis 1993, Oz 2014]. According to these references, spectra should be rejected if:
1. FWHM > 0.1 ppm
2. Asymmetric line-shape
3. Presence of artefacts (e.g. tissue-air interface “ghosts”, lipid contamination, motion
artefacts, eddy currents, etc.)
4. Poor water suppression (< 98%)
5. SNR < 3 (when metabolite used for quantification)
6. SNR < 2 (for metabolite detection only)
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7. CRLB > 50% (CRLB will be discussed in more detail in the section on quantification quality
control - 5.4.2)
8. Residuals contain unexplained features (also part of quantification quality control)
5.4.1.2 The problems of manual quality filtering
Manual quality filtering can be performed to impose these quality criteria but comes with
several problems. First, the human assessment is highly subjective and context dependent: the
same signal can be classified differently depending on the quality context it is shown in (i.e.
depends on the other spectra in the dataset), the level of experience of the rater, the time of the
day, or even her/his mood. Second, manual assessment of the spectra requires a certain minimal
degree of expertise, and, especially in clinical settings, experts are often not sufficiently available
in many centres that want to apply MR spectroscopy as a clinical routine tool. Third, manual
assessment of large datasets is extremely time-consuming. This can already be a problem in
large collections of SVS spectra, but is considerably augmented in 2D and 3D MRSI, and is
worst in high spatial resolution MRSI-techniques such as EPSI [Posse 1995, Mulkern 2001] and
SPICE [Lam 2015, Ma 2016]. Consequently, very often if automatic methods for quality control
are not available, the quality of the data is only manually checked when this is absolutely
necessary, e.g. if a clinical diagnosis depends on it.
5.4.1.3 Automatic methods
More recently, automatic and semi-automatic quality control methods have been proposed
for performing quality checks of MRS signals. An example of a semi-automated approach
is presented in one of the papers [van der Graaf 2008] on the INTERPRET project. In that
work, the quality control strategy used to assess the SVS brain tumour proton spectra of the
INTERPRET database is described. The decision whether the spectra met the quality criteria
for sufficient quality had two main steps. First, the values of the automatically determined
linewidth and SNR were used to accept or reject spectra based on pre-defined thresholds
(rejected if SNR<10 or FWHM> 8 Hz). Second, between 1 and 3 spectroscopists checked the
spectra for the presence of artefacts. More details on the workflow used can be found in the
original paper.
Several novel methods for automatic quality control can be found in more recent literature
[Wright 2008, Menze 2008, Wright 2013, Pedrosa de Barros 2016b, Pedrosa de Barros 2016a].
These methods rely on pattern recognition algorithms that are able to learn to automatically
assess spectral quality based on pre-labelled data that is used for training. Automatic methods
have shown high performance, in some cases identical to expert spectroscopists with more than
20 years of experience. These methods present a viable solution for problems that are associated
with the manual labelling: first, automatic methods are completely objective and reproducible;
second, once trained, they do not require the input of a human MRS expert anymore; and
third, are normally very fast, needing only a few seconds to classify the quality of hundreds of
spectra. These methods may contribute to the wider application of MRS in a clinical setting,
e.g. allowing the application of the techniques in clinical centres where no MR-spectroscopists
are available. The reason for this is that quality filtering is one of the most important steps for
quality assurance that needs to be performed obligatory on each spectrum, before the spectra
can further be analysed on whether they are pathologic or not.
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Wright et al. [Wright 2008] presented in 2008 an automatic method for assessing MRS
quality in single voxel brain tumour spectra. The method was trained and tested on SVS
data from the eTumour [Julià-Sapé 2012] and the INTERPRET databases that had been pre-
viously labelled as either “acceptable” or “non-acceptable”. The strategy used for the assess-
ment was the previously mentioned semi-automatic approach used in the INTERPRET project
[van der Graaf 2008]. The method followed a 2-step approach where in a first step an Inde-
pendent Component Analysis was used to reduce the dimensionality of the problem, and in a
second step the resulting features were used in a least-squares support vector machine. The
independent components used were fixed prior to the testing of the method. The method
showed a performance similar to the experts, given that it had an average agreement of 87%
with the experts’ judgements, and that the average agreement across all pairs of experts was
85%.
The same method was later on successfully applied to MRSI data of prostate tumours
[Wright 2013]. Also in this study, the agreement of the classifier with the experts was similar to
the agreement between experts. Besides the excellent classification results, the data selection
was focused on consensus labelling and, only those cases for which experts reached agreement
upon, were used to train and test the classifier. Experts agree almost every time on the “clearly
good” and “clearly bad” cases but disagree often in those cases that fall in the boundary between
acceptation and rejection. This might make it tempting to avoid these cases and interpret them
as “sources of inaccuracies” for the classifier. Learning theory shows the opposite: the cases with
most uncertainty in class membership carry the most information for the classifier [Lewis 1994].
Another automatic classifier for MRSI data was presented by Menze et al. [Menze 2008]
in 2008. This approach used the Random Forest (RF) [Breiman 2001, Liaw 2002] classifier
and tested the approach on long-TE PRESS data of brain tumour patients. The RF-classifiers
used as input features the magnitude-spectra intensities in the range between 0.5 and 3.6
ppm. The performance obtained for the spectra of the excitation volume had an area under the
curve (AUC) between 0.950 and 0.968, depending on whether borderline-quality spectra were
considered acceptable or not. The classifier was compared against SNR and Cramér-Rao-Lower-
bounds thresholding, showing consistently a higher performance.
More recently, our group presented a method [Pedrosa de Barros 2016b,
Pedrosa de Barros 2016a] for automatic control of MRSI brain tumour spectra that re-
lies also on the RF-classifier but uses a different set of features. Instead of using directly the
points of a certain chemical shift range of the spectra, a total of 47 different signal features
were extracted from both time and frequency domain. This work not only allowed to obtain
very accurate automatic classifiers (AUC in long TE 0.9769 and short TE 0.9624) that are as
accurate as an expert, but also to identify several signal features that are highly correlated with
spectral quality.
5.4.1.4 Signal features with relevant information for automatic quality assessment
Figure 5.7 shows the feature importance of the several features used in the proposed method.
The measure used to evaluate the feature importance was the error increase seen in the perfor-
mance of the classifier after permuting the values of a selected feature between the different
examples of the test set. A higher increase in the error after permuting the values of a certain
feature is interpreted as higher importance for the classification (more information about this
measure can be found in [Breiman 2001, Liaw 2002]). Seven features are worth mentioning
in more detail due to their high impact in the classification accuracy. First the SNR of the
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Figure 5.7: Feature importance plots. The vertical axis shows the mean error increase observed after permuting the values of the
corresponding feature in the dataset [Liaw 2002]. The mean and standard deviation of the error increase were calculated from
the 12 different random forests that were trained during cross-validation. The error bars show the mean ± standard deviation
of the error increase. FD, frequency domain; SNR, signal-to-noise ratio; TD, time domain. For more details on the features and
cross-validation strategy see [Pedrosa de Barros 2016b].
highest peak found in the ranges between 1.6-2.2 ppm, 2.6-3.1 ppm and 3.1-3.5 ppm. For
almost every brain spectrum, these correspond respectively to the SNR of NAA, creatine and
choline. As expected, these features correlate well with signal quality. However, these fea-
tures were not identified to be the most important features by the computed RF-classifiers. In
frequency-domain, the skewness and the kurtosis showed higher importance for long TE data.
In time-domain, the mean SNR in the ranges between 75-100 ms for long-TE, and 50-75ms and
75-100ms for short-TE, was also more important than the metabolite SNR.
5.4.1.5 Frequency-domain skewness and kurtosis
Skewness and kurtosis are measures of, respectively, the third and fourth moments about the
mean. According to Cramér [Cramér 1946, Joanes 1998] these can be estimated for a sample of
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Skewness measures the symmetry of a distribution, being zero for symmetric distribution and
increasing its magnitude with increasing asymmetry. Skewness can be positive or negative
depending on whether the distribution is left or right skewed. On the other hand, kurtosis
reflects the “peakedness” of the distribution, or more correctly, the weight of its tails. Heavy-
tailed distributions show negative kurtosis, whereas light-tailed distributions have positive
kurtosis. The formula presented here for kurtosis uses as reference the normal distribution,
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Figure 5.8: Box and whiskers-plot showing the values of the FD skewness (Left) and FD kurtosis (Right), grouped by quality label
(“Good” or “Bad”) and TE (short-30ms and long-135ms). The features were extracted after residual-water-peak removal. A total
of 19032 MRSI spectra are represented in these plots (3708 Short TE “Bad”, 5808 Short TE “Good”, 3214 Long TE “Bad”, and
6302 Long TE “Good”).
Figure 5.9: Comparison between the ground-truth (manual-labelling performed by the experts: 0 = ”reject”, 1 = ”accept”), the
prediction of the automatic classifier (raters’ acceptance probability), and frequency-domain skewness and kurtosis, for both
short (30ms) and long-TE (135ms) data. Each row corresponds to a different patient. Short and long-TE data were acquired se-
quentially and in the same exact location. Acquisition details: 1.5T Siemens Aera 2D-PRESS TR 1500ms, 12x12 k-space samples,
interpolated resolution 32x32.
whose ratio between the 4th and the squared 2nd moment about the mean is 3. Therefore, using
this formula, samples with a close to normal distribution will have a kurtosis close to zero.
Skewness and kurtosis of a spectrum can be used to assess the distribution of its intensity
values. Spectra without a strong baseline and with narrow linewidths have a higher number of
low level intensities and consequently have high skewness and kurtosis levels. On the other
hand, baseline distortions, broad linewidths and broad signal artifacts lead to flatter histograms
and, consequently, to lower skewness and kurtosis. These relations help to understand why
these two features are good quality indicators for long TE data, namely after residual water
peak removal, given that the residual water causes considerable histogram changes that are
often not related with signal quality. In the case of short TE, skewness and kurtosis are highly
reduced by the strong macromolecular baseline independently of the quality of the spectra,
and consequently these features contain less information for the identification of poor-quality
spectra. Figures 5.8 and 5.9 show the relation between these features and the quality of the
spectra for both short and long TE.
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Figure 5.10: Plots of the Time-Domain Mean SNR for different ranges, for both short and long TE data. The plots show the
average value ± standard deviation over all “Good” or “Bad” spectra of the dataset.
Figure 5.11: Comparison between the ground-truth (manual-labelling performed by the experts: 0 = ”reject”, 1 = ”accept”), the
prediction of the automatic classifier (raters’ acceptance probability), and time-domain mean SNR within the 50-75ms and the
75-100ms ranges, for both short (30ms) and long-TE (135ms) data. Each row corresponds to a different patient. Short and long-TE
data were acquired sequentially and in the same exact location. Acquisition details: 1.5T Siemens Aera 2D-PRESS TR 1500ms,
12x12 k-space samples, interpolated resolution 32x32.
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5.4.1.6 Time-domain mean SNR for different ranges
Time-domain mean SNR is another interesting feature, namely in the range between 50 and
100 ms for the tested data (Siemens Aera and Avanto, 1.5T, PRESS, TR 1500ms, TE 135 and 30
ms). The relation of this parameter with signal quality is related with the shorter T2∗ values of
the signals with poor quality. Poor quality signals, even those with extremely high amplitude
artefacts, decay more rapidly than others with higher quality. Consequently, the most relevant
time domain range to evaluate signal quality is the range where poor quality FIDs have already
decayed almost completely but where FIDs with longer T2∗ have still moderate intensities
(Figure 5.10 and 5.11). This range should be dependent on the acquisition conditions, namely
field strength. In contrast with skewness and kurtosis, time-domain mean SNR is an important
quality indicator for both short and long TE data.
5.4.2 Quantification quality control
Several metrics have been used to assess the reliability of the quantification results. In
this section we will discuss some of those measures, namely the Cramér-Rao Lower Bounds
(CRLB) [Jiru 2006, Ratiney 2005, Cavassila 2001], methods for experimental error estimation
such as the ER-ARSOS [Slotboom 2009, Slotboom 2011], and the fit quality [Slotboom 2009,
Slotboom 2011]. These measures can be used to detect the situations where the quantification
method used, due to several factors such as low SNR or line-shape distortions, was not able to
generate accurate results.
5.4.2.1 Cramér-Rao Lower Bounds
Cramér-Rao Lower Bounds (CRLB) [Jiru 2006, Ratiney 2005, Cavassila 2001] provide a theoret-
ical estimation of the minimum obtainable variance in the estimation of a model-parameter,
given the measurement data. For a given set of model parameters
θ = [θ1,θ2, . . . ,θn]
T (5.3)





















the variance of the estimator of the parameter i.
One obtains high CRLB values, for example, in cases of low metabolite SNR, or (strongly)
overlapping resonances of two or more resonance lines. CRLB error estimation is only valid
if the assumption that the model used to describe the data fully applies to the data, and the
correct probability density function of the noise is known. Therefore, in case signal artefacts are
present or the spectra contain more resonances than modelled, the error estimation provided
by the CRLB is not valid [Slotboom 2011]. Another important property of the CRLB is that
the error estimation increases with the number of estimated parameters. For this reason, the
number of parameters to estimate should be kept as low as possible. The most important way
to keep the number of parameters as low as possible is to make use of prior knowledge models.
Many groups use quality filtering based on relative CRLB (ratio between the CRLB and
the estimation of the parameter). Despite its common use, the use of relative CRLB instead
of absolute CRLB comes with several dangers. As explained in the work of Kreis [Kreis 2015],
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the usage of relative CRLB filtering may strongly bias study data, since metabolites having
low concentration values will be classified as poor quality data. Moreover, the analysis of data
from conditions leading to low metabolite concentrations might become completely impossible,
since most of the data from the patients with such condition would be potentially rejected.
CRLB are available in quantification methods such as LCModel [Provencher 1993] and
QUEST [Ratiney 2005] and several examples of their use can be found in literature. An example
of the use of CRLB is given in the work of Jiru et al. [Jiru 2006], where the authors suggest that
metabolite maps should always be accompanied by a CRLB map to help identifying spectra
with lower quality.
5.4.2.2 Experimental Error
For SVS, where signal averaging is applied to obtain sufficient SNR, the quantification error can
be estimated experimentally [Slotboom 2011, Bolan 2004, Bolliger 2013], as an alternative to
the CRLB. To determine the error, quantification is performed independently for the several
signals, and the standard deviation in the quantification of each metabolite is then calculated.
Since the number of signals might be, in some cases, too small for obtaining accurate estimates,
Bolliger et al. [Bolliger 2013] proposed the use of bootstrapping to increase the size of the dataset
artificially. The author showed that errors estimated from a bootstrapped sample are very close
to the theoretical estimations provided by CRLB.
ER-ARSOS [Slotboom 2009, Slotboom 2011] is another method that uses separately stored
signal acquisitions for experimental error estimation. In this technique, the error of the
measurement is estimated by the variance in the quantification results of the separately filtered
signals. The filtering is performed by means of All Rank Selected Order Statistic filtering
(ARSOS) [Slotboom 2009] prior to the quantification. This unique filter turns the N low-
SNR individual input signals, into N/2 high SNR output signals, which can all be quantified
meaningfully. For in vivo MRS, the observed ER-ARSOS errors that are found, are mostly larger
than the CRLB which are often too optimistic. The reason for this is that ER-ARSOS not only
depends on Gaussian noise, as CRLB does, but also on heavily tailed noise that scales with the
MRS signal itself. Examples of sources of heavily tailed noise include, for example, patient
motion and tissue pulsation.
5.4.2.3 Fit Quality Number
Another practical measure of the error associated with the quantification is given by the
“normalized fit quality number” [Slotboom 2009, Slotboom 1998]:




, where N is the number of data points from the time or frequency domain signal used, R is
the sum of the squares of the residuals (difference between the fit and the measured signal),
and σ the variance of the signal measured in a region with no metabolite signal contributions.
This measure is close to 1 for a close to perfect fit. Values of Qf it significantly larger than 1
indicate significant differences between the fit and the experimental data which could indicate
an inappropriate data model or a local minimum in the sum of least squares (χ2). On the other
hand, Qf it values smaller than 1 strongly indicate overfitting of the model to the data.
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5.5 Techniques to Improve Quality
Quality of MR spectra is a very broad subject, and many different strategies can be found in the
literature for tackling different quality issues. In this section, we mention some techniques and
corrections that can be used to improve the quality of the spectra.
5.5.1 Eddy current correction
Eddy currents cause the frequencies of all resonances to become time and spatial dependent,
leading to complex distortions of the line-shape (so called “wiggles”). If not compensated,
these distortions give rise to quantification errors. From the scanner hardware side, shielded
gradient systems, in combination with active electronic eddy current compensation systems are
used to minimize their effects [Van Vaals 1990]. Even after taking these measures to minimize
their effects, often residual eddy currents effects are still visible in the spectrum. In order
to correct these undesired residual eddy current effects, de Graaf et al. proposed already in
1990 a deconvolution method named QUALITY (quantification improvement by converting
line-shapes to the lorentzian type) [De Graaf 1990]. This method performs on the acquired
MR-signal a time domain deconvolution with a reference signal, normally the unsuppressed
water signal of the same localization, allowing to obtain perfect Lorentzian line-shapes.
5.5.2 Elimination of unwanted MRS Signals: Phase Cycling and Crusher Gradi-
ents
The flip-angles of selective RF-pulses, which are used in localized MRS, are non-ideal, i.e.
these pulses do not excite the spins uniformly over the excited target volume. Besides this, the
pulse imperfections lead also to signal excitation outside the target volume, namely for flip
angles larger than 90 degrees. Direct application of these pulses, without taking any actions
that eliminate the effects of these imperfect flip angles, results in the presence of unwanted
echoes that cause strong artefacts in the localized spectra. In order to prevent these artefact
signals, two techniques are normally used: RF-pulse phase cycling (e.g. EXORCYCLING,
[Bodenhausen 1977]), and the use of “crusher gradients pairs” that actively dephase all un-
wanted MRS-signal contributions that were excited by the RF-pulse. These two techniques are
normally combined to eliminate the unwanted echoes even more effectively.
5.5.3 Order of selection pulses
A very simple strategy that can lead to a drastic quality improvement in sequences such as
PRESS and STEAM, is the correct decision over the order of the selection pulses. This topic
is extensively discussed in the work of Ernst T. and Chang L. from 1996 on the elimination of
signal artifacts in short TE brain spectra of the frontal lobe [Ernst 1996].
"Ghost" artefacts are often seen near the sinuses, namely in the frontal lobe. These cor-
respond to signals from insufficiently dephased unwanted coherences originating from the
sinuses and the mouth. As explained in the mentioned reference, the origin of these unwanted
coherences depends on the exact order in which the three slice-selective pulses are applied.
Therefore, given that the third slice selection pulse is more subjective to insufficient spoiling,
this should cover the “least problematic” plane, and avoid regions prone to field inhomo-
geneities such the as the sinuses and the mouth. Consequently, in order to improve the quality
of the spectra acquired in the frontal lobe, the axial plane should be selected at last. Figure 5.12
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Figure 5.12: SVS spectra from the midfrontal lobe of a healthy volunteer. The slice order of the upper spectrum was axial-
coronal-sagittal, whereas from the lower was coronal-sagittal-axial. Original figure from [Ernst 1996]. Copyright by John Wiley
and Sons.
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shows a good example of the impact that the slice order can have on the quality of the obtained
localized spectra.
5.5.4 Chemical Shift Displacement Artefact
Given that the spins of the different substances measured in MR spectroscopy have different
chemical shifts, and consequently different resonance frequencies, the region that is selected
for each spin by the same RF pulse depends on its chemical shift. The resulting displacement
in the localization of the VOI caused by the differences in the chemical shift is referred to as the
Chemical Shift Displacement Artefact (CSDA).
The relation between the resonance frequency and the corresponding generic coordinate r,
depending on the gradient in the r-direction Gr , the chemical shift σ , and the main magnetic
field B0 is given by the following expression [Goelman 2007]:
ω (r,Gr ,σ ) = γGrr +γB0 (1− σ ) ⇔ r (ω,Gr ,σ ) =
ω − γB0 (1− σ )
γGr
(5.6)
, where γ is the gyromagnetic ratio. From this expression, it follows that the displacement ∆r













, where BWRF is the bandwidth of the RF-pulse, and FOVr the Field-of-View in the r-
direction. This expression shows that the chemical shift displacement increases linearly with
the magnetic field strength and the FOV, and decreases with the bandwidth of the RF-pulse
(see Figure 5.13). Therefore, the use of higher bandwidth pulses is an effective way of reducing
the displacement effect. However, it should be noted that for non-adiabatic, i.e. amplitude
modulated only, RF-pulses, the excitation bandwidth is limited by the RF-amplifiers maximum
available RF-peak power. At the same RF-peak power, adiabatic pulses can obtain much larger
excitation bandwidths than non-adiabatic RF-pulses.
Figure 5.14 shows the effect of the CSDA for a 2D-MRSI PRESS sequence, where the selection
profile of choline is shifted in the y-direction relatively to that of lactate. Knowing that the
bandwidth of the 90◦ pulse is considerably larger than the one of the 180◦ pulses, it can be
concluded that the 90◦ pulse was applied in the x-direction.
The choice of the orientation of the different pulses should consider the impact that the
chemical shift can have in each direction. For example, in 2D-MRSI slices of the brain acquired
using PRESS, the use of the 90◦ pulse in the x-direction (from right to left of patient) reduces the
impact that chemical shift has on the contralateral comparison. Moreover, for the same example,
given that the FOV in the z-direction is considerably smaller than in the other directions, it is
advisable to use one of the 180◦ pulses in that direction.
The CSDA can lead to signal cancellation in coupled spin systems [Slotboom 1994b,
Lange 2006, Kaiser 2007] when pulse echo sequences are used. This results from the fact
that the differences in displacement between the coupled spins of the same molecule (e.g. for
lactate) will create different compartments where, for each direction, both or only one of the
spins is selected (Figure 5.15). The evolution under J-coupling of these non-uniformly excited
spin systems will be different in each physical compartment, which may lead to the creation
of MR-signals with opposing phase, causing intra-voxel signal annihilation. This effect can
lead to a considerable underestimation of certain metabolites, such as lactate [Lange 2006]
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Figure 5.13: Plot showing the effect of doubling the bandwidth of the RF-pulse on the chemical shift displacement, for a given
chemical shift difference. The solid lines show the relation between frequency and the generic coordinate r for the protons
resonating at the Larmor frequency. In these lines, the gradient is adapted so that the same region is selected independently of
the bandwidth of the pulse. The 2 dashed lines show how the relation between frequency and the selected coordinate changes for
a chemical shift σi > 0. The selected FOV depending on the RF-pulse bandwidth and chemical shift is displayed on the vertical
axis.
Figure 5.14: 2D selection profiles of Cho (A) and Lac (B) and difference between them (C) showing chemical shift displacement
in the y direction for a 2D PRESS sequence (1.5T Siemens Aera, TE/TR 135/1500ms). The amplitudes of each metabolite were
normalized so that the selection profiles have the same integral as a perfect step function selecting the same VOI (amplitude 1
inside VOI and 0 outside).
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Figure 5.15: Different localized regions in the presence of chemical shift displacement for two spins I and S with different
chemical shift. The image shows the different selection compartments in the xy-plane when localization is applied in the x and y
directions. The four distinct localized regions from each spin can be distinguished in the figure.
and GABA [Kaiser 2007]. Sequences such as SADLOVE or semi-LASER offer an effective so-
lution for this artefact [Slotboom 1994b], given that the phase-compensated 2π pulse pair
[Conolly 1989b, Conolly 1989a] have a considerably large bandwidth, and the effects of J-
coupling during the 2π pulses are minimal (see Figure 5.16).
5.5.5 Metabolite cycling
Another technique that improves the quality of the spectra in challenging areas like the spinal
cord, is the so-called “metabolite cycling”. The use of this technique and the impact that it can
have on the quality of the recorded data is well exemplified by the work of Andreas Hock and his
colleagues on MR-spectroscopy of the spinal cord [Hock 2013]. Metabolite cycling consists in
the interleaved acquisition of spectra with and without the use of an inversion pulse that targets
the metabolite signals. Consequently, it is possible to separate water and metabolite signals
without performing water-suppression. Moreover, since the water signals are not distorted
by the water-suppression RF-pulses, they can be used for eddy-current correction, as well as
to correct the frequency shift of the metabolite signals caused by the patient motion and B0
field drift. The authors demonstrated the effect of performing these corrections before signal
averaging in the final result. The article also nicely demonstrates a comparison between spectra
acquired with metabolite cycling, and spectra acquired with water-suppression, showing that
the first has significant narrower linewidths and higher SNR.
5.5.6 Strategies for tackling movement artefacts
An important source of error in any MR acquisition is patient movement. As shown in the work
of Kreis [Kreis 2004], movement artefacts are not easily detected in SVS after signal averaging,
not even when the patient leaves the scanner in the middle of the acquisition. Several authors
proposed different strategies to tackle movement artefacts.
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Figure 5.16: Spatially dependent coherences for 2 spin coupled system with coupling constant J = 7Hz resulting from the PRESS
localization (left), and SADLOVE localization (right). The identification of the corresponding product operators is presented in
the middle. In the image, the grey level corresponds to the expectation value of the phase: white represents 1 and black -1. It was
considered a bandwidth of 2kHz for the selective pulses and total offset range of 4.5 kHz in both x and y directions. Especially
note that in the PRESS experiment there is a 180° phase flip over the selected volume, which results in signal annihilation.
The SADLOVE (later LASER) pulse sequence does not show this effect for the same spin system. In order to make the results
comparable, the SADLOVE sequence used was a variant of the original sequence where the first pulse was replaced by a hard 90°
pulse (similar to semi-LASER). Source: [Slotboom 1993].
Slotboom et al. introduced the ARSOS filtering technique described above [Slotboom 2009]
to detect signal outliers in the separately stored signals acquired during the process of signal
averaging. ARSOS orders the N-equivalent time point or frequency point values of the sep-
arately stored acquired signal repeats point-by-point for all points of the TD or FD signals.
After this reordering, the output signals close to the extremes (minimum and maximum output)
contain the outlier signal contributions, often dominated by the effects of movement and tissue
pulsation. The filter works similarly to a median filter, and presents a straightforward solution
to tackle movement without having to perform any changes to the sequence. Depending on the
number of outlier signals containing filter outputs, ARSOS normally reaches higher SNR than
application of conventional median filtering. The only requirement for using ARSOS is that the
different signals are stored separately.
Another solution to detect movement artefacts is proposed by Bhattacharyya et al.
[Bhattacharyya 2007] who suggest the use of an interleaved acquisition of water spectra to
detect movements. The method was applied to a MEGA-PRESS sequence, where movements
can lead to undesired differences between ON and OFF acquisitions. Besides allowing the
detection of spectra affected by patient movements, the non-suppressed water spectra can be
used to perform eddy current and frequency shift correction, similarly to what was done in the
metabolite cycling method described above.
A more advanced approach to tackle movement artefacts is the vNav EPI suggested by Hess
et al. [Hess 2011, Hess 2013]. The method consists in the interleaved acquisition of an EPI
navigator, which is used to correct, in real time, the position of the spectroscopic voxel. This
correction of the localization is then used to perform frequency adjustment as well as first-order
shimming. The navigator is acquired during the recovery time, and has no impact in the total
acquisition time. The examples presented by the authors show the clear added robustness that
this approach can provide to a PRESS sequence.
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Figure 5.17: Example showing signal cancellation due to incorrect phasing of the metabolite signals prior to coil combination.
Between the acquisitions of the first and the second row the shimming parameters were updated causing the region, where a
transition in the phase of NAA is observed, to move its location. The arrows signal the transition region. ∆θNAA corresponds to
the phase difference between the original signals (phased using first point of FID and without removing residual-water-peak) and
the same signals after removing the residual-water-peak and correctly phasing NAA. NAA maps calculated by peak integration
of magnitude signals.
5.5.7 Metabolite signal cancellation due to incorrect phasing of water-suppressed
signals
Water suppression sequences such as CHESS[Haase 1985], consist of pairs of frequency-selective
pulses and dephasing gradients. These sequences are optimized such that, for the average
T1 of water, the longitudinal magnetization (MZ) is nulled by the time the first excitation
pulse of the volume-selection takes place. Given that Mz is never completely nulled, and
that the concentration of water is several orders of magnitude greater than other substances,
the amplitude of the remaining water signal is often greater than the amplitude of the other
signals. Moreover, in case Mz is negative at the start of volume selection, water will be acquired
with an inverted phase relatively to the metabolite signals. The phase of the water signal
depends on the effect that deviations in both T1 of water and flip-angle of the pulses have on
the water-suppression sequence used. Since these phase deviations jeopardize the use of the
water peak for frequency-shift and phase correction, the time between the water saturation and
start of the volume selection can be slightly extended such that the water spins have more time
to relax towards equilibrium, resulting in a situation where the residual water and metabolite
resonances have the same phase. On Siemens scanners, this type of water suppression is referred
to as “weak water suppression”.
Due to above mentioned effects, in MRSI water-suppression may produce regions where
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Figure 5.18: A) Phase map of choline for a 32x32 dataset. ∆θCho calculated as the phase difference between the original signals
(phased using first point of FID and without removing residual-water-peak) and the same signals after removing the residual-
water-peak and correctly phasing Cho. The spectra of two adjacent voxels are presented: in the first, water and metabolites
have the same phase whereas in the second, the phase of the water and the metabolite signals differ. B) Interpolated (128x128)
choline map showing signal cancellation due to phase jumps between adjacent voxels. C) Interpolated (128x128) choline map
after residual-water-peak removal and auto-phasing. The correction in this case is not complete given that the MRSI grid had
already voxels with signal cancellation due to coil-combination of badly phased metabolite-signals.
the phase of the water (relatively to the metabolite signals) abruptly changes sign from one
voxel to another. In those regions, metabolite-signal cancellation is frequently observed. This is
seen in Figure 5.17, where two phase maps and corresponding NAA maps are shown. These
two examples were acquired using the same phantom and acquisition parameters but with
different shimming parameters. The update in shimming caused the phase-jump region to shift
its position, and consequently the signal cancellation moves with it.
The signal cancellation observed in Figure 5.17 can be explained by the combination of
incorrectly phased metabolite signals from different coils. Incorrect phasing is predominantly
caused by differences between the phase of the residual water signal and the metabolite signals,
and is especially pronounced when zero-order phasing is performed globally, using for example
the first point of the FID. The result of auto-phasing is very sensitive to signal differences in
the regions where phase-jumps are observed. Consequently, signal-combination in phased
array coils performed after incorrect phasing leads to signal cancellation in those regions
[Strasser 2012].
Besides the above mentioned mechanism of signal cancellation, cancellation can also occur
as a result of spatial interpolation by means of zero-filling, as depicted in Figure 5.18-B. In this
case, signal cancellation occurs between neighbouring voxels that have metabolite signals with
opposing phase. Figure 5.18-C shows the interpolation of the same MRSI grid when the data
is previously phased after removing the residual water using HLSVD, therefore preventing
metabolite-signal cancelation due to interpolation. Even better, if interpolation is performed
on the quantification maps, since phase is handled separately for each metabolite by the fitting
algorithm, signal cancellation can be prevented.
In summary, signal cancellation can be prevented mainly by two measures. Firstly, the
use of water-suppression techniques that do not create spatially dependent phase-jumps in
residual-water signals. Secondly, the use of auto-phasing methods prior to coil-combination
that allow for a robust phasing of the metabolite signals, regardless of the phase of the residual-
water-signal.
5.5.8 Correction of slice selection profile in MRSI data
A big practical problem for the unambiguous interpretation of MRSI-data is the non-
homogeneous excitation of the spins within the excited volume of interest. These variations
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Figure 5.19: Slice profile correction. The top row shows the metabolite maps acquired in a phantom containing a solution of
17.5 mM Cho, 17.5 mM Cr and 17.5 mM NAA, and shows the amplitude of the three metabolites measured using QUEST. In the
middle row, we see three metabolite maps (quantification using QUEST) of a healthy test person. The last row shows the in vivo
metabolite maps after correction using the normalized maps of the first row.
Table 5.2: Coefficient of variance for choline, creatine and NAA, before (second row Figure 5.19) and after correction (third row
Figure 5.19) of the slice profile.
Cho Cr NAA
Before 30.32% 28.59% 23.82%
After 24.59% 14.90% 12.76%
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are clearly visible in the metabolite maps of the top row of Figure 5.19, from data acquired in
phantoms with homogenous metabolite in water solutions. The variations in observed MRSI
signals over the voxels are dominated by the excitation profile of the RF-pulses. Under the
assumption of equal average pulse flip angles, given that the slice profiles are constant for
the same RF-pulses, the spatial signal amplitude distributions of these phantom data can be
used for correction of in vivo MRSI-data acquired using the same sequence and parameters.
Since the pulse profile depends on the exact chemical of the spin, the correction factors must
be determined for each resonance line individually. The two last rows of Figure 5.19 show
three metabolite maps from a healthy volunteer, before and after correction. The coefficient of
variance was measured for each in vivo map, showing that the correction of the slice profile
leads to a reduction in the spatial variations of the map (Table 5.2). Further developments are
in progress to incorporate the correction of these effects into a processing pipeline of clinical
routine MRS.
5.6 Conclusion
This article covered several important aspects of quality management in localized in vivo
MR-spectroscopy. First the main principles behind quality planning, assurance, control and
improvement were discussed. After this, several phantom tests were described in section 5.3,
and in section 5.4, methods for detecting errors in the acquisition and quantification were
presented. Finally, several practical suggestions for quality improvement were given.
To summarize, achieving good results in MRS does not depend only on good quality filtering
or reliability evaluation. It is also of utmost importance to have thorough knowledge of what
might fail and the consequences on the observed MR-spectra. Quality requirements should
be defined, scanner and sequences need to be periodically and thoroughly tested, and, as a
consequence of the quality cycle, better methods should be implemented/developed. The “best”
solutions for each step depend on the application and the context of use; thus, what will work
best for each user, may be different from one centre to the other.
As a final thought, we would like to emphasize here that besides recent efforts in the
standardization of in vivo MRS (e.g. [Oz 2014]), there is still a lack of generally accepted and
implemented standards. For MRS-methodology developers this is not a real drawback, since
they are searching for improvements. However, for clinicians that want to apply the MRS-
methodology, this is a real problem. Clinical routine spectroscopy requires the implementation
of these standards. With this, the clinical literature would become more consistent, contributing
to increase the clinical value of MRS.
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This chapter is based on the following publication:
N. Pedrosa de Barros, R. Mckinley, U. Knecht, R. Wiest, J. Slotboom, Automatic quality control
in clinical 1H MRSI of brain cancer, NMR Biomed. 29 (2016) 563-575. doi:10.1002/nbm.3470.
6.1 Summary
MRSI grids frequently show spectra with poor quality, mainly due to the high sensitivity of
MRS to field-inhomogeneities. These poor-quality spectra are prone to quantification and/or
interpretation errors that can have a significant impact on the clinical use of spectroscopic data.
Therefore, quality control of the spectra should always precede their clinical use. When per-
formed manually, quality assessment of MRSI spectra is not only a tedious and time consuming
task, but is also affected by human subjectivity. Consequently, automatic, fast and reliable
methods for spectral quality assessment are of utmost interest. In this article, we present a
new Random-Forest based method for automatic-quality-assessment of 1H-MRSI brain spec-
tra, that uses a new set of MRS signal-features. The Random-Forest classifier was trained on
spectra from 40 MRSI grids that were classified as acceptable or non-acceptable by two expert
spectroscopists. To account for the effects of intra-rater reliability, each spectrum was rated for
quality three times by each rater. The automatic method classified these spectra with an AUC
of 0.976. Furthermore, in the subset of spectra containing only the cases that were classified
every time in the same way by the spectroscopists, an AUC of 0.998 was obtained. Feature
importance for the classification was also evaluated. Frequency-domain skewness and kurtosis,
as well as time-domain SNR in the ranges from 50 to 75 ms, and from 75 to 100 ms, were the
most important features. Given that the method is able to assess a whole MRSI grid faster
than a spectroscopist (∼3 seconds vs ∼3 minutes), and without loss of accuracy (agreement
between classifier trained with just one session, and any of the other labelling-sessions: 89.88%;
agreement between any two labelling-sessions: 89.03%), the authors suggest its implementation
in the clinical routine. The method presented in this article was implemented in jMRUI’s
SpectrIm plugin.
6.2 Introduction
Localized in vivo Magnetic Resonance Spectroscopy (MRS) provides important biochemical
information on living tissues, and has proven its added value, for example, in brain tumour
diagnostics and evaluation of inborn diseases. However, in vivo MRS-signals are very sensitive to
susceptibility differences and consequently, near bone-tissue and tissue-air interfaces, as well as
when post-operative paramagnetic particles are present, artifacts are often found [Kreis 2004].
Other factors such as bone-marrow and subcutaneous lipid contamination, uncompensated
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eddy currents and poor water suppression can negatively affect the quality of the spectra,
and consequently reduce its clinical value. Even worse, if not aware of these phenomena,
clinicians can easily draw wrong conclusions from poor quality metabolic maps, since standard
quantification software does not check the quality of the spectra it quantifies.
A few metrics have been proposed to help identifying low quality spectra. Cramér-Rao
Lower Bounds (CRLB)[Jiru 2006, Ratiney 2005, Yan 2002], for example, have been used for
assessing the estimation error in quantification. The error is normally higher in spectra with
poor quality, given that the quantification model is not able to fit well to the data. Moreover,
these errors are only valid if the model applies to the measured MR-signals [Slotboom 2011],
which is in general not the case for MRSI data containing artifacts. Apart from this, it was
shown in a recent study [Kreis 2015] that quality filtering based on relative CRLB implies the
rejection of data with low metabolite levels, and consequently, may create a bias in the estimated
mean concentrations of group data, as well as prevent the clinical use of MRS in any disease
leading to low metabolite levels. Other metrics, such as ER-ARSOS [Slotboom 2011, Kreis 2015,
Slotboom 2009], have been proposed for estimating the error in metabolite quantification using
single voxel spectroscopic (SVS) data. ER-ARSOS differs from theoretical error estimators, such
as CRLB, in that it is obtained experimentally. Nevertheless, given that it requires the multiple
signals acquired in the process of signal averaging, it is specific to SVS.
Manual quality checking of MRSI recordings requires much time, and can only be done
by expert users. What constitutes a good quality spectrum varies between MR users, mainly
depending on their level of experience and the aim for which the recording is made. In
order to make MRSI more clinically applicable, MRSI-evaluation programs should be able to
automatically recognize bad quality spectra and mask them out. This would allow a clinical
user to base clinical decisions only on the reliable, high quality parts of the MRSI-maps. In
this paper we introduce a random forest (RF) based method for automatic quality assessment
(auto-QA) of clinical MRSI-data whose primary aim is to improve the clinical diagnostic process
by: 1) reducing the time needed for a clinical evaluation, 2) eliminating the dependency on
an experienced spectroscopist to perform the assessment, and 3) eliminating the inherently
subjective aspect of manual spectral quality assessment.
Various methods for auto-QA have been reported in the past. In the work of Wright et
al. [Wright 2008] an automatic method for assessing quality in brain tumour SVS spectra was
presented, based on SVS data from the eTumour (http://solaria.uab.es/eTumour/) and the
INTERPRET (http://gabrmn.uab.es/interpret/) databases. Data pre-processing was done
as defined in [Tate 2006]. Manual quality control was performed by multiple spectroscopists,
classifying the spectra in either acceptable or non-acceptable according to the criteria defined
in [van der Graaf 2008]. The classification was done using a least-squares support vector
machine classifier trained on features derived from Independent Component Analysis (ICA).
The classifier had an average agreement of 87% with the expert raters. Given that the average
agreement across all pairs of experts was 85%, the authors conclude that the method is at least
as accurate as an expert spectroscopist.
Later on, the same classification strategy was applied to MRSI data of prostate cancer
[Wright 2013]. In that work, the manual quality assessment was done by 4 expert spectro-
scopists, and only those spectra for which there was assessment consensus were included in
the final dataset. The discarded no-consensus spectra corresponded to 17.3% of the spectra
in the initial dataset. From the remaining spectra, a subset was separated and used to opti-
mize the parameters of the classifier. Again, the obtained results allowed the conclusion that
the performance of the automatic method was comparable to the expert spectroscopists: the
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average agreement between pairs of experts was 88.7%, while the classifier agreed with each
spectroscopist on average 87.2% of the time.
Another method for auto-QA was presented by Menze et al. [Menze 2008]. In this work, the
freely available “R” implementation of the RF-algorithm [Liaw 2002] was used in the classifi-
cation of long-TE multi-slice 2D PRESS sequence water suppressed spectra of brain tumour
patients. The input features used for classification were the magnitude-spectra intensities
between 0.5 ppm and 3.6 ppm. The authors compared the performance of the automatic
classifier with decision rules based on SNR and Cramér-Rao-bound, showing that the first
was consistently superior. The classification results obtained for the spectra within the PRESS
box had an area under the curve (AUC) between 0.950 and 0.968, depending on whether
borderline-quality spectra were considered acceptable or not.
The work on auto-QA presented here is also based on RF. However, a completely different
strategy for selecting the input features was used. Instead of feeding the classifier with a
certain range of points from the pre-processed spectra, 47 features were extracted from both
time-domain (TD) and frequency-domain (FD). The relative importance of these features was
then evaluated using intrinsically computed measures to the RF algorithm. Such analysis allows
comparing several characteristics of the spectra in terms of their relation to the perception of
spectral quality.
Another significant difference to the work of Menze et al. [Menze 2008] is the way in which
the methods were evaluated: in this paper a cross-validation scheme was used; whereas the
results of Menze et al., relied in a single split of the data between train and test datasets. The
advantage of using a cross-validation strategy is that, as it relies on several different divisions of
the data into training and testing datasets, the obtained results should generalize better to the
real application of the method in the clinical environment. As stated in [Kuhn 2013], “a test set
is a single evaluation of the model and has limited ability to characterize the uncertainty in the
results.”
The work presented in this paper was performed in the framework of the EU-
funded TRANSACT-ITN (TRANSforming Spectroscopy into a Clinical Tool: http://www.
transact-itn.eu/), and the algorithms were implemented into a novel MRSI-analysis-GUI
(SpectrIm Plug-In [Pedrosa de Barros 2014]) of the jMRUI-software (http://www.jmrui.eu/).
6.3 Methods
6.3.1 Ethics
All MRSI data used here was recorded from patients assigned to our institute with suspected
malignant glioma, which was subsequently confirmed by histology. The measurements were
performed conforming to local and national ethical regulations. All patients gave their informed
consent to use the data for scientific purposes.
6.3.2 Data
All MRSI data was acquired with two different 1.5T Siemens Scanners (Aera, Avanto), using the
2D PRESS Fast MRSI product sequence with a TR of 1500 ms and water suppression (CHESS).
Only long TE (135 ms) was used in this study. The 2D MRSI grid had an interpolated resolution
of 32x32, with a voxel size of 5x5 mm and slice thickness of 15 mm. The excited PRESS-volume
was optimized for each individual patient. In order to obtain a representative test set of spectra,
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Figure 6.1: Labelling Assistant tool for jMRUI SpectrIm plugin. The assistant helps the user to label a group of spectra, one
by one, into either acceptable or non-acceptable. The tool automatically iterates over all voxels displaying for each the spectrum
and the localization. The figure shows the labelling-assistant requesting the user to label the selected spectrum in the tumour
affected area. The tool provides information regarding the number of voxels that were already labelled by the user during the
labelling-session. After labelling every spectrum, all features and labels are saved into a user-defined labelling file. This file can
then be analysed using the Labelling Session Analyser (Figure 6.2).
a total of 12 brain tumour patients, with 2 to 4 follow-ups acquired pre- and post-operatively,
were included in the study. Overall, 40 MRSI recordings with a total of 9756 spectra, all
originating from within the PRESS box only, were used in this study. All spectra outside the
excitation PRESS-box were discarded. Two different datasets were created: one where spectral
features were extracted directly from “raw” non-pre-processed data –Water-Not-Removed
(WNR) dataset; and a second dataset where residual-water-peak removal using jMRUI’s HLSVD
method was applied– Water-Removed (WR) dataset. The peak-removal was performed in a
broad range, from 4.1ppm to 9.0ppm, given that poor water-suppression artifacts were often
found.
6.3.3 Labelling Tools
Two new tools were developed for jMRUI’s SpectrIm plugin[Pedrosa de Barros 2014]: the
Labelling Assistant (Figure 6.1) and the Labelling Session Analyser (Figure 6.2). The first
tool allows the user to quickly label a pre-selection of voxels from a MRSI grid, one by one,
and to save these labels together with the automatically computed numerical MRSI-signal
features in one file. For each voxel, the tool displays not only the spectrum but also its location,
which allows incorporation of both MR-spectra and -image related information in the labelling-
process. Additionally, any image series of the same MR-examination can potentially be used as
background image.
Labelling a user-defined set of voxels in a MRSI grid is called a “labelling-session”. Given
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Figure 6.2: Labelling Session Analyser tool for jMRUI SpectrIm plugin that allows the user to manage labelling-sessions. In the
screenshot, the table of this tool shows a list of several labelling-sessions from a certain file. In the presented case, the labels from
a previous session were loaded and are being shown as a coloured map over the MRSI grid. In the map, red and blue correspond
respectively to spectra which quality is acceptable and non-acceptable.
the large amount of data obtained in this way, a tool to support the management and analysis
of these labelling-sessions was created (called Labelling Session Analyser). Using this second
tool, the user is able to access the data of these sessions and view the following information:
used labelling classes, patient name, study date, series number and description, labelling start
date and time, labelling duration, number of classified voxels, and mean value and standard-
deviation of the (numeric) labels. The user is also able to load a labelling-session as a label map
and display it on top of the MRSI grid, as it can be seen in Figure 6.2, as well as delete a specific
session from a file.
6.3.4 Manual Quality Assessment
Using the previously described tools, 2 expert spectroscopists (having 29 and 2 years of experi-
ence) labelled all the spectra 3 times each, which allowed the analysis not only of variations
between spectroscopists, but also of variations between different sessions of the same spectro-
scopist. In this way each individual spectrum was assigned to a score between 0 (meaning 6
times classified as non-acceptable) and 6 (meaning 6 times labelled as acceptable quality).
Before labelling each grid, all residual-water resonances between 4.1 ppm and 9 ppm were
removed using jMRUI’s HLSVD method. After water-peak removal, automatic-phasing was
performed in order to prevent bad-phasing from biasing the spectroscopists’ classification. The
features extracted from the MRSI-signals are such that this auto-phasing has no impact on their
numerical value. No other pre-processing step was performed.
The criteria used by the spectroscopists for classifying spectra as having non-acceptable
quality were: a) the presence of “ghosting” artifacts [Kreis 2004], b) bad shimming (frequently
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occurring on localizations close to bone-tissue and tissue-air interfaces), c) low SNR, d) bone-
marrow and subcutaneous lipid contaminations, e) signals with strongly deviating phase (even
after auto-phasing), and f) presence of artifacts caused by post-operative paramagnetic particles
(sometimes even having consequences on anatomical images, e.g. EPI).
After the manual assessment, the ground-truth was given by the winning labels over all
sessions, following a conservative approach: a spectrum was only considered acceptable when
classified as so more than 3 times in the 6 sessions. The authors considered as non-acceptable
those spectra that were classified 3 times as acceptable and 3 times as non-acceptable. The reason
for this is that, in the clinical environment it might be worse to have a bad-quality spectrum
that was recognized as acceptable by the auto-QA, than a discarded good-quality spectrum. In
the first situation, the bad-quality spectrum might be unnoticed and its quantification results
might impact the analysis; in the later one, if the clinician realizes that relevant spectra for the
analysis with acceptable quality are being discarded, he might still include them in the analysis
but he should do it with more caution.
In some specific situations not all of the labelling-sessions were used to determine the
ground-truth. In those cases, the strategy used will be specified.
6.3.5 Spectral Features
For each spectrum, a total of 47 features were extracted. In order to avoid phase dependency,
all features were extracted from the magnitude TD- and FD-signals. The choice of the features
followed the following rationale: the classifier should not learn the fine details of each TD and
FD signal, but perceive spectral quality from a more global perspective of these signals. This
approach prevents the classifier from overfitting to specific irrelevant details of the training
spectra, and is robust against spectral misalignment caused by field inhomogeneities and tem-
perature or pH alterations, etc. Compared to previous approaches (e.g. [Menze 2008]), where
all FD-points within a given ppm-range were used as input features, the features proposed
here enable representing relevant information of a broader range of the spectra with a smaller
number of features. The features used in this article can be grouped in 5 different groups:
1. Maximum peak SNR in given range (FD)
2. Mean SNR in given range (FD and TD)
3. Relative change in given range (TD)
4. Global TD features (maximum signal strength, time point of maximum signal strength,
mean, standard-deviation, skewness, kurtosis)
5. Global FD features (maximum signal strength, ppm value of maximum signal strength,
mean, standard-deviation, skewness, kurtosis)
The maximum-peak-SNR features were calculated as the SNR of the maximum value detected
in a given range and will further be denoted simply by “SNR” followed by the range in ppm,
e.g. “SNR [1.6; 2.2]”. The mean-SNR features are identical to the previous ones but instead
of the maximum value detected in the range, the mean value of the range is used instead. In
FD, these features will be denoted by “mean SNR” followed by the range in ppm (e.g. “mean
SNR[1.6; 2.2]”); and in TD by “TD mean SNR” followed by the range in milliseconds (e.g. “TD
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Figure 6.3: Acceptable (a.) and non-acceptable (b.) spectrum examples where one can see how spectral quality affects the FD
histogram and its parameters, namely skewness and kurtosis.
mean SNR[50; 75]”). The noise-level used to calculate the SNR was computed by the standard-
deviation of the signal in the 7 to 9 ppm range, for FD-features, and in the 600 to 800 ms range,
for TD-features.
In FD, the maximum-peak-SNR and mean-SNR features were calculated for the following
ppm ranges (and corresponding metabolites): a.) 0.5-1.1 (Lipids (-CH3)), b.) 1.1-1.6 (Lipids
(-CH2)+Lactate), c.) 1.6-2.2 (NAA), d.) 2.2-2.6 (Glutamate+Glutamine), e.) 2.6-3.1 (Creatine),
f.) 3.1-3.5 (Choline), g.) 3.5-4.1 (Creatine), and h.) 4.1-5.5 (residual-water/lipid). On the other
hand, in TD the mean SNR was calculated for each of the eight ranges of 25 ms between 0 and
200 ms.
The global mean SNR0−9ppm of the FD signals in the 0 to 9 ppm range, and the global mean
SNR6−9ppm of the 6 to 9ppm range, in which only very low-concentration brain metabolites
have resonances, were also calculated. The ratio of SNR0−9ppm and SNR6−9ppm was computed
and taken as additional feature.
The relative change in a certain range of the FID was calculated using the following formula:
relative change(k, l) = ∆k,l =
sk + sk+1 + sk+2 − sl − sl−1 − sl−2
3∆max(s)
, l > k (6.1)
where k and l are two points of the discrete FID, si is the value of the discrete FID in a
point i and max(s) is the maximum value of the FID. The relative change ∆k,l was calculated for
the same intervals as the TD mean-SNR and will further be denoted by “TD Relative Change”
followed by the interval (e.g. “TD Relative Change [50; 75]”).
Finally, the global signal features will simply be denoted by the domain in which they were
measured followed by the property being measured, e.g. “FD skewness” or “TD time max”.
Regarding skewness and kurtosis, given that these measures are indicators of, respectively,
the histogram’s symmetry and “peakedness”, these features change significantly depending
on whether high SNR peaks are present in the signal or not. In Figure 6.3, two examples of
acceptable and non-acceptable FD spectra are shown with the corresponding histograms and
values of FD skewness and kurtosis.
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6.3.6 Cross-Validation and Parameter Optimization
In order to decrease the generalization error and to obtain performance measures that are
independent of a particular split of the data into training and testing datasets, the classifiers
were evaluated following a cross-validation scheme. Given that spectra from the same patient
and MRSI grid can be highly correlated, these were not mixed between training and testing
datasets. This is done to avoid artificial performance improvement. Consequently, the strategy
can be described as a Leave-Patient-Out-Cross-Validation (LPOCV) scheme, where at each time
the complete dataset of one patient was excluded from the training dataset and used as the
testing dataset. Given this, for each patient p, a vector Ŷp containing all the predictions for the
spectroscopic voxels of that single patient, is generated. The global performance of the method
was measured using the global prediction vector ŶGlobal , defined as the concatenation of all the
patient prediction vectors Ŷp:
ŶGlobal =
{
Ŷ1, Ŷ2, . . . , ŶN
}
The optimization of the parameters of the classifier was performed individually for each patient,
using the data of all the other patients. This step was nested in the model validation.
A more detailed description of the cross-validation scheme used can be found in Appendix
A (section 6.8.1), where the strategy used to incorporate the parameter optimization into the
model validation is better explained. In the same appendix, the results of the parameter
optimization are also presented.
6.3.7 Random Forest
The classification algorithm used was the “R” implementation of the RF classifier [Liaw 2002,
Breiman 2001, Criminisi 2013, Hastie 2001]. As the name suggests, this classifier corresponds
to an ensemble of decision trees that are generated in a random manner. The randomness is
introduced via bagging – i.e. each decision tree is trained with a randomly selected subset
of the data – and random selection of the input features – i.e. each node of a tree uses only
a predefined number of randomly selected input features (features/node). In this article, the
Random-Forest classifiers were created with a total of 400 decision trees.
Another interesting aspect of the RF is the possibility of defining the minimum sample
size for which a node may split the data into 2 child nodes (min-node-size [Segal 2004]). In this
article, the parameters features/node and min-node-size were optimized as described in Appendix
A (section 6.8.1).
The RF algorithm is able to output the probability of a given spectra belonging to a specific
class (acceptable/non-acceptable). In this article the probability of a spectra belonging to the
acceptable class will be denoted as probability of acceptance.
6.3.8 Automatic vs Manual Assessment
In order to analyse how the classifier’s output compares with the manual assessment, the
situation of substituting the expert’s manual assessment with the predictions of the classifier
was simulated. To do so, several RF-classifiers were trained with each labelling-session (only one
session was used for each classifier). Then, the agreement between the corresponding prediction
vectors ŶGlobal and the other labelling-sessions that were not used in the training was measured.
These results were compared with the agreement between pairs of manual labelling-sessions.
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Table 6.1: Performance results of each individual labelling-session. For every session, the ground-truth was determined by the
winning label over the other 5 sessions. The mean and standard-deviation of all session are also presented.
spectroscopist 1 spectroscopist 2 Global values
Session 1 2 3 4 5 6 Mean SD
Error rate 0.081 0.081 0.082 0.107 0.096 0.098 0.091 0.01
Sensitivity 0.953 0.951 0.926 0.903 0.911 0.928 0.929 0.018
Specificity 0.852 0.853 0.901 0.873 0.889 0.848 0.869 0.02
PPV 0.929 0.93 0.952 0.938 0.946 0.927 0.937 0.009
NPV 0.898 0.893 0.853 0.81 0.825 0.85 0.855 0.032
6.3.9 Feature-Importance
To evaluate the relative-importance of the input features in the classification task, the mean
decrease in accuracy after feature permutation was measured. This metric consists of the
classification-error increase caused by randomly permuting the values of the feature in focus
between the several data points: the bigger the error increase, the more important that feature
is for the correct classification of the data.
In this article, the impact of 2 different factors on feature-importance was evaluated. Firstly,
the impact of removing the residual-water resonances was analysed by comparing side-by-
side the feature-importance plots of two classifiers: one trained with the WR dataset and
another with the WNR dataset. Secondly, the influence of the expert that labels the spectra
was evaluated. The motivation for this second comparison was the hypothesis that, besides the
effort in evaluating the spectra under the same rules, each spectroscopist might be sensitive to
different spectral features, which may lead to systematic differences in specific features’ relative
importance. To test this, the feature-importance of a classifier trained with the labels from one
expert was compared with a classifier trained with the labels from the other expert. In this case
the ground-truth for one spectroscopist was the winning label given in the 3 sessions performed
by that spectroscopist (acceptable when classified 2 or 3 times as so and non-acceptable otherwise).
This second test was done using the WR dataset only.
6.4 Results
6.4.1 Manual Assessment
After analysing the labels given by the two spectroscopists, we obtained the following results:
1. The overall agreement between any two labelling-sessions was 0.890;
2. The inter- and intra-rater rater reliability were, respectively, 0.879 and 0.908;
3. In 75.57% of the MRSI-spectra the spectroscopists gave the same label in all 6 sessions;
4. On average it took the spectroscopists 3 minutes and 8 seconds to label all spectra of one
MRSI grid, which translates into an average required analysis-time to label one individual
spectrum of 771ms;
5. The ground-truth based in all labelling-sessions contained 65.4% of acceptable spectra.
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Table 6.2: Performance results obtained for each dataset. The following values are shown: area-under-the-curve (AUC), error-rate
(Error), sensitivity (Sens), specificity (Spec), positive-predictive-value (PPV) and negative-predictive-value (NPV). (The detailed
results obtained for each classifier of the model validation level are presented in Appendix B (section 6.8.2))
AUC Error Sens. Spec. PPV NPV
WR 0.976 0.075 0.943 0.891 0.942 0.892
WNR 0.948 0.113 0.912 0.838 0.914 0.834
Figure 6.4: Tukey boxplots of the error-rate obtained for the several MRSI-grids. The error-rate is shown for both datasets: WR
and WNR.
In Table 6.1 the performance results of each individual session are presented. For each
session, the results shown consider the ground-truth as the winning labels over the other 5
sessions (each spectrum was considered acceptable when classified more than 2 times as so
and non-acceptable otherwise). In this table we can see that – on average – each spectroscopist
classified the spectra with an error-rate of 9.1%.
6.4.2 Automatic Classification
In Table 6.2, the performance results obtained with each dataset are presented. Figure 6.4
presents the Tukey boxplots of the error obtained for each MRSI-grid, for both datasets. A few
examples of WR spectra for different values of probability of acceptance, as outputted by the
classifier trained with WR data, are presented in Figure 6.5. In order to allow the comparison
of the method here presented with previous work from Wright A. et al [Wright 2013], the
performance of the classifier was evaluated in the subset of spectra containing all the voxels
that were labelled in the same way, in every labelling-session. As in that work, this corresponds to
analysing the method in only those spectra where there was consensus in the quality assessment.
The corresponding subset of the prediction vector ŶGlobal (n=7373) had an error-rate of 1.86%
and AUC of 0.998. The results of the “automatic vs manual assessment” analysis are shown in
Figure 6.6. These results show the high level of agreement between the results of the classifier
and the assessment made by the experts. Noticeable is also the higher degree agreement with
the experts’ assessment of the classifiers trained with WR data when compared to the ones
trained using the WNR dataset.
6.4.3 Spectral Features
In Figure 6.7 two feature-importance plots are shown. These plots show the effect of residual-
water-peak removal on the features’ relative importance (left), and the dependence on the
individual spectroscopist that performed the labelling (right). In these plots are highlighted
the 7 most important features for the WR dataset.
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Figure 6.5: Examples of spectra from the WR dataset organized by different values of probability of acceptance (indicated above
each column). Each column contains spectra whose quality is considered similar by the automatic-classifier.
Figure 6.6: Mean degree of agreement between two labelling-sessions (“expert vs expert”) and between the predictions from a
RF classifier that was trained with the labels from one single labelling-session, and the remaining labelling-sessions (“expert vs
prediction”). The agreement was measured for both the predictions made using the WR and the WNR datasets. The “overall”
results represent, in the case of the “expert vs expert”, the overall agreement between any two labelling-sessions and in the case
of the “expert vs prediction” the agreement between the prediction and any other labelling-session that was not used for training
the classifier. The results “with same rater” represent in the case of the “expert vs expert” the intra-rater reliability, and for the
“expert vs prediction”, the agreement between the prediction and the labelling-sessions from the same rater as the training data.
Similarly, the results “with different rater” represent in the case of the “expert vs expert” the inter-rater reliability, and in the
“expert vs prediction” case, the agreement between the prediction and the labelling-sessions from a different rater than the one of
the training data. The error bars show the mean ± 1 standard-deviation.
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Figure 6.7: Feature importance plots. In the left plot, the feature importance of the classifiers trained using the WR dataset
(blue) is compared against the classifiers trained using the WNR dataset (red). In the right plot, is shown a comparison between
the feature importance of classifiers trained with class labels of two different experts. The x-axis shows the mean-error-increase
observed after permuting the values of the corresponding feature in the dataset (15,20). For each one of the 4 situations presented,
the mean and standard-deviation of the error increase were calculated from the 12 different random forests that are trained in
the described cross-validation scheme (Classifiers from the method validation level - Appendix A (section 6.8.1)). The error bars
show the mean ± 1 standard-deviation of the error increase. The 7 most important features for the WR dataset (dataset with best
performance) are signalled with an asterisk.
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Figure 6.8: Tukey boxplots of the values of the 7 most important features of the WR dataset grouped by score (number of times
classified as acceptable in the 6 labelling-sessions).
Figure 6.9: Comparison between the expert’s score (score from 0 to 6, representing the number of times that each spectrum was
classified as acceptable in the 6 labelling-sessions), the prediction made using the WR dataset (probability of acceptance), and the
values for the 7 most important features (values from the WR dataset), for 5 different cases. The 5 cases were selected with error-
rates close to the different marks of the corresponding boxplot (WR error-rate - Figure 6.4). Each map shows the corresponding
colour scale. For each feature, the minimum of the colour scale corresponds to the median value of that feature in the spectra
with score 0, and the maximum to the median value of the spectra with score 6 (see Figure 6.8). The maps were created using
jMRUI’s SpectrIm plugin.
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The Tukey boxplots of the values of the 7 most important features (WR dataset) grouped by
quality-score are shown in Figure 6.8. Then, in Figure 6.9, a comparison between the expert’s
score, the predictions of the classifier, and the values of the 7 most important features is shown
for 5 different MRSI-grids. In order to have a representative selection of the data, the 5 cases
with error-rates close to the different marks of the error-rate boxplot were selected (see Figure
6.4).
6.5 Discussion
6.5.1 Subjectivity in Manual Assessment
The results presented here show that quality-scores given by spectroscopists are subjective
and not fully consistent. It was shown that the same spectra were classified in different ways
by different spectroscopists. More surprising aspect is the fact that the same spectroscopist
judges the same spectra in different ways. A reason for this could be that only 771ms was
on average needed to classify a spectrum, and misclassifications can occur in performing the
repeated task. We think that this is not the only source of variance: the subjectivity of the
expert’s perception of what exactly constitutes “spectral quality” is another factor. The auto-QA
method developed here matches, to a high level of confidence, the expert knowledge and has the
advantage above human-QA that it does this task in a consistent way. Because of the invariant
aspect, the automated method should be recommended to prevent operator dependent bias in
multi-centre clinical studies.
Another interesting aspect is the difference found in terms of the feature-importance when
the classifier is trained with labels given by different spectroscopists: apparently different
experts focus on different features in the spectra they are rating.
6.5.2 Automatic Classification Performance
Regarding the classifier performance, the results show that auto-QA can substitute manual-QA
without loss of accuracy. For WR data, the agreement between the classifier trained with labels
from just one session, and any of the other labelling-sessions (89.88%) was equivalent to the
agreement of any two labelling-sessions (89.03%). For the classifiers trained with WNR data, the
overall agreement with the expert’s was slightly smaller (87.86%). It is also interesting to notice
that, when WR is used, the predictions of a classifier trained with a single labelling-session agree
more with the labelling-sessions of the other expert than the labelling-session used for training
does. This might be explained by what was already mentioned, i.e. in comparison to the expert’s
assessment, the automatic classifier is more consistent between different assessments. In the
manual case, the assessment might be biased in some situations and the variance is expected to
be higher due to inconsistent assessments and possible distraction mistakes.
With an AUC of 0.976, the method here presented compares favourably to previously
published methods (8,13,14). Moreover, our results were obtained performing only residual-
water-peak removal and no further pre-processing. Further, in earlier published work the
results were obtained using a single test-dataset, whereas here a more advanced cross-validation
scheme was used (Appendix A (section 6.8.1)).
Two other referenced methods presented higher values of AUC using approaches that don’t
mimic the clinical use of MRS auto-QA. Firstly, in the work of Menze et al [Menze 2008],
the classifier performance was computed for spectra both within and outside the PRESS
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box. Since classifying noisy spectra is not very challenging, and most of the voxels are noisy
voxels, this could explain the higher AUC-values which were obtained. Furthermore, since
spectra outside the PRESS-box have minimal clinical interest, it is more important to compute
optimized classifiers for excited MRSI voxels only. Nevertheless, a comparison with Menze et
al [Menze 2008] is still possible since the results for the PRESS-box-only were also reported,
namely an AUC of 0.968, which is smaller than the AUC achieved with the method presented in
this paper. Secondly, in the work of Wright et al [Wright 2013] on prostate MRSI, the approach
was different: only those spectra were included in the training of the classifier for which
consensus amongst 4 spectroscopists was reached. This approach, which omits all “borderline”
cases, resulted in an increased AUC of 0.983. Such strategy allows the development and testing
of the method without having to deal with the critical cases, where the classification into
acceptable or non-acceptable is not very clear. The classification of these “borderline” spectra is
more error prone, and can vary depending on the rating spectroscopist and the exact context of
the assessment. This approach is not really realistic for use in a clinical setting, since one does
not find only clearly acceptable and clearly non-acceptable cases. In order to be able to compare
the performance of our method with that of Wright et al, the AUC-performance in the subset of
spectra that had the same label in all the 6 sessions was also determined. For this “consensus”
subset, our method’s AUC reaches a value of 0.998.
At first glance, our method seems to be better-performing than previously published meth-
ods. However, one should not forget that unambiguous comparisons can only be made if the
same input data is used, and that auto-QA of spectra from different organs, regions or diseases,
might pose different challenges.
Apart from the performance indicators, the continuous output of the classifier (probability
of acceptance) shows a visible agreement with the level of spectral-quality (Figure 6.5).
6.5.3 Residual-Water-Peak Removal
In this article it was also shown that it is possible to perform auto-QA without any pre-
processing even when the manual assessment is made using residual-water-removed spectra.
This can be interesting in situations where the spectra need to be assessed immediately after
loading the spectroscopy file. However, the gain in time-to-display the results has to be weighed
against a reduction in accuracy. The difference in performance can be explained by the fact
that the HLSVD-method was applied in a broad frequency offset-range and also that, in some
situations, not only the residual-water-peak was removed, but also (ghosting) artifacts. These
artifacts can be very prominent and, when removed, lead to a considerable increase in the
quality of the corresponding spectra.
The differences in feature-importance between the classifiers trained with the WR and
the WNR datasets show the impact of the residual-water-peak removal on the classification
problem. For example, in the WNR case, the TD-features don’t play a very important role; in
contrast to the WR case in which two TD-features are amongst the most relevant ones. Another
interesting aspect is the change in the relative importance of the features SNR[1.6;2.2] (NAA),
SNR[2.6;3.1] (Creatine) and SNR[3.1;3.5] (Choline) between the two cases: in the WR case, these
features have more or less the same importance, but in the WNR case, the feature SNR[1.6;2.2]
(NAA) becomes more important than the others. This could be explained by NAA being less
affected than Choline and Creatine by the variance added by the tail of the residual-water-peak.
This effect reduces the spectral quality information present in the affected features. Once
the residual-water-peak is removed, the effect disappears and the utility of these features is
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restored.
6.5.4 Novel Features
A novel aspect of this paper is the study of the described TD- and FD-features and their relation
to measured spectral quality. The RF algorithm is not only a powerful classification tool, but also
very interesting for assessing the relative-importance of the features used (feature-importance).
The commonly used peak-SNR features, were outclassed in feature-importance by 4 completely
novel signal features that have never been used before in auto-QA, namely: FD-skewness,
FD-kurtosis, TD-mean-SNR[50;75] and TD-mean- SNR[75;100]. These 4 features were the most
important in the WR case, outclassing the commonly used peak-SNRs of Choline, Creatine
and NAA. In Figure 6.8 the positive correlation between the value of these features and the
quality-score is nicely illustrated. For the FD-skewness an almost linear relation is found. For
the 7 most important features, the close relation to spectral-quality is well visible in Figure 6.9.
Regarding FD skewness and kurtosis the corresponding maps are very close to the expert’s score
maps, confirming the close relation between their value and spectral quality. Regarding the
TD-features, the TD-SNR-decrease in the range between 50 and 100ms shows a high correlation
with spectral quality. The reason for this is that in this interval we have the best contrast to noise
ratio: the effect of field inhomogeneity on the TD-signal strength accumulates as a function of
time (both good and badly shimmed spectra start at the same amplitude, but deviate more and
more until the noise level is reached).
6.5.5 Implications for Clinical Use
Finally, for the potential added-value of this QA-method in a clinical environment one can
identify the following: (1.) In terms of its performance, it was shown that there is no significant
difference between expert manual-QA and auto-QA. (2.) Regarding the time-needed for expert
labelling (using our developed tools), a time of ∼3 minutes is needed for one MRSI grid.
However, after this time investment, any new grid may be classified by the trained classifier
almost instantaneously (∼3 seconds). (3.) If the same classifier is shared between hospitals for
compatible data, this would be an important step towards standardization of QA in multi-centre
studies, and could serve as basis for further classification of tissue (e.g. tumour sub-typing).
(4.) Last but not least, this step speeds up clinical interpretation of daily routine spectroscopy
in situations where an expert spectroscopist is not present. The clinician only has to analyse
good quality data, which drastically simplifies the interpretation of metabolite maps: only good
quality results need to be judged, and the very time intensive voxel-by-voxel visual verification
step on spectral quality can be skipped, saving up to 5-10 minutes.
6.6 Conclusion
A RF based method for automatic quality control using novel MRS-signal features has success-
fully been applied to long TE MRSI-spectra. The performance of this method to distinguish good
from bad quality spectra was shown to be comparable to that obtained by manual assessment.
Moreover, the method massively improves the applicability by non-spectroscopic-experienced-
radiologists of MRSI, since it mimics expert spectroscopist knowledge very closely. Especially
for radiology centres that do not have access to expert spectroscopists, the important decision
whether the MRS quality is sufficient to base a diagnosis upon, can be solved using the proposed
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method. The method was implemented in jMRUI’s SpectrIm plugin and, its development
enabled the exploration of a novel set of MRS signal-features that show very high correlation
with spectral quality. Future work should evaluate whether trained classifiers can be used to
classify data acquired using different scanners and from different centres. Additionally, it will
be explored whether the described spectral features can also be used for other applications,
such as tumour segmentation, typing and grading.
6.7 Acknowledgements
This work was funded by the EU Marie Curie FP7-PEOPLE-2012-ITN project TRANSACT
(PITN-GA-2012-316679) and the Swiss National Science Foundation (project number 140958).
6.8 Appendix
6.8.1 Appendix A: Nested cross-validation and parameter optimization
In this section the cross-validation scheme used to validate the presented method is explained
in more detail. In the approach used, the parameter optimization is nested in the method
validation (Figure 6.10) so that the data where the model is assessed (test sets L1) is neither
included in the data used to train the classifier nor in the data used for searching the optimal
classifier parameters. The cross-validation can then be seen as a 2-level Leave-one-Patient-
Out-Cross-Validation (LPOCV), where the parameter optimization is a sublevel of the model
validation: at each time we leave one patient out for testing the method and we use the rest
of the data to find the optimal parameters (again using LPOCV) and train the classifier. The
pseudo-code of the algorithm used is shown in Figure 6.11. The RF classifiers used for searching
the optimal parameters contained 200 trees. The results of the parameter optimization are
shown in the histograms of Figure 6.12. Based on these results, the operational versions of the
classifier should be trained using the following values: 7 features/node and min-node-size equal
to 4 for WR data, and 10 features/node and min-node-size equal to 1 for WNR data.
6.8.2 Appendix B: Detailed performance results
In this section we present the detailed performance results obtained for the data of each patient
(Table 6.3). These results correspond to the classifiers of the method validation level (see
Appendix A (section 6.8.1)).
6.8.3 Appendix C: “Probability of acceptance” threshold selection
As already mentioned, an interesting aspect of the RF classifier is its ability to provide the
probability of a given spectra belonging to the acceptable class (probability of acceptance).
Given the continuous nature of this output, it is possible to change the threshold that separates
acceptable and non-acceptable spectra, which can be seen as defining stricter or less strict
quality criteria. This has direct impact on the sensitivity, positive predictive value (PPV) and
accuracy (Figure 6.13). Changing this threshold might be interesting, for example, in some
applications that are more sensitive to bad-quality spectra. In such applications it could be wise
to increase the threshold, sacrificing some of the sensitivity for a higher PPV. On the other hand,
when the data is scarce and the methods that are being used are not so sensitive to bad-quality,
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Figure 6.10: Organization of the data used in the cross-validation scheme used. Here each numbered cube represents the data
of one patient. As it can be seen the parameter optimization is a sublevel of the method validation. The data is initially split
at the first level into a test set L1, containing the data of one patient, and a training set L1, containing the data of all the other
patients. The training set L1 is then used for the parameter optimization and sub-divided into level-2 test sets and training sets.
This subdivision is again done by removing at each time the data of one patient for testing (test sets L2) and using the remaining
patients for training (training sets L2).
Figure 6.11: Pseudo-code of the algorithm used to perform the Nested Cross-Validation.
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Figure 6.12: Histograms of the best parameter values obtained for the several data subsets. The results for both the WR and WNR
datasets are shown.
Table 6.3: Performance results obtained for the predictions made for each patient, as well as for the global prediction vector. The
results were obtained according to the Nested CV scheme described, and are shown for both the WR and the WNR datasets. The
following values are shown: number of voxels, percentage of acceptable voxels (%Accept), area-under-the-curve (AUC), accuracy
(Acc.), sensitivity (Sens.), specificity (Spec.), positive-predictive-value (PPV) and negative-predictive-value (NPV).
WR WNR
Patient voxels %Accept AUC Acc. Sens. Spec. PPV NPV AUC Acc. Sens. Spec. PPV NPV
1 768 0.848 0.997 0.982 0.994 0.915 0.985 0.964 0.996 0.974 0.988 0.897 0.982 0.929
2 960 0.861 0.977 0.954 0.977 0.812 0.970 0.850 0.967 0.940 0.955 0.842 0.974 0.752
3 768 0.682 0.965 0.922 0.956 0.848 0.931 0.900 0.930 0.884 0.954 0.734 0.885 0.882
4 624 0.311 0.967 0.913 0.856 0.940 0.865 0.935 0.928 0.854 0.825 0.867 0.737 0.916
5 736 0.781 0.969 0.916 0.943 0.820 0.949 0.800 0.946 0.851 0.863 0.807 0.941 0.622
6 1108 0.663 0.975 0.919 0.944 0.869 0.934 0.888 0.964 0.898 0.898 0.898 0.946 0.817
7 716 0.789 0.974 0.933 0.954 0.854 0.961 0.832 0.942 0.897 0.935 0.755 0.935 0.755
8 668 0.352 0.979 0.940 0.928 0.947 0.905 0.960 0.929 0.894 0.762 0.965 0.923 0.882
9 964 0.804 0.986 0.949 0.956 0.921 0.980 0.837 0.973 0.920 0.925 0.899 0.974 0.746
10 540 0.422 0.948 0.878 0.882 0.875 0.838 0.910 0.957 0.904 0.829 0.958 0.936 0.885
11 1024 0.610 0.958 0.880 0.891 0.862 0.910 0.835 0.938 0.838 0.872 0.784 0.864 0.796
12 880 0.513 0.957 0.907 0.905 0.909 0.913 0.901 0.843 0.790 0.925 0.648 0.734 0.891
Global 9756 0.654 0.976 0.925 0.943 0.891 0.942 0.892 0.948 0.887 0.912 0.838 0.914 0.834
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Figure 6.13: Sensitivity, PPV and accuracy of the classifier depending on the probability of acceptance threshold. The results are
shown for the WR dataset only.
it might make sense to lower the threshold. The ability to select the spectra from an MRSI grid
that have a probability of acceptance higher than a user-defined threshold was implemented in
SpectrIm.
7 | Improving labeling efficiency in automatic quality
control of MRSI data
This chapter is based on the following material:
N. Pedrosa de Barros, R. Mckinley, R. Wiest, J. Slotboom, Improving labeling efficiency in
automatic quality control of MRSI data, Magn. Reson. Med. (2017). doi:10.1002/mrm.26618.
7.1 Abstract
Purpose: To improve the efficiency of the labeling task in automatic quality control of MRSI
data.
Methods: 28’432 short and long-TE spectra (1.5T, PRESS, TR=1500ms), from 18 different
brain-tumour patients, were labeled by two experts as either "accept" or "reject", depending on
their quality. For each spectrum, 47 signal features were extracted. The data was then used
to run several simulations and test an active learning approach using uncertainty sampling.
The performance of the classifiers was evaluated as a function of the number of patients in the
training-set, number of spectra in the training-set, and a parameter α used to control the level
of classification uncertainty required for a new spectrum to be selected for labeling.
Results: The results showed that the proposed strategy allows reductions of up to 72.97%
for short-TE and 62.09% for long-TE in the amount of data that needs to be labeled, without
significant impact in classification accuracy. Further reductions are possible with significant
but minimal impact in performance.
Conclusion: Active learning using uncertainty sampling is an effective way to increase the
labeling efficiency for training automatic quality control classifiers.
7.2 Introduction
Bad quality spectra are commonly observed in in-vivo Magnetic Resonance Spectroscopy.
Multiple factors can cause MRS(I) signal artifacts, a topic that is extensively covered in the
work of Kreis ([Kreis 2004]). Bad quality spectra may prevent proper spectral quantifica-
tion, which on its turn may lead to misinterpretation of the spectra. In order to guarantee
proper quantification, quality control strategies are needed. For quality control of MR spec-
tra it is important to identify signal artifacts that may corrupt the quantification first, and
then to evaluate the quality of the quantification ([Slotboom 2009]) and the associated error
([Cavassila 2001, Jiru 2006, Kreis 2015, Slotboom 2011, Bolliger 2013, Ratiney 2005]). For the
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identification of artifacts, simple visual inspection is generally performed, nevertheless this
is only possible for single voxel acquisitions and when an expert is available. In the case
of multi-voxel acquisitions, thousands of spectra are usually generated in just one acquisi-
tion, making the visual inspection of all the data a Sisyphean task. In order to automatize
artifact and poor SNR detection in MRSI, a few machine-learning based methods have been pro-
posed ([Menze 2008, Wright 2013, Pedrosa de Barros 2016b, Pedrosa de Barros 2016a]). Such
methods allow to check thousands of spectra in a matter of seconds with a performance that
is identical to manual inspection ([Pedrosa de Barros 2016b, Pedrosa de Barros 2016a]) per-
formed by human MRS experts. Besides the obvious time-saving potential of these methods, a
considerable amount of time is needed for manually labeling the data that is used for training
the automatic classifiers.
The selection of the training samples is often done by identifying a "reasonable" amount of
MRSI acquisitions and by labeling all the corresponding spectra. However, not every individual
spectrum provides relevant information to the learning algorithm, and the dependency that the
training sample size has on the classifier performance is often not analyzed.
Labeling efficiency can be increased with the use of active learning approaches
([Debarr 2009, Patra 2012, Maiora 2014, Cohn 1996, Tuia 2009, Silva 2004, Kutsuna 2012])
where the learning method is able to actively select the subset of examples that need to be
labeled by the user. This is an iterative process where 1) the algorithm selects a subset of
examples, 2) the user labels these selected examples and 3) the learning method is updated
with the new data before selecting again more data for labeling.
Uncertainty sampling ([Lewis 1994]) is a sampling strategy used in active learning that
gives priority to the selection of those examples whose class membership is more uncertain.
Since these cases are usually close to the class separation boundaries, they contain most of
the information needed to separate the different classes. In different applications, uncer-
tainty sampling has shown to improve the effectiveness of the labeling procedure drastically
([Patra 2012, Maiora 2014, Lewis 1994]). In this work, we’ve investigated the use of active learn-
ing with uncertainty sampling for automatic quality control of MRSI data with the objective
of increasing manual labeling efficiency. The proposed learning strategy may contribute to a
faster and easier implementation of automatic quality control methods.
Several simulations were run to analyze the effect of the proposed strategy on the reduction
of the labeled sample size and on the performance of the classifiers. Before running the
simulations, 2 experts labeled all spectra from a long-TE and a short-TE datasets. To simulate
the partial labeling of the data in each simulation, only the examples selected for labeling were
added to the training-set. This allowed to test different sampling strategies and evaluate the
dependency of the classification performance on the training-set size.
7.3 Methods
7.3.1 Data acquisition
Short (30 ms) and long (135 ms) TE data were acquired on 1.5T MR-scanners (Siemens Aera,
Avanto) using the PRESS localization method, CHESS water-suppression, TR=1500 ms, and a
32x32 grid (interpolated from 12x12 k-space samples). A total of 28’432 spectra were included
in the study, 14’216 for each TE. These spectra were all selected from within the PRESS-box
only, and all other spectra from outside the selected volume were discarded. The spectra
were retrieved from 58 different studies of 18 brain-tumour patients, performed pre- and
7.3 Methods 121
post-operatively, and where short and long TE data were acquired sequentially in the same
localization.
The measurements were performed conforming to local and national ethical regulations,
meaning that all patients gave their informed consent to use the data for scientific purposes.
7.3.2 Data processing and feature extraction
All data processing, feature extraction and labeling were performed using the SpectrIm
plugin of jMRUI ([Pedrosa de Barros 2014], www.jmrui.eu). Residual-water-peak-removal
was performed using HLSVD prior to feature extraction. A total of 47 features were
extracted from time-domain (TD) and frequency-domain (FD) magnitude spectra, as in
([Pedrosa de Barros 2016b, Pedrosa de Barros 2016a]). The following groups of features were
used:
• Local maximum peak SNR (FD)
• Local mean SNR (FD and TD)
• Local relative change (TD)
• Global TD features (maximum signal strength, time point of maximum signal strength,
mean, standard-deviation, skewness, kurtosis)
• Global FD features (maximum signal strength, ppm value of maximum signal strength,
mean, standard-deviation, skewness, kurtosis)
A detailed description of the features used can be found in ([Pedrosa de Barros 2016b,
Pedrosa de Barros 2016a]).
7.3.3 Labeling
The spectra were manually labeled by two expert spectroscopists (further referred to as raters)
based on their quality as either "accept" or "reject". The raters could visualize both the spectra
and the voxel localization during the quality labeling process. The features for rejecting spectra
included: "ghosting" artifacts, bad-shimming, low-SNR, lipid-contaminations, strongly deviat-
ing phase, and post-operative-derived artifacts. First, the labeling was performed independently
by each rater. In a second phase, a consensus decision was made for all those spectra for which
there was disagreement between the raters. The resulting consensus-labels constituted the
ground-truth used for training and testing the automatic classifiers. For each individual session,
the time spent for labeling each MRSI-grid was recorded.
7.3.4 Random-forest
A random-forest ([Liaw 2002, Breiman 2001]) classifier ("R" implementation, 200 trees, maxi-
mum depth, 7 features per node) was used for the automatic assessment. This classifier provides
for each test example an approximation to the class membership probabilities, calculated as
the % of trees of the ensemble that vote for each class. Once these probabilities are known, a
class can be assigned to each example. Consequently, in a binary-class problem the decision
threshold is often selected as 0.5. Despite this, in the problems characterized by a considerable
class-imbalance (i.e. the number of members differ considerably between classes), this decision
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Figure 7.1: Proposed active learning strategy for training the automatic classifier where only a subsample, containing the exam-
ples with more uncertain class membership, is labeled and included in the training-set.
boundary might lead to poor sensitivity or specificity. Therefore, in those cases, a different
decision threshold is often used. The examples with the highest classification uncertainty have
class membership probabilities closer to the decision boundary. Thus, these can be selected by
defining a range of probabilities centred on the boundary. In this study, considering that we
have a binary-class problem with reasonably balanced classes([Pedrosa de Barros 2016b]), the
most uncertain cases were identified as the examples that satisfy:
−α < p(y = ”accept”|x)− 0.5 ≤ α (7.1)
where the parameter α is used to control the minimum level of uncertainty of the selected
sample. In this study, the effect of α on the number of spectra that is selected for labeling, and
on the classification performance was analyzed.
7.3.5 Active learning
The active learning strategy proposed here is depicted in Figure 7.1. As can be seen in the
workflow, for each "block" of new data, the previously trained classifier is used to determine the
subset of uncertain examples that will be manually labeled and included in the training-set. All
the cases for which the classifier is more certain regarding their class membership are rejected.
In this work, short and long TE were handled separately and one "block" corresponds to all the
spectra from all MRSI acquisitions of a single patient, collected pre- and post-operatively.
7.3.6 Simulations
In order to validate the proposed active-learning method, several simulations were performed.
Each simulation consisted of several iterations, where in each iteration the spectra from a
single patient was analyzed and the uncertain examples were added to the training-set. The
performance was measured at the end of each iteration after adding the new spectra to the
training-set and retraining the classifier. In each iteration, the labeling of the selected uncertain
examples was performed by drawing the required labels from the completely labeled dataset
containing all 18 patients (see labeling section). Simulations using short and long TE data were
performed separately.
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In each simulation, the performance was evaluated on a validation-set corresponding to the
data of one patient that was excluded from the iterative process and consequently never added
to the training-set (Leave One Out Cross Validation - LOOCV). Given that in each iteration a
previously trained classifier is required to select the spectra for labeling, the initial classifier
was trained using all spectra from the first patient (see pseudo-code, lines 10 and 11). Another
aspect that was considered was the order in which the patients were iterated over. It is expected
that data from different patients contains different levels of information and that the evolution
of the performance in each iteration might depend on the order in which the patients are
included. Consequently, the patients’ order was shuffled in each simulation, and for each set
of parameters (TE, α and patient selected for validation-set) the simulation was repeated 50
times. Five different values of α were tested: 0.1, 0.2, 0.3, 0.4 and 0.5, representing 0.5 the case
where, in each iteration, all spectra from the corresponding patient are labeled and added to
the training-set.
The pseudo-code corresponding to the simulations performed is presented below in algo-
rithm 3.
Algorithm 3 Simulations’ pseudo-code
1: for TE t ∈ {30ms,135ms} do
2: for all α ∈ {0.1,0.2,0.3,0.4,0.5} do
3: for n = 1 to 50 do
4: for all patient i ∈ {1, . . . ,N } do
5: V alidationSet←DataSet(patient = i, TE= t)
6: T rainingCandidatesSet←DataSet(patient , i, TE= t)
7: P atientIndexes← Shuf f le({1, . . . ,N } \ {i})
8: for iteration j = 1 to N − 1 do
9: index← P atientIndexes(j)
10: if isEmpty(T rainingSet) then
11: T rainingSet← T rainingCandidatesSet(patient = index)
12: else
13: for all spectrum k ∈ T rainingCandidatesSet(patient = index) do
14: p(yk = ”accept”|xk)← T est(RFj−1,xk)
15: if −α < p(yk = ”accept”|xk)− 0.5 ≤ α then




20: RFj ← T rain(T rainingSet)
21: Ŷi,j ← T est(RFj ,Xi ∈ V alidationSet)






The performance measures recorded were: Accuracy, area-under-the-curve (AUC), and
number of spectra and % of spectra with label "accept" (%accept) in the training-set (see line
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22). The %accept metric was used to evaluate the class balance of the training-set. For each TE
and α value, the mean cross-validated accuracy, area-under-the-curve (AUC), number of spectra
and %accept were calculated in function of the number of patients added to the training-set.
7.4 Results
7.4.1 Labeling
The average agreement between the raters’ individual assessments was 85.80% for short-TE and
89.05% for long-TE data. The percentage of spectra labeled, after consensus, as "accept" was
71.55% for short-TE and 74.76% for long-TE data. Regarding the time spent for labeling, each
rater required an average of 0.96 seconds to label one single spectrum during the individual
assessment. This represents the average time that a rater requires for attributing a label to
each spectrum, and does not include the time spent in other activities, such as loading data,
removing the residual water or the time which was needed to reach a consensus decision.
7.4.2 Classification Uncertainty and class-separation
Figure 7.2 shows a scatter plot of two of the most important features for the discrimina-
tion between acceptable and non-acceptable spectra: "frequency domain (FD) skewness"
and, "time domain (TD) mean SNR" in the range of 50 to 75ms after pulse echo maximum.
These features were selected based on the results concerning feature importance presented in
([Pedrosa de Barros 2016b, Pedrosa de Barros 2016a]). Besides only using two features, the plot
shows a good separation between classes. The figure shows that spectra with more uncertain
class membership (darker) are located closer to the boundary between the two groups, confirm-
ing that the information needed to determine the class separation boundaries is contained in
the more uncertain spectra.
7.4.3 Performance impact
Figure 7.3 shows the mean cross-validated AUC, and Figure 7.4 the classification accuracy
depending on the number of patients (left) and the number of spectra in the training-set (right).
The comparison between the complete-labeling case (α=0.5) and the other cases shows the
increased efficiency that uncertainty sampling can add to the labeling task and the minor
impact that it has on the performance of the classifiers, namely for α between 0.2 and 0.4.
The results show also the clear differences in performance between short and long-TE data
classification, and that AUC changes more with α than accuracy.
The analysis of the performance differences between the α=0.5 (complete-labeling) and
each other α value for the classifiers trained with data from all patients but the one used
for validation, is presented in Figure 5. In these boxplots, we see that for certain values of
α there are no statistical significant differences (two-tailed t-test, unequal variance) between
the classifiers trained with the complete dataset and the ones trained with just the uncertain
examples. For the other cases the differences are significant, but minor.
The maps showing the predictions made by classifiers trained with different α, for 4 different
MRSI grids (2 examples with both short and long TE acquisitions) are presented in Figure 7.6.
Besides the overall good match between the ground-truth and the predictions, we see a relation
between α and the certainty of the predictions: classifiers trained using a smaller α produced
generally more uncertain predictions, namely for bad-quality spectra.
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Figure 7.2: Scatter plot showing all the 14216 long TE spectra. The spectra can be distinguished based on their label (symbol
used) and p(y = ”accept”|x) (gray scale). The more uncertain cases, with class probabilities closer to 0.5, were colored darker. The
two selected features (time domain mean SNR in the range between 50 and 75 ms, and frequency domain skewness) are among
the ones with the highest correlation with the quality of long-TE spectra, as shown in previous work ([Pedrosa de Barros 2016b,
Pedrosa de Barros 2016a]). The plot shows that the cases with more class membership uncertainty are found near the class
separation boundary. For sake of simplicity, only 2 features were chosen and only long-TE data is represented.
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Figure 7.3: Mean cross-validated AUC as a function of the number of patients (left) and number of spectra (right) added to the
training-set, for both short and long TE and for different values of α.
Figure 7.4: Mean cross-validated accuracy as function of the number of patients (left) and number of spectra (right) added to the
training-set, for both short and long TE and for different values of α.
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Figure 7.5: Boxplots of the cross-validated accuracy and AUC for short and long TE data and for different values of α. The perfor-
mance measures were calculated using the classifiers trained with data from all patients (but the one excluded for testing). The
boxplots show how the performance changed between different repetitions of LOOCV. The differences in performance between
different repetitions are mainly caused by the differences in the order in which the patients are iterated over, but also by the
random aspect of the classifier used (random forest). The statistical significance of the differences, between the accuracy and
AUC of α = 0.5 and the other α values, was computed using a two-tailed t-test considering 2 distinct populations with unequal
variance.
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Figure 7.6: Ground-truth and classifier predictions for short and long-TE data of 2 spectroscopy studies. The predictions are
shown for classifiers trained using different α values. For each MRSI example a different classifier was used where the data from
the same patient was not used for training.
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Figure 7.7: Number of spectra selected for labeling in each iteration, for both short and long TE and for different values of α.
Uncertainty sampling is only performed after the first iteration, given that all spectra from the first patient are selected to train
the first classifier.
7.4.4 Percentage of spectra added for each new patient
Figure 7.7 shows the number of spectra that were identified as uncertain and that were added to
the training-set in each iteration. The curves confirm that the value of α allows controlling the
% of spectra that a rater needs to label. Moreover, it is seen that more spectra were identified as
uncertain in the first iterations, without considering the very first iteration where all spectra
were used to train the first classifier. Another effect seen in this figure, is that more spectra are
identified as uncertain, for the same α<0.5, in short TE than in long TE simulations. This is
well matched with the performance results, which showed that proper discrimination between
"accept" and "reject" of short TE data was more challenging than of long TE data.
7.4.5 Class balance
Figure 7.8 shows the effect of the proposed strategy in the class balance of the training-set. In
these plots the mean % of spectra with label "accept" (henceforth %accept) is initially equal to
the average %accept found in each patient (which does not consider the differences in number
of spectra between patients). As more patients are added, the %accept converges in the case of
α=0.5, to the mean %accept found over all spectra of the respective dataset (long or short TE).
More interestingly, for all other α , 0.5, the proposed approach has a gradual positive effect on
the class balance as more and more data is added.
7.5 Discussion
7.5.1 Performance impact vs time-saving
The results presented above support the idea that the proposed method allows reducing the
data needed to train the classifiers drastically, with minor or no impact on their performance.
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Figure 7.8: Mean % of spectra with label "accept" as a function of the number of patients (left) and as a function of the number
of spectra (right) added to the training-set, for both short and long TE and for different values of α.
This increase in labeling efficiency can be seen in three different perspectives:
1. If the amount of data and the time available are limited, a rater can use the proposed
approach to speed-up the labeling process. In this case the choice of the α value will reflect
the personal relative importance between labeling time and performance reduction.
2. If there is a large amount of data available, the best classifier will be obtained, label-
ing the maximum number of different patients/cases. A small value of α is therefore
recommended, as this corresponds to the most efficient way of labeling the data.
3. If there is not a lot of data but there are no time restrictions, a rater might either label the
dataset completely, or choose a value of α with no significant impact on the performance.
Another aspect that should be taken in consideration is the difference between the impact
in AUC and in accuracy. AUC is more sensitive than accuracy to changes in α. This can be
explained by the fact that accuracy is only affected by wrong class predictions, being insensitive
to variations in the outputted class-probabilities that do not change the attributed label. On the
other hand, AUC measures the probability that for a randomly selected pair containing one
"accept" and one "reject" examples, the %trees that vote for the class "accept" is higher for the
"accept" example. Consequently, small variations in class probabilities that do not change the
attributed label, can have an impact in AUC.
7.5.2 Short vs long-TE
The choice of the adequate α might be different depending on the TE. The same value of α led
to the selection of more training data using short-TE than using long-TE data. Moreover, the
relation between α and the impact on performance was different for each dataset.
7.5.3 Class balance
Regarding the positive effect that the proposed strategy had on the class balance, this might be
connected to the relation between the training-set size and the uncertainty of the predictions
seen in the results of Figures 7.6 and 7.7. As it was seen, when the training-set contains less
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examples, the classifier produces more uncertain predictions. Therefore, a possible interpreta-
tion of the results of Figure 7.8 might be that classes with smaller number of examples have
more uncertain predictions, and consequently, will be more likely selected with uncertainty
sampling. The higher probability of selecting examples of classes containing less members
helps balancing the training-set.
7.6 Conclusion
The results show that the proposed labeling strategy allows a considerable increase in the
labeling efficiency. This can be translated into less labeling time needed to obtain the same
classification performance, or into achieving a higher classification performance with the
same labeling time. Consequently, the proposed method contributes to an easier and better
implementation of methods for automatic quality control of MRSI data.
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Part III
Assisting the interpretation of brain
tumor MRS data

8 | Highlighting differences between GBM and metas-
tasis using cNMF
This chapter is based on the following material:
Pedrosa de Barros, NM, Mocioiu, V, Ortega Martorell, S, Knecht, U, Arús, C, Slotboom, J
and Julià-Sapé, M.,Highlighting differences between GBM and brain metastasis using a blind source
separation method applied to MRSI data, ESMRMB 2015, Edinburgh, UK
8.1 Purpose
The differentiation between GBM and Metastasis is one of the most challenging tasks in
Neuroradiology. Here we describe exploratory work on MR spectroscopic imaging (MRSI)
data from both metastasis and GBM patients using Convex non-Negative Matrix Factorization
(cNMF), a blind source separation method.
8.2 Data
A total of 38 preoperative fast-MRSI studies (1.5T, PRESS, water-suppressed, TE 135ms) from
patients with GBM (n=32) and brain metastasis (n=6) were analyzed retrospectively. The 32x32
(interpolated from 12x12) MRSI grids contained spectra from both tumor and healthy tissue.
Only spectra contained in the PRESS box (excluding the border ones for their lower SNR) were
included, leading to a total of 7406 analyzed spectra.
8.3 Convex non-Negative Matrix Factorization
Convex non-Negative Matrix Factorization (cNMF) [Ortega-Martorell 2012a,
Ortega-Martorell 2012b] is a method that allows describing a group of data-vectors -
in this case spectra - as a positive linear combination of K sources, with K being user-defined
(Figure 8.1). One of the main advantages of cNMF is the interpretability of its results, since the
sources generated using this method are a convex combination of the data. Consequently, when
applied to a group of spectra, the sources generated using cNMF can be interpreted as real
spectra.
The columns of the mixing matrix G (reconstruction vectors) can be normalized to 1, so
that its values may be interpreted as the proportion of each source used in the reconstruction of
each spectrum of the analyzed dataset.
In this work cNMF was applied with K = 3 and G was normalized as described.
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Figure 8.1: Example showing cNMF (with K=3) applied to a dataset (X) containing several spectra. The matrix F contains the
generated sources, and the matrix G (mixing-matrix) the factors for reconstructing the data as a linear combination of sources.
8.4 Nosologic Maps
Nosologic maps were produced for each MRSI grid using SpectrIm. In those maps the values of
Red, Green and Blue are given by the ratios found in the normalized mixing matrix for each
source (Figure 8.2). In this way, different spectra, with different reconstruction vectors, are
mapped using different colors.
8.5 GBM vs Metastasis
The differences between the MRSI maps obtained for the GBM and for the metastases were
analyzed using the t-test statistic, comparing both the mean and standard deviation of the
values found in the normalized mixing matrix for each source, in each MRSI grid.
8.6 Results
The obtained sources, and nosologic images for each MRSI grid are presented, respectively, in
Figures 8.3 and 8.4. Figure 8.5 compares both GBM and Metastasis in terms of the obtained
normalized-G values for each CSI grid. Figure 8.5 shows the comparison between GBM and
metastasis in terms of the mean and standard deviation of the mixing matrix values for each
source obtained for all the MRSI grids. The most significant differences were found in the
"red source" maps, namely in their heterogeneity, here represented by the standard deviation.
Significant differences were also found in the standard deviation of the "green" source maps.
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Figure 8.2: Example showing the process used to generate the nosologic maps using the normalized mixing-matrix values for
each source.
Figure 8.3: Sources obtained applying the cNMF factorization to the described GBM and Metastasis data. The "blue-source"
corresponds to typical necrotic-tissue-spectra and the "green-source" to typical healthy-brain-spectra. The obtained "red-source"
might be related with tumor infiltration, still, this hypothesis needs to be further evaluated.
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Figure 8.4: Nosologic maps obtained for the 38 analyzed MRSI grids (#1-32 GBM cases; #33-38 Metastasis cases) overlaid over
T1c MRI slices (except for #14, #25, and #33 where a TRUFI sequence was used for the first one and a FLAIR sequence for the
other two). The Nosologic maps were created as described in Figure 8.2 and the relation between color and source is the same as
the one shown in Figure 8.3 (Green-healthy spectrum; Blue-Necrotic tumor core; Red- possibly related with infiltrated tissue but
still requiring validation).
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Figure 8.5: Box and whiskers plot comparing metastasis against GBM cases in terms of the mean and standard deviation of the
mixing matrix values for each source obtained for all the MRSI grids. The plots show either the mean (left) or the standard
deviation (right). In each comparison is included the p-value associated with the differences in the corresponding measure
found between GBM and metastasis cases (t-test performed considering a single tail and 2 samples with unequal variance). The
significant results (p<0.05) are shown in bold.
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8.7 Discussion/Conclusion
The results confirm the idea that the biggest differences between GBM and Metastasis, regarding
spectroscopic information, are found in the periphery of the tumor[Wijnen 2012], given that
the best discriminating source ("red-source") is found frequently in this region. We hypothesize
that the presence of this source might be correlated with tumor infiltration, a hypothesis which
will require further evaluation. It is, in our perspective, interesting to notice that the main
differences between these two groups are found in the heterogeneity of these maps, rather than
in their mean values.
Despite these preliminary results, where it was possible to highlight differences between
GBM and metastasis cases using cNMF, these findings do not yet allow an accurate discrim-
ination between the two groups of tumors. Moreover, the dataset analyzed here contains
significantly less metastasis examinations than GBM examinations, which might affect consider-
ably the results. To correct this, a more balanced dataset should be used.
Another aspect to be considered is that metastases from different primary tumors have dif-
ferent characteristics, with certain types typically infiltrating more than others [Baumert 2006].
Consequently, instead of considering all metastases as one homogeneous group, it might be
interesting to look at different types of metastases separately. This will require more cases for
each metastasis type, which will also be beneficial for balancing the number of cases between
GBM and metastasis.
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9.1 Synopsis
Clinical-routine MRSI-data analysis is commonly performed through visual inspection of multi-
ple metabolite and metabolite-ratio maps, and aims at translating the different spectroscopic pat-
terns into known tissue-types, such as, necrosis, solid tumor, tumor-infiltration, normal-brain-
tissue, etc. Such translation/segmentation requires solid expertise in MR-spectroscopy, which
most clinicians do not have. Bad-quality-data, as well as non-homogeneous and frequency-
dependent-selection-profiles further complicate proper interpretation of MRSI-data. Therefore,
to ease the clinical-use of MRSI, we present an automatic MRSI-tissue-type segmentation algo-
rithm, that includes automatic-quality-filtering and selection-profile-correction. The method
was tested in glioblastoma and the tissue-types were compared against an MRI-based tumor-
segmentation-method.
9.2 Purpose
The work here presented had the following goals:
1. To identify the most important spectroscopic patterns characteristic of different tissue-
types present in 1H-MRSI of glioblastoma.
2. To develop a tissue-classification-method for segmenting MRSI maps of glioblastoma
patients.
3. To compare the spatial-distributions of the different identified MRS-based tissue-types
with the tissue-types identified by an MRI-based automatic-tumor-segmentation-method,
BratumIA [Porz 2014, Meier 2016].
9.3 Methods
The development of the MRSI-segmentation method was made in two steps. First, the main
spectroscopic patterns that are present in MRSI data of gliobastoma patients were identified
by clustering a training-set containing data from 17 different patients (Figure 9.1). Second,
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Figure 9.1: Diagram showing the pipelined used to learn the spectroscopic patterns and identify those patterns to classify new
MRSI examinations.
the mean feature-values of the different identified clusters were used to classify the spectra
of 5 new patients, thus segmenting the MRSI-grid into the previously-identified tissue-types.
An important aspect of the strategy used here is the choice of the clustering method. For
that purpose, X-means [Pelleg 2000] was used, which has the advantage that it determines the
number-of-clusters based on the data, not requiring any assumption regarding the number
of existent spectroscopic-patterns/clusters beforehand. Moreover, given that it works in a
hierarchical fashion it allows for the detection of clusters of different sizes, what is especially
relevant for this problem, given that the number of healthy-brain-tissue voxels is normally
considerably larger than that of tumorous-tissue voxels.
The 22 pre-operative imaging studies of glioblastoma patients used in this study contained
imaging (T1, T2, T1c, FLAIR) and 1H-MRSI (2D-PRESS, CHESS, TE=135ms, TR=1500ms;
32x32 interpolated from 12x12), and were acquired on two 1.5T Siemens scanners (Aera,
Avanto). The measurements were performed conform the local and national ethical regulations:
all patients gave their informed consent to use the data for scientific purposes.
All spectra were pre-processed using jMRUI’s SpectrIm plug-in (residual-water-removal
HLSVD, automatic-quality-filtering [Pedrosa de Barros 2016b], frequency-shift-correction,
auto-phasing). Quantification was performed with QUEST [Ratiney 2004], using a model
containing the following metabolites: Cho, Cr, NAA, Lip1.3, Lac, Lip0.9, mIno, and Glx. In
this work, Glx, mIno and Lip 0.9 were not included in the features used for clustering the
data. Lactate and Lip1.3 were combined given the common errors in resolving these two peaks.
The quantification results were corrected for differences in the RF-pulses’ selection profile and
chemical shift displacement errors, using pre-acquired MRS-phantom data.
For the clustering using X-means the following features were used: Cho/Cr, NAA/Cho,
NAA/Cr, (Lip1.3+Lac)/Cr, (Lip1.3+Lac)/NAA, (Lip1.3+Lac)/Cho). For each cluster, a tissue-
type/metabolic-state was assigned by an experienced spectroscopist, based on the correspond-
ing cluster-mean feature-values and cluster-mean spectra. The MRSI-segmentation performed
on the 5 test studies, assigned to each spectroscopic-voxel the closest cluster. The metabo-
lite maps were interpolated to 64x64 prior to MRSI-segmentation and the resolution of the
BratumIA segmentation was downscaled to match the resolution of the spectroscopy. MRI seg-
mentation was performed using BratumIA [Porz 2014, Meier 2016], an automatic segmentation
method that was trained on manually segmented MR-images of glioblastoma patients. In order
to be applied, BratumIA requires as input T1, T1c, T2 and FLAIR, and segments the images
into the following tissue-types: white-matter, grey-matter, CSF, edema, non-enhancing-tumor,
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enhancing-tumor and necrosis. The results of MRSI and MRI segmentations were compared.
9.4 Results/Discussion
Figure 9.2 shows the different representative cluster spectra of the identified clusters, which
were ordered according to their degree of change relatively to healthy brain spectra. The differ-
ent clusters were grouped into 4 main groups: Healthy, Infiltration, Solid Tumor and Necrosis.
All these associations require further validation with histopathology. In the case of the Infiltra-
tion clusters, given that this group shows important but very subtle differences with healthy
brain spectra (increased Cho/NAA ratio relatively to normal brain tissue [Croteau 2001]), a
question mark was added to the name of the group to indicate the uncertainty of the class.
In Figures 9.3 and 9.4 the different MRSI-segmentations are shown together with the
corresponding MRI (BraTumIA) segmentations. Finally, in Figure 9.5 the confusion matrix
comparing both types of segmentation is shown. The table shows the number of voxels of
the test-set assigned to each cluster, as well the ratio of voxels from each cluster assigned to
each of the MRI-segmentation tissue-types. Besides a general good agreement between both
types of segmentation, it should be stressed that the proposed method detected patterns that
are expected to be associated with tumor infiltration in regions identified by BratumIA as
white-matter. These results are in agreement with previous results from [Cordova 2016] and
[Stadlbauer 2004], showing that Cho/NAA abnormalities extend beyond structural imaging
abnormalities and can improve brain tumor delineation.
9.5 Conclusion
A novel method for mapping different brain and brain-tumor tissue types based on 2D-MRSI
was presented. The method assigns tissue types to spectral patterns, and may assist clinicians
interpreting MRSI examinations of brain tumors. One of the most interesting aspects of the
results presented is the detection of patterns that may be associated with tumor infiltration.
Given that the association between spectra and tissue-types was done using information from
several spectroscopic features, it is expected that this approach may be used to increase the
specificity of the detection of patterns such as infiltration, in comparison with approaches that
rely solely on a single parameter (e.g. detection of tumor infiltration using only Cho/NAA (
[Cordova 2016]). This is, however, an aspect that requires further validation.
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Figure 9.2: Different representative cluster spectra of the identified clusters, which were ordered according to their degree of
change relatively to healthy brain spectra. For each cluster, the corresponding normalized feature vector is also shown. The
normalization was done by first performing 99% winsorization followed by rescaling to [0,1] interval.
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Figure 9.3: Comparison between the MRI and MRSI segmentations for one of the cases included in the test-set. MRI segmentation
performed using BratumIA.
Figure 9.4: Comparison between the MRI and MRSI segmentations for 4 of the cases included in the test-set. MRI segmentation
performed using BratumIA.
Figure 9.5: Table showing the number of voxels from the test-set assigned to each cluster, as well as the ratio of the voxels
from each cluster associated with each of the tissue-types outputted by BratumIA. (GM=grey-matter; WM=white-matter; NE
Tum.=non-enhanching tumour; E Tum.=enhancing tumour).
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10.1 Abstract summary
Clinical-routine MRSI-data analysis is commonly performed through the visual inspec-
tion of multiple metabolite and metabolite-ratio maps and aims at translating the differ-
ent spectroscopic patterns into known tissue-types, such as necrosis, solid tumor, tumor-
infiltration, normal-brain-tissue, etc. Such translation/segmentation requires solid expertise in
MR-spectroscopy, which clinicians often do not have. Therefore, to ease the clinical-use of MRSI,
we present a new method named BraTSIS (Brain Tumor Spectroscopic Imaging Segmentation)
that allows identifying the main spectroscopic patterns seen in GBM patients. The method was
developed using 50 MRSI examinations (2D PRESS, TE 135ms) of 30 GBM patients and tested
in an extra 20 MRSI examinations from 12 other patients. MRSI data was processed using jM-
RUI’s SpectrIm plugin and included automatic-quality-control and selection-profile-correction.
The MRI-segmentation performed by BraTumIA, which is an automatic image segmentation
method, was used for the development and validation of BraTSIS. The comparison between
BraTSIS and BraTumIA provided further insights into the complementary aspects of MRSI
and structural MRI. The BraTSIS protocol aims at supporting the clinical interpretation of
malignant glioma MRSI data and represents an effort towards the standardization of MRSI
analysis, which is essential for the further development of MRSI as a reference technique for
the non-invasive characterization of brain tumors.
10.2 Introduction
Magnetic Resonance Spectroscopy (MRS) provides relevant information for the assess-
ment of brain tumors, allowing to distinguish different tumor types and grades [Zou 2011,
Zeng 2011, Law 2003], distinguish radiation effects (pseudoprogression) from true progression
[Matsusue 2010, Lichy 2004] and identify regions with high tumor cellularity that are not visi-
ble in structural MRI (sMRI) [Cordova 2016, Guo 2012, Stadlbauer 2004]. Many publications
[Hollingworth 2006] focus on the translation of one or two MRS features, such as Cho/NAA
and Cho/Cr, into clinically meaningful information for the tasks described above. Regardless
of what can be achieved with single-feature-MRS-analysis, multi-feature-analysis of MR-spectra
has the potential to allow better characterization of the different tissues in brain tumor patients.
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However, the combined analysis and the interpretation of the various metabolites and metabo-
lite ratios is complex[García-Figueiras 2016] and requires solid expertise in MRS. Furthermore,
there is a lack of consistent guidelines for the use of the information provided by the different
MRS features[Oz 2014], which complicates the identification of consensus on the clinical mean-
ing of the data obtained using MRS. Therefore, MRS interpretation varies depending on the
place and person who performs the analysis.
To facilitate the clinical interpretation of MR spectra, different authors [Preul 1996,
Preul 1998, Luts 2009, Li 2013a, Raschke 2015, Yang 2015] have proposed various methods
that support the translation of spectra into different tissue-types. These methods require a
library of spectral patterns, where a tissue-type is assigned to each pattern. Once the translation
is performed, the results can then be presented in the form of nosologic images, images where
color is used to identify different tissue-types or diseases. The dimensionality reduction together
with the improved data-visualization provided by these methods reduces the complexity of the
analysis and facilitates the clinical interpretation of MRSI data. Despite the very interesting
results, the translation of the proposed approaches into a standard for MRSI data analysis is
complicated, requiring the libraries of the considered spectral patterns to be shared between
centers. Moreover, the list of GBM-specific patterns considered in previous libraries is not
complete, missing, for instance, patterns with high levels of Glx.
To tackle these problems, we performed a thorough analysis of the main types of spectra
existent in 50 MRSI examinations (2D PRESS, TE 135ms) of 30 GBM patients, and developed a
simple decision-tree based protocol to recognize the identified tissue types. The development
and evaluation of the BraTSIS (Brain Tumor Spectroscopic Imaging Segmentation) protocol
were supported by BraTumIA (Brain Tumor Image Analysis)[Meier 2016, Porz 2014], which
is an automatic brain tumor segmentation method trained to reproduce the manual MRI
segmentation performed by experienced neuroradiologists. The BraTSIS protocol aims at
supporting the clinical interpretation of MRSI data of patients with malignant glioma and
represents an effort towards the standardization of MRSI analysis, which is essential for the
further development of MRSI as a reference technique for the non-invasive characterization of
brain tumors.
This paper is organized as follows. First, the spectra of the training dataset were clustered
using X-means to help to visualize the different spectroscopic patterns existent in MRSI data of
GBM patients. The representative spectra of the differently identified clusters were essential
for defining the different classes that were considered in BraTSIS, as well as the structure
of the decision tree that was developed to identify them. For the definition of the decision
rules used in BraTSIS to detect Necrosis and Solid Tumor, MRI segmentation was used as a
reference. The differentiation of normal versus abnormal values for certain MRS features was
made using the data collected from healthy volunteers. The paper finishes with a comparison
between the segmentation results obtained using BraTSIS and the MRI segmentation performed
by BraTumIA. This was performed using a test dataset containing 20 MRSI examinations
and MRI segmentations of extra 12 patients that were excluded from the development phase.
The comparison between the MRI and MRS segmentations provided further insights into the




Data acquisition was performed using two 1.5 T Siemens scanners (models ‘Aera’ and ‘Avanto’,
Siemens, Erlangen, Germany). A total of 70 pre- and post-operative MRSI examinations (PRESS,
CHESS water suppression, TE=135 ms, TR=1500 ms) were collected from 42 different GBM
patients. The MRSI data had an original resolution of 12x12, with a voxel size of 13.33x13.33x15
mm, and were interpolated before DICOM storage to a resolution of 32x32 and a voxel size of
5x5x15 mm. All spectra from outside the PRESS-box, as well as one single outer voxel row of
the excited PRESS volumes, were discarded given that often unreliable quantification results
are found on the edges of the PRESS box due to partial excitation. The data was separated
into a training dataset, containing 50 MRSI studies from 30 different patients and test dataset
with the remaining 20 cases of an extra 12 patients. After exclusion of the outer voxels, each
data set contained respectively 8604 and 3808 spectra. The test dataset was not considered
during the development of the protocol and was only included for the final comparison between
BraTSIS and BraTumIA segmentations. Besides spectroscopy, the protocol included acquisition
of T1-weighted (MP RAGE, TE 2.67 ms; TR 1580 ms, TI 900 ms; 1x1x1 mm), T1-weighted
gadolinium-enhanced (MP RAGE, TE 4.57 ms; TR 2070 ms, TI 1100 ms; 1x1x1 mm), T2-
weighted (SPACE, TE 380ms, TR 3000ms; 1x1x1 mm), and FLAIR-weighted MRI (TE 88 ms, TR
8000 ms, TI 2500 ms; 1x1x3.3 mm).
In parallel to these patients, 7 MRSI normal control recordings were collected from 3 healthy
volunteers using the same acquisition parameters. This healthy control dataset contained a
total of 1372 spectra after exclusion of the outer-voxel row of the excited volume.
The measurements were performed in conformance with local and national ethical regula-
tions, meaning that all patients gave their written informed consent for the data to be used for
scientific purposes.
10.3.2 MRS Data Processing Pipeline
All spectra were processed using jMRUI’s SpectrIm plugin (www.jmrui.eu). The processing
pipeline included the following six processing steps:
1. Residual water peak removal using HLSVD [den Boogaart 1994];
2. Automatic Quality Control [Pedrosa de Barros 2016b, Pedrosa de Barros 2016a];
3. Frequency-Shift Correction;
4. Auto-phasing;
5. Quantification using QUEST[Ratiney 2004];
6. Selection profile correction[Pedrosa de Barros 2017b].
In order to get meaningful and consistent results, strict MRSI-quality control is essential.
Therefore, all low-quality voxels (i.e. voxels with a probability of acceptance by an expert < 0.5)
were excluded from the analysis. For more details on automatic quality filtering the reader is
referred to [Pedrosa de Barros 2016b, Pedrosa de Barros 2016a, Pedrosa de Barros 2017b].
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The metabolite model used for quantification using QUEST included the following metabo-
lites: choline (Cho), creatine (Cr), N-acetyl aspartate (NAA), glutamate (Glu), glutamine (Gln),
lactate (Lac), lipids 1.3 (Lip1.3), lipids 0.9 (Lip0.9), myo-inositol, glycine. The latter two
metabolites were not analyzed in this paper given their quantification results were found to be
non-reliable for the given echo time.
Excitation profile imperfections of amplitude modulated RF-pulses, which are used in the
PRESS sequence, cause non-uniform spatial excitation. Additionally, the scanners’ limited
gradient and RF-power cause spins resonating at different chemical shifts to be excited in a
spatially shifted manner, which is the so-called chemical shift artifact (CSA). These effects can be
corrected using phantom MRSI recordings performed on metabolite solutions that use the same
acquisition parameters as the in-vivo measurements. To the best of the authors’ knowledge, the
CSA correction applied in this study has never been used before in the study of malignant glioma
brain tumors. If not corrected, this has a disastrous effect not only on the observed metabolite
values but also metabolite ratios. The CSA effect is generally observed in volume localization
sequences such as PRESS and STEAM, and to less extent in (semi)LASER[Slotboom 1991,
Slotboom 1994b], namely for low selection RF pulse bandwidth, weak B0 gradients and high
field strength. Metabolite ratios such as Cho/NAA are considerably more affected than Cho/Cr,
given that NAA has a higher chemical shift difference with Cho than Cr. Detailed information
on the applied CSA and selection profile correction is found in [Pedrosa de Barros 2017b]. An
average Cho/NAA map before and after correction for both healthy controls and GBM patients
was included in the results section to highlight the importance of this correction.
10.3.3 Image Segmentation using BraTumIA
For each MRSI examination, the corresponding MR images were segmented into the following
compartments: white-matter (WM), gray-matter (GM), cerebral-spinal-fluid (CSF), edema,
non-enhancing tumor (NE-Tumor), enhancing tumor (E-Tumor) and necrosis. MRI-visible-tumor
was defined as the union of NE-Tumor, E-Tumor, and necrosis.
The enhancing tumor is visible on T1c-weighted MR images as a hyperintense region caused
by the contrast-enhancement due to the blood-brain barrier disruption. Enhancing tumor is
usually surrounded by a large edema which appears hyperintense on T2-weighted images and
hypointense on T1-weighted images. The FLAIR image is utilized to differentiate edema from
CSF, which appears also hyperintense in the T2 sequence but dark in the FLAIR image due
to the suppression of the free water signal. Glioblastoma can contain necrotic parts which
do not enhance on T1c-weighted images but appear hyperintense on T2-weighted images
and hypointense on T1-weighted images. The most difficult compartment to identify is the
non-enhancing tumor which does not enhance in T1c-weighted images and exhibits generally a
lower intensity in T2-weighted images than necrosis with the corresponding T1-hypointensity.
The segmentation of the different compartments was performed using BraTumIA
[Meier 2016, Porz 2014], an automatic method that was trained to reproduce the manual image
segmentation performed by experienced neuroradiologists. This method uses as input the
previously introduced MR image sequences: T1, T1c, T2, and FLAIR. BraTumIA is a machine
learning-based segmentation method, which was trained on an independent dataset of 54 pre-
and postoperative MRI examinations of glioblastoma. It uses supervised learning to generalize
from manually segmented ground truth data. A more detailed description of the algorithm and
training data can be found in the study of Meier et al. [Meier 2016].
The process of manually segmenting glioblastoma includes first the segmentation of the
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complete tumor visible as a hyperintense area in the FLAIR image. Second, the gross tumor
volume (including necrosis, non-enhancing and enhancing tumor) is delineated using mainly
the co-registered T1c and T2 sequences. This region exhibits a lower intensity in T2 than the
surrounding edema. The mismatch between both regions is considered as the edema. The
enhancing tumor is segmented based on the hyperintense region in the T1c sequence. Necrosis
is differentiated from non-enhancing tumor based mainly on information from the T2-weighted
sequences.
Image segmentation could not be performed in 4 out of the 50 training cases, given that
not all required image sequences were available. To facilitate comparison with MRS, the image
segmentation results were converted to the same orientation and resolution as MRSI.
10.3.4 Clustering
The spectra from the training set were clustered using the Weka [Hall 2009] implementation of
X-means [Pelleg 2000], a hierarchical clustering method based on K-means that automatically
identifies the number of clusters in a dataset. The clustering was performed using the following
17 MRS features: %NAA, %Cho, %Cr, %Glx, %Lac, %Lip, Lac/Cr, Lip/Cr, Cho/Cr, Cho/NAA,
Glx/NAA, Glx/Cr, %(Lip+Lac), Lac/NAA, Lip/NAA, (Lac+Lip)/Cr, and (Lac+Lip)/NAA. Glu
and Gln were not included separately given that, due to their overlap, the quantification of
these metabolites on a spectrum by spectrum basis is difficult and may lead to the creation of
extra non-meaningful clusters.
Prior to clustering, 99% winsorization [Tukey 1962] was applied to each feature followed





Feature standardization was not performed given that several of the features presented
highly skewed distributions. The distance metric chosen for clustering was the Manhattan dis-
tance (L1), which is expected to provide a better overall discrimination between the different fea-
ture vectors than the Euclidean distance (L2) for the number of features used [Aggarwal 2001].
To test the stability of the clusters found with X-means, the training set was partitioned into
5 different groups containing 10 MRSI examinations each. The data was organized such that the
examinations of each patient were all in the same group. The clustering was then performed 5
times, excluding every time one of the five partitions completely.
10.3.5 BraTSIS: MRSI Segmentation Protocol
The results of X-means showed 5 main types of spectra that are well represented in the example
shown in Figure 10.1.
BraTSIS was designed to standardize the identification of these patterns consider-
ing the most relevant and state-of-the-art decision rules[Vigneron 2001, Horská 2010,
Ricci 2007, Zou 2011, Zeng 2011, Law 2003, Matsusue 2010, Lichy 2004, Cordova 2016,
Guo 2012, Stadlbauer 2004, Hollingworth 2006] for the interpretation of brain tumor MR spec-
tra. Its development was driven by the following objectives:
1. The protocol should focus on the main aspects that make MRS complementary to MRI in
the characterization of brain tumors, namely:
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Figure 10.1: Pre-operative MRSI acquisition of a GBM patient showing all of the main types of spectra identified after clustering
the training dataset using X-means, and their location. A FLAIR image was used to indicate their locations. The selected case
corresponds to one of the cases of the training set.
(a) Accurate detection of tumor necrosis/cysts whose spectroscopy patterns are easily
identifiable: very high levels of Lip and/or Lac and low levels of other metabolites
[Vigneron 2001, Horská 2010].
(b) Detection of spectroscopy features characteristic of high-grade tumors [Zeng 2011,
Law 2003], namely very high Cho/Cr and Cho/NAA.
(c) Detection of tumor infiltration [Cordova 2016, Guo 2012, Stadlbauer 2004] not visi-
ble using sMRI, allowing to improve delineation of tumor borders: Cho/NAA higher
than in healthy brain tissue.
(d) Detection of features associated with neuronal loss and demyelination seen often
in peritumoral edema of GBM patients [Ricci 2007]: Glx/Cr higher than in normal
brain tissue.
2. The protocol should be based on simple decision rules, allowing it to be easily applied in
different centers, and easily updated and adapted to different sequences and acquisition
parameters, if needed.
Considering these objectives, BraTSIS was defined as a decision tree that starts by identifying
the tissue types that have the biggest differences with normal brain tissue. Consequently, the
first tissue-type to be detected is Necrosis, which can be easily separated from the remaining
spectra by the very high levels of Lip and/or Lac relatively to the remaining metabolites. Once
Necrosis spectra are excluded, the high values of Cho/Cr and/or Cho/NAA allow to identify
the spectra characteristic of Solid Tumor. Infiltration is then defined as spectra which have
abnormal values of Cho/NAA and/or Cho/Cr that were not included in the Solid Tumor class.
Finally, if none of the previous tests is positive, the levels of Glx are evaluated. If abnormal
levels of Glx are detected, the spectra are included in the High Glx group, otherwise, the spectra
are considered Healthy. The description of each class and the strategy used to define the
corresponding class membership tests are described below:
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1. Necrosis: Spectra with very high levels of Lip and/or Lac relatively to other metabolites.
Multiple membership tests using different features that capture this property of necrosis
were tested and optimized to maximize the agreement (Dice-score) with the Necrosis class
in MRI segmentation. The specific tests that were evaluated to optimally detect necrosis
are listed in the next section.
2. Solid Tumor: Spectra with very high Cho/Cr and/or Cho/NAA associated with the MRI-
visible tumor. Different membership tests using different combinations of these parameters
were tested and optimized to maximize the agreement (Dice-score) with the MRI-visible
tumor. The specific tests evaluated to detect Solid Tumor are described in the next section.
3. Infiltration: Spectra whose values of Cho/NAA and/or Cho/Cr are significantly higher
than in normal brain tissue but lower than in Solid Tumor. Due to the importance of
this class and the broad range of spectra that it contains, this class was divided into
two subgroups: Infiltration I and II, the second one including the spectra with higher
levels of Cho/NAA and/or Cho/Cr. The division was made simply using the mid-values
between the thresholds used to detect Infiltration I and the ones used to detect Solid Tumor.
The detection of Infiltration I is made using the 99.9th percentile of Cho/NAA in healthy
volunteers as reference.
4. High Glx: Spectra with abnormally high levels of Glx but with normal Cho/NAA. Given that
the Glx increase has been associated with neuronal loss and demyelination [Ricci 2007], it
is expected that the ratio with NAA increases the sensitivity to detect the deterioration
and/or loss of neurons. Due to this reason, Glx/NAA was selected for the class membership
test associated with the class High Glx. As in the detection of Infiltration I, the class
membership test used as a threshold the 99.9th percentile of the Glx/NAA in healthy
volunteers.
5. Healthy: Applies if none of the previous class membership conditions is met.
For the classes Infiltration I and High Glx, where the threshold values were determined as the
99.9th percentile of the selected features in healthy volunteers, the associated 95% confidence


















, xi,(1) < xi,(2) < · · · < xi,(n)are the order statistics for the feature i, n denotes the size of the
sample collected from healthy volunteers, and k is the position of a given element of the order
statistics of the analyzed feature. Prior to determining the percentiles and corresponding confi-
dence intervals, the size of the healthy control dataset was artificially increased interpolating
each feature map by a factor of 4 (zero-filling) in each spatial direction.
The different features and thresholds selected to be used in BraTSIS are presented in the
results section (Figure 10.6 and Table 10.1).
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The structure and classes of BraTSIS were determined based on the representative spectra
and features values of the clusters identified by X-means. To ensure that the rules defined to
classify the clusters identified by X-means applied to the classification of individual spectra,
the following test was performed. First, the different clusters obtained for each of the five
different solutions of X-means were classified using BraTSIS. The clusters of the training set
were then used to classify the spectra of the test set. This was done by assigning to every test-set
spectrum the class of the closest training set cluster, i.e. the cluster whose median feature values
had the smallest L1 difference with the feature values of the new spectrum. These are named
as the indirect BraTSIS results, which varied depending on the clustering solution used. The
direct BraTSIS results were obtained simply by classifying each new spectrum directly. Both
approaches were compared by measuring the average agreement between the direct BraTSIS
and the different indirect BraTSIS results, and comparing it to the average agreement between
the indirect BraTSIS solutions. The agreement was evaluated as the Dice-Score for each class.
The results (included in part B of the Supplementary Material) showed that both approaches
produce nearly identical results, confirming the applicability of the rules to the classification of
individual spectra.
10.3.6 Optimized detection of Necrosis and Solid Tumor
The decision rules used in BraTSIS to assign new spectra to the Necrosis and Solid Tumor classes
were optimized using MRI Segmentation as a reference. For the necrosis class, several decision
rules were tested that aim at detecting high levels of Lip and/or Lac and low levels of other
metabolites:
1. (Lac+Lip)/NAA ≥ θa.1
2. (Lac+Lip)/Cr ≥ θb.1
3. Lac/Cr ≥ θc.1
4. Lip/Cr ≥ θd.1
5. Lip/NAA ≥ θe.1
6. Lac/NAA ≥ θf .1
7. (Lac+Lip)/NAA ≥ θg.1 AND (Lac+Lip)/Cr ≥ θg.2
8. (Lac+Lip)/NAA ≥ θh.1 OR (Lac+Lip)/Cr ≥ θh.2
9. Lac/Cr ≥ θi.1 AND Lip/Cr ≥ θi.2
10. Lac/Cr ≥ θj.1 OR Lip/Cr ≥ θj.2
11. Lac/NAA ≥ θk.1 AND Lip/NAA ≥ θk.2
12. Lac/NAA ≥ θl.1 OR Lip/NAA ≥ θl.2
The thresholds θi of each decision rule were optimized to achieve the best agreement
(Dice-Score) with the segmentation of the Necrosis class as identified by BraTumIA. For this
optimization, only the pre-operative examinations of the training set that contained necrotic
voxels were included. The inclusion of only pre-operative data results from the fact that
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resection cavities, namely the ones filled with blood, are often classified by BraTumIA as
necrosis. There was a total of 7 MRSI examinations from 7 different patients meeting these
requirements.
In the case of the Solid Tumor class, the aim was to detect very high Cho/Cr and/or Cho/NAA
values that are associated with the parts of the tumor visible in sMRI. Consequently, the
following rules were tested:
1. Cho/Cr ≥ θm.1 AND Cho/NAA ≥ θm.2
2. Cho/Cr ≥ θn.1 OR Cho/NAA ≥ θn.2
3. Cho/Cr ≥ θo.1
4. Cho/NAA ≥ θp.1
In this case, the thresholds were optimized to achieve the best agreement (Dice-Score) with
the segmentation of the MRI-visible tumor (Necrosis U E-Tumor U NE-Tumor) as performed by
BraTumIA. Similarly to the previous optimization, only pre-operative data from the training set
was used. In this case, only examinations with MRI-visible-tumor voxels were included. There
were 13 MRSI examinations from 13 different patients meeting these requirements.
The optimization of the thresholds was performed using Leave-One-Out-Cross-Validation
(LOOCV), where every time one of the selected MRSI examinations were removed from the
dataset used to optimize the thresholds and used to evaluate the performance.
10.3.7 BraTSIS validation and comparison with MRI-segmentation (BraTumIA)
The t-SNE method [Van Der Maaten 2008] was used to allow for the visualization of all the
examples of the test set in a single 2D map. This map was then colored in various ways to
highlight different aspects of the data:
1. Coloring/Labelling according to the closest cluster of the 5 different cluster solutions
obtained with X-means only;
2. Coloring/Labelling according to the BraTSIS class of the closest cluster of the 5 different
cluster solutions obtained with X-means;
3. Coloring/Labelling according to the BraTSIS class after classification of each individual
spectra;
4. Coloring/Labelling according to the MRI-segmentation class.
Then, the median spectra and corresponding 5th, 25th, 75th and 95th percentile spectra were
calculated for each class, using the examples of the test set. The same was performed for the
values of each normalized feature used for clustering.
The MRS and MRI segmentations for all the cases of the test set, together with the maps
of the different MRS features used in BraTSIS, were analyzed. Due to the high number of
figures, the images of the second half of the test set were only included in the Supplementary
Material. Finally, the relation between the MRI and MRS classes was further evaluated using
the normalized confusion matrices containing the probabilities of each MRI class given a fixed
MRI class, as well as the probabilities of each MRS class given a fixed MRI class.
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Figure 10.2: Average of localized Cho/NAA maps before and after selection profile correction, for healthy volunteers and GBM
patients. The Cho/NAA maps were interpolated by a factor of 2, using zero-filling. Only data from within the PRESS-box is
shown. The outer rows and columns of the PRESS box were removed before interpolation. The averaged maps are all transversally
oriented, with the Left and Right sides of the patient inverted in the image (neuroradiological view).
10.4 Results
10.4.1 Selection-Profile Correction
Figure 10.2 shows the average Cho/NAA map for all healthy volunteers and GBM patients,
before and after selection profile correction. The results show the high impact of the chemical
shift artifact on the Cho/NAA maps. Without excitation profile and CSA-correction, normal
brain tissue in the central frontal areas of the excited volume may be classified as tumor or
infiltration. Similarly, if no correction is performed, tissue infiltration in the occipital areas may
be classified as healthy brain tissue.
Besides these effects and despite the not perfect alignment of the different Cho/NAA maps,
the average Cho/NAA map in GBM patients seems to indicate a higher prevalence of GBMs
located in the right lobe than in the left lobe, confirming the results reported by Larjavaara et
al.[Larjavaara 2007].
10.4.2 Clustering with X-means
The clustering performed with X-means produced an average of 52 clusters, in the range of
46 to 56 clusters. The clusters obtained in the first clustering solution, excluding the first 10
MRSI examinations of the training set, are shown in Figure 10.3. In that figure, the clusters are
grouped by the corresponding BraTSIS class. The analysis of the clustering results was essential









































































































































































































































































































































































































158 10. BraTSIS: Brain Tumour Spectroscopy Imaging Segmentation protocol
Figure 10.4: Dice scores between MRI Necrosis and MRS Necrosis defined using different features. In each case, the thresholds
used were optimized to achieve the highest Dice-score with Necrosis as defined in MR imaging. The bar-plots show the standard
deviation of the different results obtained with LOOCV. For each feature, it is shown the values of a paired t-test comparing the
performance values obtained with that feature and the ones obtained with the one selected (Lac/Cr OR Lip/Cr). Considering
the Bonferroni correction and a significance level of 0.05, there are no significant differences (p<0.0042) between the different
features and the selected one.
10.4.3 Optimizing the detection of Necrosis and Solid Tumor
Figure 10.4 shows the agreement with the image segmentation of the decision rules using
different features that were optimized to detect necrosis. The rule with the highest average
Dice-score (0.571), and consequently selected to be used in BraTSIS, was “Lac/Cr OR Lip/Cr”,
with average θj.1 and θj.2 equal to 1.701 and 2.436. Despite this, several other tested decision
rules lead to similar performances, as seen in the bar plot.
Similarly to Figure 10.4, Figure 10.5 shows the Dice-scores obtained with the different
decision rules that were tested to detect Solid Tumor. As in the previous optimization, there
were no significant performance differences between the different rules. Despite this, Cho/Cr
alone provided the best average Dice-score (0.710). Moreover, the different optimal threshold
values obtained with this parameter alone and in the “Cho/Cr AND Cho/NAA” and “Cho/Cr
OR Cho/NAA” decision rules were considerably more stable than the optimal Cho/NAA values
(coefficient of variation 8.4% vs 19.5%). These results suggest that Cho/Cr is more important to
detect the solid part of the tumor than Cho/NAA. As a result, Cho/Cr alone was selected for the
detection of Solid Tumor.
All the thresholds and performance measures related to the evaluated decision rules are
included in the Supplementary Material in Table 10.2 and Table 10.3.
10.4.4 Infiltration I vs Infiltration II
The final decision rule to be fixed is the one related to the division of the Infiltration class into
two subgroups with, assumingly, different malignancy levels. It is known that the two most
commonly used metabolite ratios, Cho/Cr and Cho/NAA, are markers for tumor malignancy
[Zeng 2011, Law 2003], but their relative importance may change at different stages of tumor
development. The results of Cordova et al. [Cordova 2016] suggest that Cho/NAA is more
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Figure 10.5: Dice scores between MRI-visible-tumor (Necrosis, E-Tumor, NE-Tumor), and MRS Solid Tumor defined using differ-
ent features. In each case, the thresholds used were optimized to achieve the highest Dice-score with MRI-visible-tumor. The
bar-plots show the standard deviation of the different results obtained with LOOCV. For each feature, it is shown the values of a
paired t-test comparing the performance values obtained with that feature and the ones obtained with the selected one (Cho/Cr).
Considering the Bonferroni correction and a significance level of 0.05, there are no significant differences (p<0.0125) between
the different features and the selected one.
suitable to detect tumor infiltration than Cho/Cr. On the other hand, the results obtained with
the optimization of the detection of Solid Tumor show that Cho/Cr is better at detecting the parts
of the tumor visible in MRI. Considering this, it is expected that the division of the two subtypes
of Infiltration occurs in a region where the importance of both features is similar. Consequently,
the decision rule selected to separate these two subgroups considered both features:
Cho/Cr ≥ θ3.1 OR Cho/NAA ≥ θ3.2 (10.4)
, where θ3.1 is the midpoint between the Cho/Cr threshold selected to identify Solid Tumor and
the 99.9th percentile of Cho/Cr in healthy volunteers, and θ3.2 is the midpoint between the
best Cho/NAA threshold to detect Solid Tumor using Cho/NAA alone, and the 99.9th percentile
of Cho/NAA in healthy volunteers. The use of an OR in the decision rule guarantees that all
Infiltration spectra with high values of Cho/Cr and/or Cho/NAA are identified, i.e., classified as
Infiltration II.
10.4.5 BraTSIS and selected class membership tests
The BraTSIS decision tree with the different selected class membership tests is presented in
Figure 10.6. All decision threshold values θk that were used in BraTSIS are shown in Table 10.1.
Here, the uncertainty on the selected values is shown differently depending on the method used
to determine the optimal threshold. For the thresholds optimized using image segmentation
as reference, the uncertainty is reported as the standard deviation over the different results
obtained using cross-validation. On the other hand, for the values determined as the 99.9th
percentile in healthy volunteers, the value is reported as the associated 95% confidence intervals,
calculated as described in the methods section.
10.4.6 BraTSIS validation and comparison with MRI-segmentation (BraTumIA)
Figure 10.7 provides an overview of the different classifications of the test dataset. All
the feature vectors of the test dataset were converted to points in a 2D-space, using t-SNE
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Figure 10.6: BraTSIS decision tree.
Table 10.1: All spectral features with their associated thresholds used in the current BraTSIS implementation. The first four
values were obtained using LOOCV and therefore, the uncertainty is reported as the standard-deviation of the results obtained in
the different iterations of the cross-validation. For the latter 3 features, the uncertainty is reported through the 95% CI associated
with the 99.9th percentile, calculated as described in the methods’ section. The thresholds θ2’ and θ4’ were not directly used in
BraTSIS but are essential to calculate the midpoint thresholds used to divide the two Infiltration type classes.
Threshold Feature Value CV std 95%CI Approach used
θ1.1 Lip/Cr 2.436 0.301 - Optim. with Img. Segmentation
θ1.2 Lac/Cr 1.701 0.271 - Optim. with Img. Segmentation
θ2 Cho/Cr 1.342 0.021 - Optim. with Img. Segmentation
θ′2 Cho/NAA 1.105 0.053 - Optim. with Img. Segmentation
θ3.1 = (θ2 +θ′4)/2 Cho/Cr 1.258 - - Midpoint
θ3.2 = (θ′2 +θ4)/2 Cho/NAA 0.898 - - Midpoint
θ4 Cho/NAA 0.691 - [0.684, 0.702] 99.9th %ile healthy volunteers
θ′4 Cho/Cr 1.174 - [1.157, 1.207] 99.9
th %ile healthy volunteers



























































































































































































































































































































































































162 10. BraTSIS: Brain Tumour Spectroscopy Imaging Segmentation protocol
Figure 10.8: Magnitude spectra and normalized feature vectors for each class identified using BraTSIS directly on the test set. For
each class, the plots show the median values as well as 5th, 25th, 75th and 95th percentiles. For the normalized feature values,
the coloring scheme used reflects the position of the value relative to the other values for that feature in the tested data set (dark
red for values close to the maximum, and dark blue for values close the minimum value). In the titles of the plots, the number of
spectra that were assigned to each class is given.
[Van Der Maaten 2008]. The maps of the first row are colored based on the closest cluster
number of each of the 5 cluster solutions. The second row shows the BraTSIS class of the
clusters assigned to the first row. Finally, the last two maps show, on the left, the BraTSIS
classification applying BraTSIS directly to the classification of each individual spectrum and,
on the right, the BraTumIA classes of the corresponding regions in MRI.
The maps show that there are no well-isolated clusters in the test set, and besides not being
shown here, the same is observed in the training set. This should explain the variability of the
results of the first row of Figure 10.7. The results show that X-means succeeds in grouping
similar spectra together, which is extremely valuable for the visualization of the different types
of spectra existent in large datasets, as seen in Figure 10.3. Despite this, the variability of the
clustering solutions and the elevated number of clusters indicates that X-means alone fails
to identify reference groups that, once associated with a certain tissue-type, may directly be
used to classify new spectra. This emphasizes the need for methods such as BraTSIS, based on
clear rules that incorporate prior-knowledge in the classification of spectra. The maps show
that BraTSIS succeeds in grouping similar spectra together while providing meaning to each
spectrum/cluster.
Figure 10.8 shows the spectra and feature vectors from the test set grouped by BraTSIS class.
In that figure, it is noticeable the low variance between the spectra of each group, a result that
confirms the ability of BraTSIS to identify the major spectroscopic patterns of GBM patients.
The MRS and MRI segmentations of the first case of the test set are shown in Figure 10.9. In
the same figure, different MR modalities (T1, T1c, T2, FLAIR, SWI, and ADC) were also included.
This example shows clearly that the Infiltration I class is found in regions with no alterations
visible in MRI. Moreover, the combination of both segmentations may allow distinguishing
infiltrated from non-infiltrated edema. In the same example, there is no agreement on the
location of the necrosis.
Figure 10.10 shows the different segmentation results and metabolite maps of the first half
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Figure 10.9: Example showing the segmentations obtained with BraTSIS and BraTumIA together with six different MR modalities
with the same location and resolution as the segmentation maps. The pixel intensities of the 6 different MRI images show the
mean value of the image voxels that correspond to each voxel of the interpolated MRSI grid. The example shown in the figure
corresponds to the first example of the test set. The metabolite maps of this example are shown in the first row of Figure 10.10.
of the test set. The maps of the second half of the test set were included in the Supplementary
Material. The different maps nicely illustrate the ability of BraTSIS to merge the information of
the various metabolite ratios into a single map. The different examples show also interesting
discrepancies between BraTumIA and BraTSIS, such as regions classified by BraTumIA as
edema that show highly malignant features in MRS. The disparities between MRS and MRI
segmentations reflect the differences in the information provided by these two techniques.
The complementary aspect of MRI and MRS is particularly well analyzed in a recent paper
[Lopez 2017] comparing different features extracted from T1c- and T2-weighted images and
features extracted from MRSI. In that paper, the authors show, for instance, that Cho-derived
maps show little correlation with MR imaging. Another study [Pirzkall 2004], where the use
of MRSI to define target volumes for radiotherapy treatment planning was evaluated, found
substantial differences in the spatial relationship between MRSI and MRI, further emphasizing
the differences in the information provided by these two modalities.
The relations between the two classification methods are better understood with the nor-
malized confusion matrix of Figure 10.11. Here we see that it is very unlikely for a spectrum
to be classified as Healthy in spectroscopy and not healthy (Edema, NE-Tum., E. Tum., Necrosis)
in MRI. On the other hand, about 30% of the spectra classified as Infiltration I and 21% of the
spectra classified as Infiltration II, are found in WM.
Another interesting result is that the High Glx class is often found in Edema, which suggests
an association between these two classes. The results show that 82.5% of the necrosis voxels
identified in MRI are classified as necrosis in MRS, but only 30% of voxels classified as necrotic
in MRS are identified as such by BraTumIA. This discrepancy may be explained by the under-
segmentation of necrosis performed by BraTumIA previously described by Velasquez et al
[Rios Velazquez 2015].
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Figure 10.10: Segmentation results and metabolite maps for the first 10 MRSI examinations of the test set. The other 10 exami-
nations were included in the Supplementary Material. The last column shows the quality score maps, representing the predicted
probability that the quality of each spectrum is accepted by an expert rater [Pedrosa de Barros 2016b]. The regions of the MRS
maps with quality scores below 0.5 were discarded and are shown in black. The color scales of both segmentations are shown
next to the corresponding maps.
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Figure 10.11: Normalized confusion matrices. The left matrix shows the probabilities of each MRI segmentation class for the
voxels of a fixed MRS segmentation class. The right matrix shows the opposite: the probabilities of each MRS segmentation class
for each MRI segmentation class. The results were calculated after applying BraTSIS directly to the interpolated test set.
10.5 Discussion
10.5.1 Automatic Quality Control and Selection Profile Correction are essential
pre-processing steps
The results shown in the previous section confirm the feasibility of using a decision-tree based
protocol to perform meaningful segmentations of brain tumor MRSI examinations in a sim-
ple and straightforward manner. Moreover, the development process of BraTSIS provided
valuable insights into multiple metabolite ratios that are important for the characterization
of brain tumors. For the successful development of BraTSIS, two processing steps were es-
sential: Automatic Quality Control and Selection Profile Correction. Bad quality data, if not
removed, prevents meaningful data exploration. The quality of the signals was assessed using
SpectrIm’s quality control [Pedrosa de Barros 2016b] algorithm, which can assess every grid
almost instantaneously and with the same accuracy as a MRS-expert. Not only this saves a
considerable amount of time compared to the manual assessment of the data, but also prevents
subjective assessments of the quality of the signals, and enables fully automatic MRS data
processing. With respect to Selection Profile Correction, which is a step that is often omitted
in MRS data processing, the results demonstrated the negative impact that it can have on one
of the most commonly used metabolite ratios: Cho/NAA. The step used for correction just
requires a reference MRSI-scan of a phantom filled with appropriate metabolite solutions and
is able to reduce significantly the impact of the CSA and of the non-perfect selection pulse
profiles. More advanced corrections may provide further elimination of these effects. However,
these artifacts are solved best at the pulse sequence level. MRSI pulse sequences suffering
from these undesired effects are broadly used in clinical practice, emphasizing the need for
such corrections. Consequently, there is an urgent need for such correction methods in the
manufacturers’ processing tools for the clinical routine use of MR spectroscopy.
10.5.2 Further research is needed to characterize the tissue properties associated
with the High Glx class
The High Glx class originated from the clear identification by X-means of patterns showing
overall healthy appearance but with significantly higher levels of Glx than other clusters.
Despite its clear spectroscopic features, several questions are left open regarding the meaning
of this class. Most of the Edema class seems to be divided in either High Glx or Infiltration,
which may suggest that High Glx corresponds to non-infiltrated edema. Despite this, increased
levels of Glx are associated with tumor growth [Takano 2001]. It is, therefore, necessary to
understand whether the High Glx region corresponds mainly to peritumoral tissue under stress
that has a minimal concentration of infiltrative tumor cells, or if this class captures the first
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signs of tumor infiltration. Consequently, a future biopsy/MRS study evaluating the relation
between Glx/NAA and tumor cellularity is necessary. The name “High Glx” chosen for this class
reflects the need for a better understanding of the tissue characteristics associated with this
metabolic pattern.
10.5.3 Comparison between hard and soft MRSI classification needs to be per-
formed
BraTSIS is a hard classifier, i.e. assigns only one class to each spectrum. Soft classifiers, on the
other hand, do not consider class membership as a binary decision and use continuous values
(often a probability distribution) to describe the proximity between a given example and each
class. The use of hard boundaries between classes may prevent interesting analysis related
with elevated levels of Glx in other classes than High Glx. Similarly, the analysis of the overlap
between Solid Tumor and Necrosis features could potentially allow a better description of the
tumor core. Despite these possible drawbacks, the definition of well-defined classes with sharp
boundaries reduces ambiguities and should benefit the standardization of MRSI analysis. The
trade-offs between hard and soft classifications should be evaluated in a further study.
10.5.4 Cho/NAA and Cho/Cr are complementary features for tumor detection
Another interesting aspect that emerged from the development of BraTSIS was the comparison
between Cho/NAA and Cho/Cr. Interestingly, Cho/Cr seemed to contain more information
to identify the regions of the tumor visible in MRI (see results Figure 10.5). On the other,
from previous research [Cordova 2016] it is known that Cho/NAA allows to better detect
tumor infiltration. These results show that both features complement each other on the
characterization of the different tumor regions of GBM.
10.5.5 Classification of spectroscopic patterns requires inclusion of prior-
knowledge
Despite not being extensively discussed in this paper, the cluster analysis that laid the foun-
dations for BraTSIS showed also that, in the analyzed dataset, there are no clear boundaries
between the different types of spectra, a property that is well visible in the maps of Figure 10.7.
This is most likely a result of the low resolution of the MRSI data. The low-resolution leads
to spectra of mixed sources (partial-volume-effects) that fill the regions of the feature-space
between clusters, connecting them. Alternatively, it is possible that the lack of clear cluster
boundaries just reflects a continuous evolution of the metabolic patterns between healthy brain
tissue and tumor tissue or necrosis, with no demarked stages. To test this hypothesis, it would be
necessary to evaluate to apply BraTSIS using high-resolution MRSI data, using sequences such
as EPSI [Mulkern 2001] or SPICE [Ma 2016, Lam 2015]. The lack of clear cluster boundaries
causes the variability of the results of X-means seen in the first row of Figure 10.7. Apart from
this, BraTSIS showed that it is possible to robustly identify different classes of spectra in case
prior-knowledge is included in the classification. In this case, prior-knowledge corresponds
not only to the class membership tests optimized using MRI segmentation or the abnormality
thresholds derived from healthy volunteers, but also to everything that supported the decisions
regarding the definition of the different classes, the structure of the decision-tree, and the choice
of the features to be tested for each class membership test. The inclusion of prior-knowledge
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is essential for the translation of the different spectroscopic patterns into clinically relevant
information that can be used in the management of brain tumor patients.
10.5.6 BraTSIS may allow identification of tumor infiltration and improve delin-
eation of tumor borders
The segmentation results of Figure 10.10 (and Figure 10.13 of the Supplementary Material)
show that BraTSIS identifies regions that have features associated with tumor infiltration
in MRS but the appearance of normal brain tissue or edema in conventional imaging. This
mismatch between BraTSIS and BraTumIA is seen in almost every case of the test set. Cho/NAA
alone has shown to be able to identify regions with high tumor cellularity not visible with
sMRI [Cordova 2016, Guo 2012, Stadlbauer 2004], which supports the belief that these regions
identified by BraTSIS correspond to tissue with elevated tumor cellularity and that BraTSIS
may be used to improve the delineation of brain tumor borders. Despite the strong evidence
from the previous literature that supports this idea, further validation with histopathology is
required. The inclusion of Cho/NAA maps to delineate GBM lesions and plan Gamma Knife
stereotactic surgery has shown to improve patient survival in a Phase II trial conducted at the
Case Western Reserve University Kettering, Ohio, in 2012 [Einstein 2012].
10.5.7 BraTSIS improves detection of tumor necrosis
In GBM patients, the existence of a necrotic core is associated with poor prognosis [Burger 1987,
Barker 1996]. Necrosis can be easily identified in MRS by the high levels of lipids and/or lactate
and low levels of other metabolites [Vigneron 2001, Horská 2010]. The examples number #5,
#9 and #10 of Figure 10.10, show 3 tumors where BraTumIA identifies only a few voxels as
necrosis but BraTSIS shows relatively big necrotic cores, with high levels of Lip/Cr and Lac/Cr.
Moreover, the latest MICCAI BraTS’17 challenge (www.med.upenn.edu/sbia/brats2017.html)
(Multimodal Brain Tumor Segmentation Challenge) does no longer distinguish between Necrosis
and NE Tumor, which reflects the known difficulties in detecting tumor necrosis using sMRI
described by Velasquez and Meier et al. [Rios Velazquez 2015]. This further emphasizes the
importance of MRSI brain tumor segmentation for the complete characterization of brain
tumors.
10.5.8 BraTSIS may help to identify the most malignant parts of the tumor
Several studies [Zeng 2011, Law 2003] have shown the ability of MRS to distinguish different
tumor grades, based on Cho/Cr and Cho/NAA. Furthermore, MRS has been shown to help to iden-
tify foci of higher tumor malignancy in stereotactic brain biopsy [Hermann 2008, Son 2001],
which may avoid wrong tumor grading due to sampling errors. BraTSIS considers different
classes whose features are associated with different malignancy levels, namely Solid Tumor,
Infiltration II and Infiltration I. Therefore, BraTSIS may help to identify the most malignant
parts of the tumor and provide relevant information for guiding stereotactic brain biopsy.
10.6 Conclusion
The BraTSIS protocol presented here combines several feature threshold rules in a simple
decision-tree. Despite its simplicity, BraTSIS effectively identifies the main types of spectra seen
in MRSI examinations of GBM patients. The results showed the potential of this approach to
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Table 10.2: Feature thresholds and performance measures obtained after optimizing different MRS features to obtain the high-
est Dice scores with Necrosis as segmented by BraTumIA. (std – standard deviation, Acc – accuracy, Sens – Sensitivity, Spec –
Specificity, Prec – Precision, F1 – F1-score)
θX.1 std θX.2 std Acc std Sens std Spec std Prec std F1 std
(Lac+Lip)/NAA 2.521 0.271 0.921 0.271 0.715 0.271 0.939 0.271 0.481 0.271 0.512 0.271
(Lac+Lip)/Cr 3.158 0.440 0.911 0.050 0.764 0.284 0.927 0.059 0.489 0.249 0.513 0.153
Lac/Cr 1.502 0.264 0.926 0.040 0.644 0.351 0.942 0.051 0.430 0.268 0.468 0.227
Lip/Cr 2.032 0.300 0.903 0.046 0.741 0.310 0.923 0.054 0.435 0.264 0.446 0.166
Lip/NAA 1.523 0.232 0.915 0.050 0.812 0.275 0.934 0.054 0.492 0.260 0.521 0.171
Lac/NAA 1.127 0.071 0.933 0.043 0.635 0.346 0.948 0.050 0.520 0.352 0.511 0.272
(Lac+Lip)/NAA AND
3.055 0.416 2.300 0.098 0.928 0.042 0.723 0.258 0.948 0.044 0.540 0.233 0.550 0.149
(Lac+Lip)/Cr
(Lac+Lip)/NAA OR
7.016 6.628 2.734 0.924 0.919 0.040 0.723 0.258 0.938 0.047 0.479 0.264 0.502 0.169
(Lac+Lip)/Cr
Lac/Cr AND Lip/Cr 1.354 0.140 0.251 0.565 0.929 0.040 0.644 0.351 0.945 0.052 0.448 0.288 0.477 0.229
Lac/Cr OR Lip/Cr 1.701 0.271 2.436 0.300 0.926 0.046 0.759 0.233 0.939 0.053 0.523 0.213 0.571 0.142
Lac/NAA AND
1.127 0.071 0.151 0.370 0.928 0.045 0.601 0.363 0.950 0.051 0.529 0.364 0.480 0.261
Lip/NAA
Lac/NAA OR
1.135 0.065 1.773 0.467 0.926 0.046 0.701 0.281 0.936 0.056 0.543 0.309 0.513 0.207
Lip/NAA
Table 10.3: Feature thresholds and performance measures obtained after optimizing different MRS features to obtain the highest
Dice scores with the MRI-visible-tumor as segmented by BraTumIA. (std – standard deviation, Acc – accuracy, Sens – Sensitivity,
Spec – Specificity, Prec – Precision, F1 – F1-score)
θX.1 std θX.2 std Acc std Sens std Spec std Prec std F1 std
Cho/Cr AND
1.308 0.060 0.747 0.159 0.891 0.082 0.771 0.247 0.903 0.111 0.686 0.265 0.683 0.198
Cho/NAA
Cho/Cr OR
1.575 0.199 1.212 0.134 0.883 0.083 0.784 0.213 0.894 0.117 0.652 0.237 0.679 0.164
Cho/NAA
Cho/Cr 1.342 0.021 0.891 0.074 0.838 0.163 0.893 0.109 0.673 0.222 0.710 0.125
Cho/NAA 1.105 0.053 0.892 0.076 0.730 0.245 0.915 0.102 0.699 0.252 0.673 0.177
(a.) identify tumor infiltration and improve the tumor delineation performed using sMRI, (b.)
identify tumors with necrotic cores, and (c.) help to identify the most malignant parts of brain
tumors. The simplicity of the approach facilitates its use as a standard for MRSI interpretation
and allows it to be easily extended and improved in the future to maximize the utility of MRSI
for brain tumor characterization.
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10.8 Supplementary Material
10.8.1 A: Detailed results of the optimization of the detection of Necrosis and
Solid Tumor
Table 10.2 and Table 10.3 show the results of the optimization of different decision rules for the
detection of Necrosis and Solid Tumor.
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Figure 10.12: Comparison between the classification of spectra of the test set directly using BraTSIS to classify each individual
spectrum, and indirectly, using BraTSIS to classify the clusters identified using X-means. The indirect approach was tested using
the 5 different cluster solutions. The statistical significance of the differences between the agreement of indirect approaches with
the direct approach and the agreement between the different indirect solutions was evaluated using a two-tailed t-test considering
2 samples with unequal variance.
10.8.2 B: Classification of individual spectra using BraTSIS
Figure 10.12 shows the comparison between the application of BraTSIS to classify individual
spectra (direct BraTSIS) and classification by copying the BraTSIS class of the closest cluster
(indirect BraTSIS). The test was performed applying both approaches to classify the spectra
of the test set. The results show that there are only small significant differences between
these approaches in the detection of Solid Tumor and Necrosis. Interestingly, the extreme
classes, Healthy and Necrosis, are the ones with the highest overall agreement. The relatively
low Dice scores seen in the other classes demonstrate the variability of the results caused by
the differences in the cluster solutions used in the indirect approach. This further supports
the interest in using BraTSIS directly to classify each spectrum without relying on clustering
solutions for intermediate cluster assignment.
10.8.3 C: Segmentation results of the second half of the test set
Figure 10.13 shows the segmentation results of the second half of the test set.
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Figure 10.13: Segmentation results and metabolite maps for the second half of the test set. The last column shows the
quality score maps, representing the predicted probability that the quality of each spectrum is accepted by an expert rater
[Pedrosa de Barros 2016b]. The regions of the MRS maps with quality scores below 0.5 were discarded and are shown in black.
The color scales of both segmentations are shown next to the corresponding maps.
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11.1 Abstract
Purpose: To improve the detection of peritumoral changes in GBM patients by exploring the
relation between MRSI information and the distance to the solid tumor volume (STV) defined
using structural MRI (sMRI).
Methods: 23 MRSI studies (PRESS, TE 135ms) acquired from different patients with untreated
GBM were used in this study. For each MRSI examination, the STV was identified by segmenting
the corresponding sMRI images using BraTumIA, an automatic segmentation method. The
relation between different metabolite ratios and the distance to STV was analyzed. A regression
forest was trained to predict the distance from each voxel to STV based on 14 metabolite ratios.
Then, the trained model was used to determine the Expected Distance to Tumor (EDT) for each
voxel of the MRSI test data. EDT maps were compared against sMRI segmentation.
Results: The features showing abnormal values at the longest distances to the tumor were:
%NAA, Glx/NAA, Cho/NAA and Cho/Cr. These 4 features were also the most important for
the prediction of the distances to STV. Each EDT value was associated with a specific metabolic
pattern, ranging from normal brain tissue to actively proliferating tumor and necrosis. Low
EDT values were highly associated with malignant features such as elevated Cho/NAA and
Cho/Cr.
Conclusion: The proposed method enables the automatic detection of metabolic patterns
associated with different distances to the STV border and may assist tumor delineation of
infiltrative brain tumors such as GBM.
11.2 Introduction
Glioblastoma Multiforme (GBM) is the most aggressive type of primary brain tumor and is
characterized by an extensive infiltration of tumor cells into the tissues surrounding the tumor
[Claes 2007]. Structural MRI (sMRI) is the imaging technique of reference for the management
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of GBM patients [Weller 2014, Niyazi 2016] but fails to show the full extent of the infiltrative
tumor part [Yamahara 2010], complicating the treatment of this disease.
In order to improve the delineation of these tumors, several research groups [Cordova 2016,
Guo 2012, Stadlbauer 2004, Ganslandt 2005] have used Magnetic Resonance Spectroscopy
(MRS), a non-invasive technique that provides metabolic in-vivo information of the tissues
examined and complements sMRI in the characterization of brain tumors [Hollingworth 2006].
Results have shown that MRS is able to detect regions with tumor cells outside the tumor
limits defined in T2-weighted images [Ganslandt 2005]. Improvement in the delineation of
glioblastoma has the potential to improve patient treatment and increase the overall survival
of these patients, as indicated by a phase II clinical trial [Einstein 2012] where a significant
increase in GBM patient’s overall survival was observed after incorporating MRS in the planning
of radiosurgery. Similarly, during brain surgery, the increased delineation accuracy that can be
achieved by using 5-aminolevulinic acid (5-ALA) tumor fluorescence [Schucht 2014], translates
into a more effective tumor resection with increased survival to the patients [Aldave 2013].
Despite these promising results on the detection of tumor infiltration using MRSI, in the
above-mentioned work, as in current clinical practice, only a very limited amount of the
information provided by MRS is used. More precisely, the improvement in tumor detection
is usually achieved simply by thresholding the metabolite ratio Cho/NAA. Therefore, it is
important to evaluate alternative approaches that, using more information, may further improve
tumor delineation and detection of tumor infiltration.
Several researchers have developed methods that, instead of analyzing each
metabolite or metabolite ratio individually, aim at identifying metabolic patterns as-
sociated with different tissues [Preul 1998, Sajda 2004, Du 2004, Du 2008, Su 2008,
Luts 2009, Ortega-Martorell 2012a, Lu 2013, Li 2013b, Li 2013a, Yang 2015, Raschke 2015,
Mocioiu 2016, Pedrosa de Barros 2015]. These methods can be divided into two main groups:
classification methods [Preul 1998, Luts 2009, Lu 2013, Yang 2015] and (blind) source sepa-
ration methods [Sajda 2004, Du 2004, Du 2008, Su 2008, Ortega-Martorell 2012a, Li 2013b,
Li 2013a, Raschke 2015, Mocioiu 2016, Pedrosa de Barros 2015]. In the first group the anal-
ysis of each spectrum corresponds to the classification of each spectrum into one of a set
of predefined classes. Therefore, the tumor boundary is simply the region delimited by the
voxels classified as tumoral tissue. In contrast, the second group presents a set of methods
that model each spectrum as a linear combination of different reference spectra of predefined
tissue-types (e.g. necrosis, tumor and normal brain tissue). By doing so, tumor delineation
can be performed based on the estimations of the tumor-tissue contribution in each spectrum.
This type of methods is more suitable for delineating GBM since they are prepared to deal
with diffuse tumor boundaries and with partial-volume effects that originate from the low
spatial resolution of MRSI data. In both cases, the results can be made easily interpretable by
converting the output into nosologic images, i.e. images where each color represents a given
tissue type [De Edelenyi 2000].
The two types of methods presented above enable a better use of the MRSI data for tumor
delineation, however, their availability in clinical practice is still very limited. One of the
main challenges for the incorporation of such methods into clinical routine is that their results
depend on the set of classes or reference spectra used, which not only may vary considerably
depending on the dataset and methodology used, but also usually require a non-trivial decision
regarding the number of classes or reference spectra that should be considered.
In this work, a novel approach to explore MRSI information for brain tumor delineation is
presented. The method was developed considering the solid tumor volume (STV) identified in
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sMRI as the core of the tumor. Moreover, it was assumed that the probability of finding tumor
cells decreases as the distance to the STV increases. Under these assumptions, we explored the
relation between metabolic patterns and the distance to the STV defined in sMRI. In this way, it
may be possible to detect tumor infiltration by simply identifying metabolic signatures that are
associated with close distances to the STV.
The work here presented starts with an analysis of the relation between individual metabo-
lite ratios and the distance to Solid Tumor Volume (STV). For comparison, we looked also at the
values of these metabolite ratios for the different MRI-segmentation classes (white-matter (WM),
gray-matter (GM), cerebral-spinal-fluid (CSF), enhancing-tumor (E-Tumor), non-enhancing
tumor (NE-Tumor) or necrosis). The analysis of the relation between each feature and the
distance to STV was supported by an MRS-Feature Spatial Distribution (MRS-FSD) model that is
introduced in this article.
After the analysis of the different features separately, a regression forest [Breiman 2001,
Liaw 2002] was trained to predict the distance to STV based on the value of 14 metabolite
ratios in each spectroscopic voxel. The relation between metabolic patterns and the distances
predicted by the regression forest, or Expected Distances to Tumor (EDT), was analyzed. Finally,




A total of 23 pre-operative MRSI examinations (PRESS, CHESS water suppression, TE=135 ms,
TR=1500 ms) were collected from different GBM patients using two 1.5T Siemens scanners
(models ‘Aera’ and ‘Avanto’, Siemens, Erlangen, Germany). The MRSI data had an original
resolution of 12x12, with a voxel size of 13.33x13.33x15 mm, and was interpolated before
DICOM storage to a resolution of 32x32 and a voxel size of 5x5x15 mm. All spectra from outside
the PRESS-box, as well as the border voxels of the excited PRESS volumes, were discarded as
these voxels are not properly excited. Moreover, the border voxels of the PRESS volume are
usually highly affected by the chemical shift displacement artifact and cannot be corrected using
methods such as the selection profile correction discussed in the next section. After removing
the outer voxels, the dataset contained a total of 4452 spectra. Besides spectroscopy, the protocol
included acquisition of T1-weighted (MP RAGE, TE=2.67ms; TR=1580ms, TI=900ms; 1x1x1
mm), T1c-weighted post-contrast (MP RAGE, TE=4.57ms; TR=2070ms, TI=1100ms; 1x1x1
mm), T2-weighted (SPACE, TE=380ms, TR=3000ms), and FLAIR MRI (TE=88ms, TR=8000ms,
TI=2500ms).
Apart from the data collected from GBM patients, 7 MRSI recordings were acquired from
3 healthy volunteers using the same acquisition parameters. This healthy control dataset
contained a total of 1372 spectra after exclusion of the outer-voxel row of the excited volume.
The measurements were performed in conformance to local and national ethical regulations,
meaning that all patients gave their written informed consent that their data could be used for
scientific purposes.
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11.3.2 MRS Data Processing Pipeline
The MRSI data was processed using jMRUI’s SpectrIm plugin (www.jmrui.eu) and included
the following processing steps:
1. Residual water peak removal using HLSVD [den Boogaart 1994];
2. Automatic Quality Control [Pedrosa de Barros 2016b, Pedrosa de Barros 2016a,
Pedrosa de Barros 2017a];
3. Frequency-Shift Correction;
4. Auto-phasing;
5. Quantification using QUEST [Ratiney 2004];
6. Selection profile correction [Pedrosa de Barros 2017b].
Quality Control was performed using a random forest model that was trained to reproduce
the judgment of an expert. The criteria for rejection of the training data was the presence of
visible signal artifacts and low SNR. The trained model outputs a probability of acceptance
by an expert. Therefore, after assessing all spectra with the automatic classifier, all spectra
with a probability of acceptance by an expert below 0.5 were removed from the dataset. After
quality filtering, the dataset contained 3733 spectra, meaning that around 16% of the spectra
(719 spectra) were classified as having unacceptable quality. For more details on automatic
quality filtering the reader is referred to [Pedrosa de Barros 2016b, Pedrosa de Barros 2016a,
Pedrosa de Barros 2017a, Pedrosa de Barros 2017b].
Quantification was performed using QUEST and a metabolite model that included the
following metabolites: Cho, Cr, NAA, Glu, Gln, Lac, Lip1.3, Lip0.9.
Chemical-Shift Displacement artifact (CSDA) and RF selection pulse profile effects of the
PRESS sequence were corrected using metabolite maps recorded of phantoms using the same
acquisition parameters as the in-vivo measurements. This correction is essential for the analysis
of MRSI, reducing the spatial variations of the relative metabolite content that originate from
the non-ideal selection pulses. In-depth information on the selection profile correction is found
in [Pedrosa de Barros 2017b].
11.3.3 Image Segmentation using BraTumIA
The sMRI images acquired for each MRSI examination were segmented into the following
compartments: white-matter (WM), gray-matter (GM), cerebral-spinal-fluid (CSF), edema,
non-enhancing tumor (NE-Tumor), enhancing tumor (E-Tumor) and necrosis. Solid Tumor
Volume (STV) was defined as the union of NE-Tumor, E-Tumor, and necrosis.
The segmentation was performed fully automatically using BraTumIA [Porz 2014,
Meier 2016]. BraTumIA is a machine learning-based segmentation method that was trained on
an independent dataset of 54 pre- and postoperative MRI examinations of glioblastoma that
were manually segmented by experienced neuroradiologists. For the automatic segmentation,
the following modalities are required as input: T1, T1c, T2, and FLAIR. A more detailed descrip-
tion of the algorithm and training data can be found in the study of Meier et al. [Meier 2016].
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11.3.4 MRS features
Two types of features were analyzed: (I.) %metabolite, calculated as the ratio between the area
of a given metabolite and the total sum of the areas of all metabolites, and (II.) conventional
ratios between the areas of two metabolites. The areas were calculated by integration of the
complete metabolite signal of the basis set after fitting with QUEST and were corrected for the
selection profile. Considering this, the following 14 MRS features were analyzed in this paper:
%NAA, %Cho, %Cr, %Glx, %Lac, %Lip, Cho/Cr, Cho/NAA, Glx/NAA, Glx/Cr, Lac/Cr, Lip/Cr,
Lac/NAA and Lip/NAA. In these features, Lip stands for the sum of Lip1.3 and Lip0.9, and
Glx for the sum of Glu and Gln.
11.3.5 Spectra and MRS features for different distances to the STV and different
Image Segmentation Classes
For each spectroscopic voxel, the assigned MRI-segmentation class was selected based on
majority voting, considering the voxels of the image segmentation mask that are contained
within the spectroscopic voxel. Then, the distance from each voxel to the STV was calculated as
the Euclidean distance to the nearest voxel assigned to one of the classes of the STV (NE-Tumor,
E-Tumor, Necrosis). The distance was calculated in the plane of the MRSI grid and rounded to
the closest distance corresponding to an integer number of voxels.
The spectra of all spectroscopic voxels were grouped based on the rounded distance to STV
and based on the segmentation class. All spectra were normalized using L1-normalization, and,
for each group (i.e. range of distances to STV or segmentation class), the median spectra and
the 5th, 25th, 75th and 95th percentile spectra were calculated.
Similarly to the spectra, the 14 previously described features were also grouped based on the
segmentation class and the distance to STV. For each MRSI examination, the different feature
maps were spatially interpolated by a factor of 4 (zero-filling) to enable a finer analysis of the
relation between each feature and the distance to STV. After interpolation, the final in-plane
resolution was 1.25x1.25 mm. For each distance to STV and for each image segmentation
class, the median values as well as the 5th, 25th, 75th and 95th percentiles were calculated. The
same percentiles were calculated for all voxels of the healthy volunteers’ dataset and used as a
reference.
11.3.6 MRS-Feature Spatial Distribution (MRS-FSD) model
In order to compare the spatial properties of the different metabolite ratios, namely their
relation with the distance to STV, the following MRS-Feature Spatial Distribution (MRS-FSD)
model was introduced:
xi(d) = Ki +Aie
− dλi (11.1)
where d is the distance, and Ki , Ai and λi are the model parameters for the feature i.
In this expression, Ki represents the value of the feature i when the distance to the tumor
approaches infinity (Ki = xi(d =∞)). The fit parameter Ai (amplitude) represents the difference
between the values found in the STV and the values found in regions far from the STV (Ai =
xi (d = 0)−xi(d =∞)). The distance parameter λi , or spectral feature normalization length, controls
the characteristic rate at which the parameter normalizes as the distance to the tumor increases.
To facilitate the comparison between different features, the values of each feature were
rescaled before fitting the model using the following expression:














X95thi correspond respectively to the 5th and the 95th percentiles of the
same feature in healthy subjects, and xi and x′ i correspond to the value of the feature in GBM
patients before and after rescaling. The rescaling enables direct comparison of the different
model parameters between different MRS features and allows for an easier interpretation of the
results.
Following the above described feature rescaling, we define the abnormality distance of a
given feature i, Dabn,i , as the distance at which each feature crosses the abnormality threshold.
The abnormality threshold was defined as
H
X95thi for features that are increased in tumoral
tissue relatively to normal brain tissue, and as
H
X5thi for features that are decreased in tumoral
tissue. Therefore, Dabn,i is calculated as:
Dabn,i =
−λi · log(1−KiAi ) ,Ai > 0−λi · log(−KiAi ) ,Ai < 0 (11.3)
Spectroscopic features that are, in average, abnormal in large peritumoral volumes are
associated with larger Dabn,i values.
The MRS-FSD was fitted to the median curves of the 14 different features, i.e. the curves
described by the median feature values in function of the distance to STV. This was motivated
by the fact that the number of voxels decreases considerably as the distance to the tumor
increases. Moreover, the STV voxels (d=0) have often skewed distributions. Finally, the use of
the median curves instead of the voxels separately improves the robustness of the results to the
presence of outliers.
In order to test the stability of the results, the fitting was performed 6-times, excluding
every time the data from one-sixth of the patients. This was done on par with the 6-fold
cross-validation scheme used to test the predictions of the distance to the STV described in the
following section. The mean and standard deviation of the fitting results were determined.
11.3.7 Expected Distance to Tumor (EDT) Maps
To test the ability to identify metabolic patterns associated with different distances to the STV,
a regression forest [Breiman 2001] was trained to estimate the distance to solid tumor based on
all of the 14 features previously described. For comparison, the distance to the STV was also
predicted based on individual features using the corresponding inverted MRS-FSD models. In
both cases, the training followed a 6-fold Cross-Validation (CV) scheme, where in each iteration
the data from one-sixth of the patients were excluded from the training and used to test the
trained model.
The regression forests [Breiman 2001] (R, randomForest package [Liaw 2002]) were trained
using 500 trees and standard parameters (minimum size of terminal nodes equal to 5, and
number features per node equal to one-third of the total number of features [Hastie 2001],
i.e., 14/3 = 4.667 ≈ 5). The trained regressors were used to evaluate which features carry the
most information to estimate EDT values. Two different measures of feature importance were
analyzed: increase in Mean Squared Error (MSE) and residual sum of squares. The first one is
calculated as the average increase in error as a consequence of permuting the values of a given
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feature between different Out-Of-Bag (OOB) examples, a group of examples that are excluded
from the training in each tree as a result of bagging [Breiman 1994]. The greater the error
increase, the greater the importance of the permuted feature for the predictions. Regarding
the second measure, the residual sum of squares, this measures the ability of a given feature
to separate the examples into different groups with different properties. Features that, during
training, have a higher contribution to the separation of the training examples, are considered
more important. More details on these feature importance measures that are characteristic of
regression forests can be found in the original paper from Breiman [Breiman 2001].
In order to allow the regression forest models to distinguish the different tumor compart-
ments, virtual distances were assigned to the voxels of these classes before training. A distance
of -2 mm was used for necrosis, -1 mm for E-Tumor and 0 for NE-Tumor.
Regarding the estimation of the distance to STV based on the value of a feature i and the
corresponding MRS-FSD model, this were determined as:
d (xi) =
−λi · log(xi−KiAi ) , xi−KiAi ≥ ε−λi · log(ε) , xi−KiAi < ε (11.4)
where ε is an arbitrarily small number that, in this work, was defined as 0.001. This
prevents problems with close-to-0 and negative arguments of the logarithm function and sets
the maximum expected distance that can be predicted using the corresponding model.
11.4 Results
11.4.1 Spectra per MRI Segmentation Class
Figure 11.1 shows the different spectra for each MRI segmentation class. The results show that
the spectra vary considerably for each MRI class, especially for the tumor classes. This is caused
not only by the differences between the information provided by MRS and sMRI [Lopez 2017,
Pirzkall 2004], but also by the partial volume effects derived from the low resolution of the
acquired MRSI data. Despite the variability, the grouping of the spectra per MRI-segmentation
class highlights several distinctive characteristics of the different tissues. As expected, the
highest levels of Lip and Lac, and lowest levels of NAA and Cr are normally found in necrosis.
Enhancing and Non-Enhancing Tumor have very similar spectra, reflecting that contrast leakage
caused by blood-brain-barrier disruption does not necessarily translate into differences in
metabolic features. Interestingly, in Edema we find the highest levels of Glx (see difference
spectrum between 3.7 and 3.8 ppm, and between 2.1 and 2.4 ppm).
Regarding the CSF spectra, pure CSF spectra are expected to contain no metabolites, which
conflicts with the results of Figure 11.1. However, as described in the methods section, each
spectrum was assigned to the MRI-segmentation class of the majority of the corresponding
image voxels. This means that, due to this strategy and the low resolution of the MRSI protocol
used, most of the spectroscopic voxels are not "pure" CSF voxels, which explains the existence
of visible metabolites in the "CSF" spectra presented here. Moreover, since all spectra are
normalized, the height of the peaks in CSF is identical to the one seen in GM or WM.
11.4.2 Spectra per distance to the STV
Figure 11.2 shows the magnitude spectra depending on the distance to the STV. In this plots,
a distance of 0 mm corresponds to all spectra of the classes of the STV (E-Tumor, NE-Tumor,
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Figure 11.1: Spectra per MRI-Segmentation class. The black line shows the median magnitude spectra for each class and the
shades of the gray show the corresponding 5th, 25th, 75th and 95th percentiles. The green line shows the median magnitude
spectra of data collected from healthy controls (includes GM, WM and CSF), and the red line the difference between the two
median magnitude spectra. All spectra were normalized using L1-normalization. The normal brain tissue pattern seen for the
CSF class is a consequence of the partial volume effects and the normalization of the spectra.
Figure 11.2: Spectra for different distances to the STV. The black line shows the median magnitude spectra for each distance and
the shades of the gray show the corresponding 5th, 25th, 75th and 95th percentiles. The green line shows the median magnitude
spectra of data collected from healthy controls (includes GM, WM and CSF), and the red line the difference between the two
median magnitude spectra. All spectra were normalized using L1-normalization.
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Necrosis). By visual inspection, it is difficult to detect changes in distances greater than 30/35
mm. From distances between 5 and 30 mm, the most noticeable effects are the increase in NAA
and decrease in Cho as the distance to tumor increases. For distances of 5 mm, some spectra
contain elevated levels of lipids, which should come as result of partial volume effects or errors
in MRI segmentation. A closer look at the spectra shows that Glx levels are visibly elevated in
regions with distances between 5 and 15 mm from the tumor.
11.4.3 MRS features as a function of the distance to the STV and Image Segmen-
tation Class
The values of the six %metabolite features as a function of the distance (blue) and MRI segmen-
tation class (green) are presented in Figure 11.3. The reference values of the 5th, 25th, 50th, 75th
and 95th percentiles of each feature in healthy volunteers are shown in red for reference. For
sake of simplicity, the plots corresponding to the remaining metabolite ratios are included in
the Supporting Information (Figures 11.10 and 11.11).
The data shows that %NAA and %Cr levels are reduced in the brain of GBM patients, even
in regions that are located very far from STV. As expected, both features get further reduced, as
the distance to STV decreases. In contrast, the relative quantities of the remaining metabolites
increase from normal brain tissue to tumor. The feature %Glx shows a unique characteristic:
the maximum value is observed in the peripheral zone of the tumor, in edema and for distances
between 5 and 10 mm from the STV.
11.4.4 MRS-FSD model
Table 11.1 shows the results obtained by fitting the MRS-FSD model described (Eq. 11.1) to
the rescaled data (see Eq. 11.2). Figure 11.4 shows a plot of the spectral feature normalization
lengths and amplitudes for all ratios except %Glx, for which the normalization length is
considerably larger when compared to the remaining metabolites. The introduced model is
able to well describe the relation between the feature values and the distance to STV, as shown
by the high R2 values, with the exception of %Cho. For this feature, the differences in value
between tumor and healthy brain tissue are close to the level of the noise and, therefore, the
model fails to explain a considerable part of the variance of the data. The plots showing the
fitting results are included in the Supporting Information (Figures 11.12 to 11.25).
Regarding Glx ratios, Glx/NAA seems to be more sensitive than Glx/Cr to detect the effects
of tumor presence, showing a larger normalization length and amplitude. This result can
be explained by the fact that, compared to Cr, NAA is reduced in a broader volume that
extends farther from the STV, as shown by the larger absolute value of the amplitude and larger
normalization length. Given that the increase in Glx has been associated with neuronal loss
and demyelination [Ricci 2007], it is expected that the ratio with NAA increases the sensitivity
to detect deterioration and loss of neurons.
The Lip and Lac ratios showed the smallest normalization lengths, reflecting the fact that
these features are significantly altered only in a very confined region, namely in necrotic tissue.
Besides Cho/NAA, whose sensitivity to detect peritumoral changes has been extensively
discussed in the literature, two other features stand out as a result of their large abnormality
distances: %NAA and Glx/NAA.
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Figure 11.3: Value of several %metabolite features as a function of the sMRI segmentation class (green), and the distance to STV
(blue). For each value of the horizontal axis, the 5th, 25th, 50th, 75th and 95th percentiles are shown as depicted in the legend. For
each feature, the horizontal level lines in red mark the 5th, 25th, 50th, 75th and 95th percentiles in healthy volunteers (includes
GM, WM and CSF).
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Table 11.1: Fitting results of the MRS-FSD model for different features. The model was fitted to the median curve of the feature
values in function of the distance to STV. Before curve fitting, the data was rescaled as described in expression 11.2. For each
feature, model fitting was performed six times, excluding every time the data from one-sixth of the patients. The mean and
standard error of the mean (SEM) of the fitting results are shown for the coefficient of determination (r2), model parameters (K,
amplitude A and normalization length λ) and abnormality distance (Dabn). Values of λ and Dabn are given in mm.
Feature mean R2 SEM R2 mean K SEM K mean A SEM A mean λ SEM λ mean Dabn SEM Dabn
%Cho 0.470 0.073 0.746 0.008 0.290 0.041 6.963 1.273 0.354 0.730
%Cr 0.943 0.005 0.274 0.014 -1.121 0.018 4.623 0.305 6.479 0.277
%NAA 0.946 0.006 0.406 0.027 -1.484 0.018 9.571 0.802 12.308 0.600
%Glx 0.886 0.008 0.003 0.100 0.996 0.097 60.884 9.453 -0.423 1.140
%Lip 0.925 0.015 0.562 0.011 1.650 0.053 3.043 0.162 4.008 0.119
%Lac 0.848 0.060 0.465 0.017 1.064 0.023 4.393 0.295 3.004 0.179
Cho/NAA 0.967 0.003 0.725 0.020 3.357 0.058 4.230 0.251 10.602 0.558
Cho/Cr 0.975 0.001 0.903 0.012 2.700 0.075 3.162 0.083 10.583 0.265
Glx/NAA 0.959 0.001 0.500 0.017 2.379 0.021 8.706 0.238 13.577 0.235
Glx/Cr 0.948 0.006 0.470 0.014 1.389 0.015 9.409 0.373 9.043 0.263
Lip/Cr 0.959 0.004 0.631 0.009 4.250 0.188 1.915 0.084 4.660 0.150
Lac/Cr 0.930 0.013 0.540 0.011 3.228 0.072 2.183 0.087 4.252 0.161
Lip/NAA 0.961 0.005 0.515 0.012 4.293 0.175 2.064 0.101 4.482 0.158
Lac/NAA 0.930 0.012 0.451 0.017 3.252 0.095 2.547 0.113 4.529 0.205
Figure 11.4: Plot of the different amplitudes (A) and normalization lengths (λ) for each feature. The plot shows the mean values
± 1.96 times the standard error of the mean of the fitting results shown in Table 11.1. The results of %Glx are not shown in this
plot, given that this feature shows a considerably larger normalization length relative to the other ratios.
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Figure 11.5: Abnormality distances and relative importance for the prediction of the distance to STV of the different MRS features.
The abnormality distances (green) were calculated based on the MRS-FSD models for each feature. The two feature importance
measures (blue) were determined by the RF-models trained to estimate the distance to the tumor. The bar plots show, for each
feature, the mean values ± 1.96 times the standard error of the mean of the 6-fold CV results. For a better explanation of the
meaning of the feature importance measures please see the Section 11.3.7.
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11.4.5 Expected Distance to Tumor (EDT)
The feature importance results associated with the regression forest models, as well as the
Dabn values for each feature, are shown in Figure 11.5. As it can be seen, the abnormality
distances are highly correlated with feature importance for the prediction of the distance to
STV. The Pearson correlation coefficient between the average values of Dabn and ∆MSE was
0.836 (p=0.0002), and between the average values of Dabn and RSS 0.833 (p=0.0002).
The results show that the four features that contain the most information to estimate the dis-
tance to the tumor are %NAA, Glx/NAA, Cho/NAA and Cho/Cr. From the Lip and Lac related
features, Lip/Cr seems to be the most important. Since the different tumor compartments were
labeled with different virtual distances (-2 for Necrosis, -1 for E-Tumor and 0 for NE-Tumor), it
is expected that the importance of the Lip/Cr ratio is related to its role in identifying necrotic
tissue.
The comparison between the estimated and measured distances to STV for the RF model
and for the inverted MRS-FSD models of 5 of the most important features, are presented in
Figure 11.6. Compared to the single-feature models, the predictions made by the RF-model are
more accurate and show a smaller variance. However, the predictions of the RF-model show
a positive bias for regions close to the STV, and a negative bias in regions far from the solid
tumor. Interestingly, the median curve of the RF-model is approximately monotonic. Due to
the superiority of the RF-model, this was the model selected to generate the EDT values used in
the following results of this paper.
Figure 11.7 shows the values of different features per EDT and Figure 11.8 the characteristic
spectra associated with different EDT values. These results show the relations between feature
values and distance to the STV that were learned by the RF model. The different plots of Figure
11.8 show that, for each EDT value, there is a specific spectroscopic pattern associated with
it. Compared with the results of Figure 11.2, which show the spectra for different distances
to STV, the grouping of the spectra per EDT value shows a better ordering of the spectra in
terms of malignancy. More specifically, the ordering per EDT value shows more pronounced
malignant features, i.e. higher Cho/NAA and Cho/Cr, for shorter (expected) distances and
less malignant features, i.e. spectra identical to normal brain spectra, for spectra with large
(expected) distances to the tumor.
Finally, Figure 11.9 shows the sMRI segmentation overlaid with the isolines of the cor-
responding EDT maps. In general, the EDT maps show a good agreement with the sMRI
segmentation. However, in several of these maps, regions identified as edema or even nor-
mal brain tissue have small EDT values, which, potentially, may indicate regions of tumor
infiltration.
11.5 Discussion
11.5.1 MRS data shows significant metabolic alterations far from solid tumor vis-
ible in MRI
The results of Figure 11.3 show that several of the metabolite ratios are significantly altered in
regions outside the STV. Previous studies have shown that MRS is not only able to detect changes
being solid tumor visible MRI but also beyond any T2 abnormalites [Cordova 2016, Guo 2012,
Stadlbauer 2004, Ganslandt 2005], a characteristic that has been explored to improve tumor
delineation. It is expected that the main contribution to the peritumoral changes seen in Figure
184 11. MRS features and distance to MRI-visible Solid Tumor in GBM
Figure 11.6: Comparison between the predictions of the distance to the STV made using different models. The plots show the
predicted distances as a function of the measured distances to the tumor. In each plot, the blue line and the blue shades show
the median and the 5th, 25th, 75th and 95th percentiles of the predicted distances as a function of the measured distances to the
tumor, similarly to the shades seen in the plots of Figure 11.3. The red line shows the mean absolute error in function of the
distance to STV. In each plot, the mean absolute error (MAE) for all voxels and corrected MAE are shown. The corrected MAE
corrects for the differences in the number of voxels of different distances and corresponds to the average value of MAE for each
distance, i.e. the average value of the red curve. The virtual distances used to distinguish the different tumor compartments are
highlighted in each plot (-2 for Necrosis, -1 for E-Tumor and 0 for NE-Tumor). All results produced using 6-fold CV.
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Figure 11.7: Feature values in function of the EDT values predicted using 6-fold CV. For each value of the horizontal axis, the
5th, 25th, 50th, 75th and 95th percentiles are shown (blue shades), as in Figure 11.3. For each feature, the horizontal level lines in
red mark the 5th, 25th, 50th, 75th and 95th percentiles in healthy volunteers (includes GM, WM and CSF). The negative and zero
EDT values correspond to Necrosis (-2 mm), E-Tumor (-1 mm) and NE-Tumor (0 mm), as it is highlighted in every plot.
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Figure 11.8: Spectra for different EDT values predicted using 6-fold CV. EDT values were rounded to the closest distance value
shown in these plots. Spectra with EDT values equal or bigger than 47.5mm were not included. The negative and zero EDT values
correspond to Necrosis (-2 mm), E-Tumor (-1 mm) and NE-Tumor (0 mm). The black line shows the median magnitude spectra
for each class and the shades of the gray show the corresponding 5th, 25th, 75th and 95th percentiles. The green line shows the
median magnitude spectra of data collected from healthy controls (includes GM, WM and CSF), and the red line the difference
between the two median magnitude spectra. All spectra were normalized using L1-normalization. No spatial interpolation was
performed.
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Figure 11.9: Isoline maps of the Expected Distance to Tumor (EDT), determined based on the spectroscopic information from
each voxel, overlaid over the corresponding sMRI segmentation. The EDT maps were calculated using the described RF-model
and following a 6-fold CV scheme, i.e. the maps from each row where calculated using models trained based only on the data
from the other rows. The color code used for the background image (sMRI segmentation) is shown on the left side. All regions
for which the spectra had insufficient quality are shown in black. The color scale of the EDT isolines is shown on the right.
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11.3 originate from phenomena of clinical interest, such as tumor infiltration, edema, and
inflammatory response. This is supported by the mentioned results from the previous literature,
as well as by the structure seen in the peritumoral region that is made visible by the EDT maps
of Figure 11.9. Despite this, the low resolution of the acquired data means that effects caused
by signal bleeding [Pedrosa de Barros 2017b, Kreis 2004, Bovée 1998], which causes the voxels
near the tumor to have altered spectra regardless of the presence of any tumor-related effect,
cannot be ignored. The severity of the signal bleeding depends not only on the native resolution
of each MRSI examination but also on other factors such as k-space filtering and on the shape
of the source of the signal, in this case, the tumor. The impact that signal bleeding can have
on MRSI data can be assessed by measuring and analyzing the point-spread-function (PSF),
as described for instance in [Bovée 1998], or simply performing phantom studies to evaluate
the accuracy of tumor delineation as described in [Heikal 2008]. These two aspects should be
included in further studies. Besides studies to evaluate the impact of the low resolution in
the analysis of the relation between the distance to tumor and MRSI features, it is essential to
perform a similar study using higher resolution MRSI data acquired, for instance, with EPSI
[Posse 1995, Sabati 2015]. For an even finer resolution, upscaling of MRSI can be performed
based on the structure found in high-resolution MRI images, as shown in [Jain 2017]. However,
in this case, it would be necessary to evaluate the use of the mentioned super-resolution method
for brain tumor data.
11.5.2 The MRS-FSD model, a tool to analyze the spatial properties of MRS fea-
tures
The MRS-FSD model introduced in this paper describes the main aspects of the relation between
each MRS-feature and the distance to STV. More precisely, the model characterizes each feature
in terms of (1.) the magnitude and sign of the differences between healthy brain tissue and
solid tumor, and (2.) the spatial rate of the change. This allows to identify different groups of
features: features that are highly altered locally in solid tumor, such as those associated with
tumor necrosis like Lip/Cr and Lip/NAA; features that are reduced in solid tumor, such as
%Cr and %NAA; and features showing abnormal values in a broad peritumoral region, such as
Glx/NAA and %NAA. For the detection of tumor-related changes, the latter group is obviously
the most interesting. To help the interpretation of the model parameters, the abnormality
distance Dabn was introduced. As it was shown, Dabn can be used to identify the features that
carry the most information for determining the distance to STV. These results, show that the
MRS-FSD model is a simple tool that may be used to assist the analysis of the spatial properties
of different MRS features in relation to the distance to the solid tumor. Nevertheless, it should
be highlighted that the simplicity of the model does not allow to completely describe features
such as %Glx, for which the maximum values occur neither in STV or healthy brain tissue but
in between these two regions.
11.5.3 Glx/NAA and %NAA may allow detecting early signs of tumor infiltration
The results shown in Figure 11.5, show that %NAA and Glx/NAA are the metabolite ratios
with the largest Dabn. These features are also the ones that contain the most information for
predicting the distance to the STV, followed by Cho/NAA, a metabolite ratio that is known to be
associated with tumor infiltration [Cordova 2016]. The ability of Cho/NAA to identify tumor
infiltration is justified by the combination of two opposed effects [Oz 2014, Govindaraju 2000,
Mountford 2010]: on the one hand, the high membrane turn-over seen in tumor cells leads
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to high values of (free) Cho and, on the other hand, the neuronal loss/dysfunction as a result
of the tumor causes a decrease in NAA. Despite elevated Cho levels being associated with
tumor metabolism, the results of Cordova et al. [Cordova 2016] show that Cho/Cr is not a good
predictor for tumor infiltration, which may suggest that NAA is the metabolite that mainly
explains the correlation between Cho/NAA and tumor cellularity. This is supported by the
results presented in this paper, showing that %Cho (not to be confounded with the concentration
of Cho) is relatively constant regardless of the distance to the tumor or the tumor compartment,
in contrast with %NAA, the “%metabolite” feature that shows the biggest differences between
normal brain tissue and solid tumor. These results further indicate that %NAA might be a good
marker for detecting infiltration. Regarding the ratio Glx/NAA, high values of this ratio can
occur as a result of an increase in Glx, which has been associated with inflammation, neuronal
loss, demyelination and tumor proliferation [Ricci 2007, Takano 2001, DeBerardinis 2010],
combined with a decrease in NAA. This combination of effects suggests that, similarly to
%NAA, Glx/NAA might also be an interesting metabolite for the detection of tumor infiltration.
Future studies are needed to evaluate the value of these two metabolite ratios for the prediction
of tumor infiltration.
11.5.4 EDT maps facilitate clinical interpretation of MRSI data
The RF-model trained to predict the distance to the STV based on the different metabo-
lite ratios translates each spectrum into a single EDT value. Moreover, this model was
trained to distinguish different tumor compartments, since Necrosis, E-Tumor and NE-
Tumor were labeled with different virtual distances (0 for NE-Tumor, -1 for E-Tumor and
-2 for Necrosis). The results shown in Figures 11.8 and 11.7 seem to indicate a clear as-
sociation between metabolic patterns and EDT values. This characteristic suggests that
EDT maps may be regarded as a novel of type of nosologic image, allowing an easier clin-
ical interpretation of GBM MRSI data. Moreover, compared to blind source separation
methods [Sajda 2004, Du 2004, Du 2008, Su 2008, Ortega-Martorell 2012a, Li 2013b, Li 2013a,
Raschke 2015, Mocioiu 2016, Pedrosa de Barros 2015], no assumptions on the number of basis
spectra that need to be considered are required, which may simplify its implementation in
clinical practice. Despite this, it would be important to study the correspondence between EDT
values and the tissue contributions identified by blind source separation methods.
11.5.5 EDT maps may improve detection of infiltration
As described in the previous paragraph, EDT models convert MR spectra into a single “expected
distance” that is hypothesized to have a correspondence to a stage in tumor growth. Compared
to Cho/NAA thresholding, the RF-based model uses multiple features and is able to learn
complex relations between them. Consequently, under the assumption that the probability of
tumor infiltration decreases as the distance to STV increases, it is possible that RF-based models
may provide a better detection of tumor infiltration than Cho/NAA maps alone. In the case
of EDT maps, tumor infiltration is expected to be represented by regions of low EDT values
that reflect that these regions share some of the properties seen in regions close to the STV,
where infiltration is most likely. An encouraging fact that supports the idea that EDT may help
identify infiltration is that, as we see in Figure 11.6, the RF-model shows that for distances to the
STV greater than 20 mm, there is less information for determining EDT values. This suggests
that spectra with distances greater than 20 mm are identical to normal brain spectra. These
results match the findings described by Pallud et al. [Pallud 2010], that describe that for diffuse
190 11. MRS features and distance to MRI-visible Solid Tumor in GBM
low-grade gliomas MIB-1-positive cells are not normally found in samples collected at distances
greater than 20 mm from MRI-defined abnormalities. The relation between EDT maps and
tumor infiltration should be validated in future studies. Moreover, it could be interesting to
compare the performance for detecting tumor infiltration between the EDT method and blind
source separation methods.
11.5.6 EDT maps can be easily implemented in clinical practice
The data required to train a new model for generating EDT maps consists of a set of processed
MRSI examinations and the corresponding sMRI segmentations. In this work, both the pro-
cessing of MRSI data and the segmentation of sMRI were performed fully automatically using,
respectively, SpectrIm and BraTumIA. Though these two software applications are currently
only available for research, they demonstrate that it is feasible to fully automatically generate
the training data based on raw examinations. Once the model is trained, the quantification
results of each MRSI examination can be converted into EDT maps almost instantaneously.
The automation of the process of training new EDT models does not only simplifies its
implementation but also ensures the reproducibility of the results between centers. In case
automatic tumor segmentation is not available, semi-automatic methods may also enable
reproducible identification of the STV in sMRI [Huber 2017].
Finally, another factor facilitating the introduction of the EDT maps in clinical practice
is the easy interpretation of the results: an EDT value of 10 mm, for instance, can be easily
interpreted as a metabolic pattern that is likely to be found at a distance of 10 mm from the
solid tumor border.
Despite these advantages, the results shown in this article can only be regarded as a proof
of concept, since clinical validation of the method is currently missing.
11.6 Conclusion
The results of the presented study confirmed that most 1H-MRS visible metabolites are altered
beyond the STV. Moreover, using the MRS-FSD model, it was possible to compare the spatial
properties of several of the most commonly used metabolite ratios for the characterization
of brain tumors. The analysis suggests that besides Cho/NAA, features such as %NAA and
Glx/NAA, which are often significantly altered far from the tumor, may allow detecting early
signs of tumor infiltration. Finally, the relation between the distance to the STV and the values
of the different metabolite ratios was explored to produce a novel type of map: the EDT maps.
This approach converts the information concerning multiple metabolites into a single number,
whose value may have a correspondence with the different tissues seen at different stages of
tumor growth. EDT maps simplify the interpretation of MRSI data of brain tumor patients
and may help to identify early signs of tumor infiltration. Further studies should explore this
new concept with higher resolution MRSI data and evaluate its potential application for the
diagnosis, follow-up, neurosurgical treatment, and radiotherapy planning of glioma patients.
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11.7 Supporting Information
11.7.1 Metabolite ratios per sMRI segmentation class and per distance to STV
Figure 11.10: Value of several features as a function of the sMRI segmentation class (green), and the distance to STV (blue). For
each value of the horizontal axis, the 5th, 25th, 50th, 75th and 95th percentiles are shown as depicted in the legend. For each
feature, the horizontal level lines in red mark the 5th, 25th, 50th, 75th and 95th percentiles in healthy volunteers (includes GM,
WM and CSF).
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Figure 11.11: Value of several features as a function of the sMRI segmentation class (green), and the distance to STV (blue). For
each value of the horizontal axis, the 5th, 25th, 50th, 75th and 95th percentiles are shown as depicted in the legend. For each
feature, the horizontal level lines in red mark the 5th, 25th, 50th, 75th and 95th percentiles in healthy volunteers (includes GM,
WM and CSF).
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11.7.2 MRS-FSD Fitting Results
Figure 11.12: MRS-FSD fitting results for %Cho. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.13: MRS-FSD fitting results for %Cr. Each plot corresponds to one fold of the 6-fold CV scheme used, where at each
time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.14: MRS-FSD fitting results for %Glx. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.15: MRS-FSD fitting results for %NAA. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.16: MRS-FSD fitting results for %Lac. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.17: MRS-FSD fitting results for %Lip. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.18: MRS-FSD fitting results for Cho/Cr. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.19: MRS-FSD fitting results for Cho/NAA. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.20: MRS-FSD fitting results for Glx/Cr. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.21: MRS-FSD fitting results for Glx/NAA. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.22: MRS-FSD fitting results for Lac/Cr. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.23: MRS-FSD fitting results for Lac/NAA. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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Figure 11.24: MRS-FSD fitting results for Lip/Cr. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
Figure 11.25: MRS-FSD fitting results for Lip/NAA. Each plot corresponds to one fold of the 6-fold CV scheme used, where at
each time one-sixth of the examinations were excluded from the data used to fit the model. Each plot shows the percentiles per
distance to the STV, similarly to what is described in the legend of Figures 11.10 and 11.11. The fitted curves, shown in red, were
fitted to the median curves, shown in yellow. The fitting was performed after feature rescaling as described in Section 11.3.6
(after rescaling 0 corresponds to the 5th percentile of the feature in healthy volunteers, and 1 to the 95th percentile). Each plot
shows the corresponding coefficient of determination (R2).
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12.1 Discussion
This thesis addressed several aspects that currently limit the use of proton MRS in clinical
practice, namely the need for extensive user expertise and the considerable amount of time
required to process and analyze MRS data. Before presenting the research results of this doctoral
thesis, the first part of thesis introduced the reader to the main basic concepts underlying
Nuclear Magnetic Resonance (NMR), Magnetic Resonance Imaging (MRI) and Spectroscopy
(MRS) (chapter 2), MRS data processing & machine learning (chapter 3) and the clinical use
of proton MRS for the characterization of brain tumors (chapter 4). The research results were
presented in the second and third parts of this thesis.
12.1.1 Part II - quality management of MRS and automation of quality control
The second part of the thesis starts with chapter 5, where several of the aspects that need
to be considered to guarantee reproducible and unambiguous results in in vivo proton MRS
were discussed. More specifically, the chapter covered different important details on the use of
phantom experiments for quality assurance, described different methods for detecting errors
in the acquisition and quantification, and presented different strategies that can be used to
improve MRS data quality. Proper quality management is essential for the simplification of
MRS, given that signal artifacts and bad quality data are some of the main factors that limit
the clinical use of MRS and require (neuro)radiologists/clinicians to have solid expertise in
MRS. In other words, if quality assurance is performed correctly by the technical staff, and the
software used to handle MRS data takes care of controlling the quality of the data, not only
interpretation errors can be prevented but clinicians may focus on the purely clinical aspects of
MRS.
Continuing the topic of quality management, chapter 6 presents a method for the automatic
quality control of MRS data. The method corresponds to an automatic classifier (Random Forests
[Breiman 2001]) that was trained to mimic the subjective judgment of an expert regarding the
quality of MR spectra. The results showed that the developed approach is able to classify several
hundreds of spectra almost instantaneously and with the same accuracy as an expert. Given
that the method outputs an estimation of the probability of a given spectrum being "accepted"
by a rater, i.e. the output is continuous, it is possible to perform quality filtering using different
thresholds. This feature can be useful for specific situations where, for instance, the quality
requirements are particularly high, or alternatively, in cases where low-quality spectra are still
able to provide an answer for the clinical question at hand.
Another important aspect of automatic quality control is the consistency and objectiveness
of the automatic approach. As the results showed, different raters often disagree in their
assessments and even the same rater is often inconsistent when repetitively rating the quality
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of the spectra. This shows that, beyond the time-saving potential and the facilitation of the
analysis that results from removing "bad" quality data, automatic quality control contributes
to a more consistent and objective assessment of the quality of MR spectra. Moreover, its
performance can always be improved using new learning approaches and classification methods,
incorporating more features, etc.. The subjectivity of the manual assessment of the signal
quality in MRS, and the dependency of the classification performance on the type of features
and classification method used, are well covered in a recently published paper by Kyathanahally
et al. [Kyathanahally 2017].
Following the development of the presented automatic quality control method, a new
approach using the concept of active learning was presented that aimed at improving the
labeling efficiency of MRSI data (chapter 7). The study showed that it is possible to drastically
reduce the number of spectra that need to be labeled without sacrificing the performance of
the classifier in distinguishing "good" from "bad" quality data. Moreover, it allowed to better
understand the relationship between classification performance and the number of training
examples, as well as to conclude that the spectra that contain the most information for training
automatic classifiers are the ones whose classification is more uncertain. This is due to the
fact that these spectra are the ones that ultimately will define the hyperplanes in the feature
space corresponding to the class separation boundaries. Finally, the results demonstrated that
the most efficient strategy to label MR spectra corresponds to a combination of diversity and
uncertainty, i.e., the classifier learns more efficiently if the most uncertain spectra from as many
different examinations as possible are selected.
12.1.2 Part III - assisting the interpretation of brain tumor MRSI data
After the initial part dedicated to quality aspects of MRS, the doctoral work changed the
focus to methods that aim at assisting in the interpretation of MR spectra. The methods were
developed for the specific case of brain tumors, however, the concepts used are general and may
be applied to other organs and, possibly, other (focal) diseases. The different methods have all
in common that they use information from previously analyzed data to help to interpret new
spectra. Moreover, the different methods transform each new MRSI acquisition into an easily
interpretable map that places the new examination in the context of the already known data.
Consequently, not only these methods lower the requirements in terms of expertise required to
properly interpret the results, they can also be very interesting for experienced users, allowing
them to easily incorporate more information into the analysis of MRS examinations. Regardless
of the experience, given that proper interpretation of MRS examinations can be extremely
time-consuming, the assistance in interpreting MRS data is expected to have a considerable
time-saving potential.
Going now into more detail on the different methods presented, chapter 8 showed the
results of using convex NMF to the analysis of data from GBM and metastasis patients. The
results showed that several interesting aspects of the data can be highlighted using 3 sources to
describe the MRSI data of these two types of brain tumors. The cNMF with 3 sources converges
to a solution where one source represents normal brain spectra, the second source represents
solid tumor/necrotic tissue, and a third source was interpreted as a tumor infiltration pattern
(high Cho/NAA but only slightly increased Cho/Cr, presence of lactate and no mobile lipids).
The results of the study seem to indicate that the infiltration source is usually more prevalent
in GBM patients, however the p-value of the difference in the mean mixing matrix for the
infiltration source between GBM and metastasis is only 0.058, meaning that more data would
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be needed to confirm or reject the null hypothesis. Despite this, the standard deviation of the
mixing matrix associated with the infiltration source was significantly higher in GBM patients.
The results of this study confirmed the findings reported by other researchers, describing that
the main differences between brain metastasis and GBM are found in the tumor periphery
([Server 2010, Wijnen 2012]), given that the sources that showed significant differences between
the two types of tumors are usually found in the periphery of these tumors.
The experience gained with the project of chapter 8 showed that the use of reference spectra
can assist in the interpretation of MRS data but that different aspects of such approaches need
to be tackled. The first one is related to a known effect of MRS acquisitions: the chemical shift
displacement artifact (CSDA). Due to the differences in the resonance frequency of the main
resonances of Cho and NAA, the selection profiles of these two metabolites are shifted relative to
each other. Consequently, even in a homogeneous phantom, the Cho/NAA ratio is not constant
in the different voxels of the MRSI grid (This artifact is discussed in more detail in 5.5.4). Given
that increased Cho/NAA is a marker for tumor infiltration, and a distinguishing feature of the
infiltration source of chapter 8, the presented results showed a tendency to identify red-source
in the upper (frontal) voxels of the grid, where due to the CSDA, Cho/NAA was "artificially"
increased. This problem led to the development of the method presented in section 5.5.8,
which consists in the use of phantom measurements with the same acquisition parameters of
the acquired data to correct the selection profile and CSDA. The method was included in the
processing pipeline of the methods developed posteriorly to prevent the incorrect identification
of infiltration features (see, for instance, Figure 10.2 of chapter 10).
Another important aspect that was missing in the processing pipeline used to produce
the results of chapter 8 was quality filtering. In this case, the problem had already been
identified, however, the method presented in chapter 6 was still being developed at that time
and consequently, it was decided not to include it at that moment.
Finally, one of the main problems identified with cNMF was the difficulty in defining
objective criteria to decide the number of sources to use. This motivated the interest in X-means
([Pelleg 2000]), a method that despite being substantially different from NMF, can be used
in a similar way since it is able to identify groups of spectra that share similar spectroscopic
properties. More importantly, in X-means the identification of the number of clusters is implicit
to the method and performed based on a hierarchical approach, where at every the time the
algorithm decides based on the Bayesian Information Criterion (BIC) whether to divide a
group into two subgroups or not. After identifying the different groups, the average spectra
(prototype spectra) of each cluster can be used to assign new spectra to each group. The use of
the prototype spectra in X-means to interpret new spectra, despite different, can be compared to
the use of the different sources retrieved using cNMF for interpreting new cases. In both cases,
the reference spectra used correspond to an average over a certain group of spectra, however,
cNMF is a factorization method and the selected sources correspond to basis vectors that may
be used to reconstruct new cases. This means that fuzzy clustering is implicit to cNMF and
that cNMF is particularly suitable to handle low-resolution data where the majority of voxels
contain mixtures of tissues. In the case of X-means, fuzzy clustering can be achieved using the
value of a given distance metric applied to evaluate the similarity between a new spectrum and
the reference spectra. However, in this thesis, the prototype spectra identified with X-means
were simply used to identify the "closest" cluster and not explored for fuzzy-clustering.
The first results obtained with X-means, which included selection profile correction and
automatic quality control, were presented in chapter 9. The MRSI segmentation achieved with
this method revealed a total of 9 different groups and allowed to identify more pronounced
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features than the previous method, such as spectroscopy patterns with very high Cho/Cr but
almost any mobile lipids. Moreover, in this case MRI segmentation was available and could be
used to compare the segmentation results obtained with MRI and MRSI. In these preliminary
results, it could be seen that despite a rough agreement between imaging and spectroscopy,
both modalities carry different information. Despite the interesting results, a new problem
arose with the use of X-Means: depending on the dataset, features, processing pipeline, etc. the
number of clusters identified by X-means changed considerably. This meant that the proposed
approach could not be used clinically since the number and type of clusters would change
considerably depending on the dataset used for clustering to define the reference spectra. This
problem led to the development of BraTSIS (Brain Tumor Spectroscopic Imaging Segmentation).
BraTSIS (chapter 10) was developed with the aim of defining clear rules that could stan-
dardize the identification of the main types of spectra seen in MRSI data of GBM patients.
Therefore, the use of well-defined and widely available references to define the different groups
was one of the main concerns since the method had to be reproducible between different
centers. Consequently, MRI segmentation and data from healthy controls were the two selected
references. To guarantee the transparency of the method and inspired by the majority of
guidelines used in clinical practice, a decision tree was defined that could be easily applied in
any center and improved over different iterations. This ability to improve it iteratively, and
possibly through the collaboration between different centers, was seen as an essential aspect to
guarantee that BraTSIS adequately addresses the needs of clinical users. The structure of the
tree was defined considering the results obtained with X-Means. Compared with the method of
the previous chapter, an extended feature set was used that included, besides other metabolite
ratios, Glx/NAA and Glx/Cr. This allowed identifying a novel type of metabolic pattern (named
High Glx), that besides being widely present in the analyzed dataset hasn’t been described in
previous literature. The High Glx pattern is characterized by a close to normal brain spectrum,
with the exception of extremely elevated Glx levels, which may be related to inflammatory
processes associated with the tumor. The results showed that BraTSIS can successfully identify
the main types of spectra consistently and may be a starting point for the standardization of
the analysis of MRSI data in GBM patients.
Finally, the work presented in chapter 11 originated from several questions that arose
during the development of BraTSIS. BraTSIS explores the concept that in different types of
patterns, different features represent the differentiating factor needed to identify them. This is
the case, for instance, with spectra found in tissue necrosis, which can be easily identified by
the very high mobile lipid content and very low levels of creatine and NAA. However, despite
this assumption, it was not clear the behavior of different metabolite ratios in the transition
between different groups. While trying to answer this and other questions, it was noticed that,
relatively to the tumor border, different tissues are usually found at different distances of the
border. More precisely, healthy brain tissue is found usually in regions very far from the tumor,
infiltrated tissue in regions outside the tumor border but very close to the tumor, solid/active
tumor in the peripheral zone of the tumor, and necrosis in the core of the solid tumor. This
general relation between tissue types and the distance to solid tumor – which may certainly find
numerous exceptions – was the motivation for analyzing the relationship between the distance
to the tumor border visible in structural MRI and several metabolite ratios.
The analysis of the relationship between the distance to tumor and the different metabolite
ratios was the starting point for the concept of the Expected Distance to Tumor (EDT) maps,
presented in the same chapter (11). After identifying a clear relationship between almost every
metabolite ratio and the distance to the tumor border, it was hypothesized that a model trained
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to learn the relationship between metabolic information and the distance to solid tumor could
identify tumor infiltration as regions with a short expected distance to solid tumor, compared
with regions with normal spectroscopic patterns, which would be expected to be found at large
distances to solid tumor. Consequently, a regression model (Regression Forests [Liaw 2002])
was trained to estimate the distance to solid tumor based on spectroscopic features of a single
voxel. The results showed that the different metabolic patterns are associated to different EDT
values. More importantly, the ordering of the spectra by the predicted distances, i.e. the EDT
value, corresponds to an ordering of different metabolic patterns ranging from normal brain
spectra to necrosis, with a clear association between malignant features, such as high Cho/NAA
and high Cho/Cr, and short EDT values. This method that was developed at the end of the Ph.D.
programme is seen – in the perspective of the author – as a very interesting solution to assist
the interpretation of brain tumor MRS data. Not only can it be easily reproduced by different
centers since the definition of tumor borders in which it relies is one of the most well-defined
tasks in neuroradiology, it does not require the definition of a fixed number clusters (as in
X-means1 or cNMF). Moreover, it provides a linear scale that orders the majority of metabolic
patterns seen in GBM patients in terms of their usual distance to the tumor borders, which
seems to correspond to the ordering of metabolic patterns in terms of their malignancy. The
output is also of easy interpretation: an EDT value of 10 mm, for instance, can be easily
interpreted as a metabolic pattern that is usually found at a distance of 10 mm from the tumor
border. Finally, the identification of a border for tumor-related abnormalities may be performed
simply using as reference the EDT values found in regions known to contain only healthy brain
tissue.
12.2 Overview and outlook
This thesis was part of a European Marie-Curie project named TRANSACT (TRANSforming
magnetic resonance spectroscopy into A Clinical Tool). In the context of this project, the
doctoral work here presented contributed to solving some of the strongest obstacles for the
clinical use of MRS. The different results presented here confirmed that it is possible to greatly
simplify the processing and analysis of MRS using machine learning. Moreover, in SpectrIm it
was possible to define fully automatic processing pipelines that allow clinical users to focus
solely on the interpretation of the final results.
One of the main topics of this thesis was the automation of the quality control of MRS data.
The results showed that it is not only possible to develop classifiers as accurate as expert users,
they can classify huge amounts of data almost instantaneously and consistently. Moreover,
a new optimized approach to label the training MR spectra was also presented. To continue
the work of the development of automatic quality control classifiers, it could be interesting to
compare the performance of such methods for the identification of different types of artifacts
and identify in which cases it could be further improved. It is expected, for instance, that less
common artifacts may be recognized with a poorer performance than more common ones. Such
a study would not only allow to improve the overall classification performance but also to better
understand the limitations of the method. Another important aspect that was not analyzed
in this thesis was the relationship between spectral quality and the quantification error. The
1In the case of X-means, the determination of the number of clusters is done automatically, meaning that, in
theory, the definition of the number of clusters is not a problem for the user. However, in practice, different solutions
may be obtained as a result of minor changes in the dataset and a considerable amount of work may be required to
obtain meaningful and reproducible results.
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signal quality control method presented is based solely on the human perception of the quality
of spectra and aims at identifying artifacts that not only lead to quantification errors, but also
to wrong estimations of the quantification error. Given that the results’ uncertainty induced by
signal artifacts should be the main factor driving the decision on whether to reject or accept a
given spectrum, it could be interesting to develop machine learning based systems that could
robustly and accurately predict the quantification error in the presence of signal artifacts. In a
further step, the error-prediction could move to an estimation of the impact that the quality of
the data would have on the uncertainty of the clinical interpretation of the data.
On the topic of selection profile correction, it was showed that it can be easily done using
simple phantom acquisitions. However, it should be possible to more precisely calculate the
correction factors simply using the information from the pulse sequence, namely the pulse
shapes and bandwidths. This is an artifact that, besides having a simple solution, is currently
affecting examinations used in clinical practice and can lead to wrong interpretation of MRS
data. Therefore, it would be important to develop and distribute correction approaches for this
effect that could be brought into clinical practice in the near future.
Moving now to the third part of the thesis, different strategies were explored to assist
the analysis of brain tumor MRSI data: cNMF, X-Means, BraTSIS and EDT maps. In all
cases, the results presented in this thesis showed that automatic quality control and selection
profile/CSDA correction are essential for the success of these approaches. The presented
approaches showed that, using such methods it is possible to highlight interesting aspects of
the MRSI data of brain tumors. It is now necessary to validate the different results obtained
with the developed methods using follow-up data and histology. Their validation should also
enable to further improve and adapt them to maximize their clinical utility. Moreover, it would
be extremely interesting to evaluate some of these methods using high spatial resolution MRSI
data, acquired with sequences such as EPSI [Mulkern 2001] or SPICE [Lam 2015, Ma 2016].
For several years, the clinical value of MRS has been shown in different research papers,
some of which were covered in this thesis, namely in chapter 4. However, the complexity of MRS
has greatly limited the use of this technique causing it to be only available in a few specialized
centers. The limited amount of users means less motivation for the main vendors to develop new
and more attractive systems that improve and simplify the handling of MRS data. Moreover,
the existence of less clinical users means also that the knowledge and understanding of the
associations between the information provided by MRS and distinct diseases and conditions
evolves slowly. Overall, the combination of all these interconnected effects has limited the
clinical application and applicability of MRS greatly.
Despite this, the recent technological developments in MRI scanner hardware and MRS
pulse sequences lead to an improvement in the quality of MRS data. More importantly, the
democratization of machine learning and data sciences, and the increasing availability of better
and more advanced IT solutions means that it is now easier than ever to handle complex
data. The ability to handle complex data in an easy fashion and the growing interest in
information-rich data are expected to contribute to a shift in the perception of MRS, from a
situation where its complexity is seen as limitation for the clinical use, to another where the
complexity is regarded as an advantage that enables clinicians to perform tasks not possible
with other techniques. Consequently, the clinical use of MRS is expected to rise in the next
years, accompanying, at least, the annual growth in MRI examinations per capita (see Figure
12.1).
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Figure 12.1: Evolution of the number of MRI examinations per year, in Europe. Data source: OECD (2017), Magnetic resonance
imaging (MRI) exams (indicator). doi: 10.1787/1d89353f-en.
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Magnetic resonance imaging (MRI) is considered the method of choice for glioblastoma multi-
forme diagnosis and follow-up. MRI provides structural information and plays a crucial role in
progression monitoring, treatment planning, and analysis of brain tumors. Two-dimensional
measurement of tumor diameters is considered the gold standard for neuro-oncologic therapy
response assessment as of today. In recent years magnetic resonance spectroscopy (MRS) is used
increasingly to gain additional information on a metabolic level to improve tumor diagnosis.
The additional information comes at the cost of a considerable amount of experience needed by
clinicians to translate spectral information into histopathological tissue information. Therefore,
the aim of this work was to investigate a tissue segmentation method to help facilitate the use
of MRS in neuro-oncologic glioblastoma assessment by automating the translation process. The
22 pre-operative data sets from patients with histologically confirmed glioblastoma multiforme
contained four MRI sequences (T1, T1c, T2 and FLAIR) and 1H MRSI scan data (2D-PRESS,
CHESS, TE=135ms, TR=1500ms) acquired at a native resolution of 12×12 and interpolated
to 32×32 voxels. The data sets were acquired on 1.5T Siemens scanners (Area, Avanto). The
measurements were performed conforming to local and national ethical regulations: all patients
gave their informed consent to use the data for scientific purposes. In the first step of the
proposed method, 17 randomly selected data sets were pre-processed with jMRUI’s Spectrim
plugin (residual water removal HLSVD, qualityfiltering, frequency-shift correction, and auto-
phasing). After QUEST quantification a feature set of metabolite-ratios Cho/Cr, NAA/Cho,
NAA/Cr, (Lip1.3+Lac)/Cr, (Lip1.3+Lac)/NAA, (Lip1.3+Lac)/Cho was extracted from the 17
data sets. The feature set was then clustered by the x-means algorithm. The clustering revealed
nine characteristic sources (Necrosis 1, Necrosis 2, Necrosis + Active Tumor, Active Tumor,
Active Tumor + Infiltration, Infiltration, Normal WM1, Normal WM2, and Normal GM) which
were labeled and ordered by an experienced spectroscopist. In the second step, the nine sources
were used to segment the remaining five test data sets which were excluded from the clus-
tering. The result of the segmentation was visualized as a map with colors ranging from red
(malignant) to blue (healthy) for each type of tissue found. Additionally, a visual and statistical
comparison to a structural segmentation of the same data sets, generated by the Brain Tumor
Image Analysis (BraTumIA) software, was performed. The resulting segmentation maps show a
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good visual resemblance of the structural segmentation. A quantitative analysis with the Dice
similarity coefficient yielded a mean spatial overlap of 0.62±0.29 for the malignant regions and
0.71± 0.20 for healthy regions, both areas excluding the Infiltration and Edema classes. Only
low correspondence of 0.22±0.14 was found between Infiltration and Edema. We conclude that
the proposed method has the potential to enhance the clinical use of MRS in neuro-oncologic
glioblastoma assessment. It facilitates and largely automatizes the translation of spectral in-
formation into histopathological tissue information. In future research, the method could be
applied to other types of brain tumors to gain a better understanding of the differences between
those.
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